WO2010039960A1 - Stabilization of perhydrolases in a formulation with a carboxylic acid ester - Google Patents

Stabilization of perhydrolases in a formulation with a carboxylic acid ester Download PDF

Info

Publication number
WO2010039960A1
WO2010039960A1 PCT/US2009/059232 US2009059232W WO2010039960A1 WO 2010039960 A1 WO2010039960 A1 WO 2010039960A1 US 2009059232 W US2009059232 W US 2009059232W WO 2010039960 A1 WO2010039960 A1 WO 2010039960A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
enzyme
formulation
excipient
activity
Prior art date
Application number
PCT/US2009/059232
Other languages
French (fr)
Inventor
Robert Dicosimo
Arie Ben-Bassat
Mark S. Payne
Raymond Richard Zolandz
Original Assignee
E.I. Dupont De Nemours And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41338635&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2010039960(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by E.I. Dupont De Nemours And Company filed Critical E.I. Dupont De Nemours And Company
Priority to JP2011530232A priority Critical patent/JP5777517B2/en
Priority to BRPI0913702A priority patent/BRPI0913702B8/en
Priority to CN2009801485098A priority patent/CN102239264B/en
Priority to EP09793245.3A priority patent/EP2342349B1/en
Priority to BR122018012459A priority patent/BR122018012459B1/en
Publication of WO2010039960A1 publication Critical patent/WO2010039960A1/en
Priority to ZA2011/01650A priority patent/ZA201101650B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18Liquid substances or solutions comprising solids or dissolved gases
    • A61L2/186Peroxide solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/22Phase substances, e.g. smokes, aerosols or sprayed or atomised substances
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/04Detergent materials or soaps characterised by their shape or physical properties combined with or containing other objects
    • C11D17/041Compositions releasably affixed on a substrate or incorporated into a dispensing means
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/02Inorganic compounds ; Elemental compounds
    • C11D3/04Water-soluble compounds
    • C11D3/06Phosphates, including polyphosphates
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/02Inorganic compounds ; Elemental compounds
    • C11D3/04Water-soluble compounds
    • C11D3/10Carbonates ; Bicarbonates
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2003Alcohols; Phenols
    • C11D3/2006Monohydric alcohols
    • C11D3/201Monohydric alcohols linear
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2003Alcohols; Phenols
    • C11D3/2006Monohydric alcohols
    • C11D3/2017Monohydric alcohols branched
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2003Alcohols; Phenols
    • C11D3/2041Dihydric alcohols
    • C11D3/2044Dihydric alcohols linear
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2003Alcohols; Phenols
    • C11D3/2041Dihydric alcohols
    • C11D3/2048Dihydric alcohols branched
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2068Ethers
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2075Carboxylic acids-salts thereof
    • C11D3/2079Monocarboxylic acids-salts thereof
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2075Carboxylic acids-salts thereof
    • C11D3/2082Polycarboxylic acids-salts thereof
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2075Carboxylic acids-salts thereof
    • C11D3/2086Hydroxy carboxylic acids-salts thereof
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/2093Esters; Carbonates
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/22Carbohydrates or derivatives thereof
    • C11D3/221Mono, di- or trisaccharides or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/20Organic compounds containing oxygen
    • C11D3/22Carbohydrates or derivatives thereof
    • C11D3/222Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin
    • C11D3/226Natural or synthetic polysaccharides, e.g. cellulose, starch, gum, alginic acid or cyclodextrin esterified
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/26Organic compounds containing nitrogen
    • C11D3/32Amides; Substituted amides
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/36Organic compounds containing phosphorus
    • C11D3/361Phosphonates, phosphinates or phosphonites
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/16Organic compounds
    • C11D3/38Products with no well-defined composition, e.g. natural products
    • C11D3/386Preparations containing enzymes, e.g. protease or amylase
    • C11D3/38636Preparations containing enzymes, e.g. protease or amylase containing enzymes other than protease, amylase, lipase, cellulase, oxidase or reductase
    • CCHEMISTRY; METALLURGY
    • C11ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11DDETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D3/00Other compounding ingredients of detergent compositions covered in group C11D1/00
    • C11D3/39Organic or inorganic per-compounds
    • C11D3/3947Liquid compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00Preparation of oxygen-containing organic compounds
    • C12P7/40Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01001Carboxylesterase (3.1.1.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18Liquid substances or solutions comprising solids or dissolved gases
    • A61L2/183Ozone dissolved in a liquid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20Targets to be treated
    • A61L2202/24Medical instruments, e.g. endoscopes, catheters, sharps
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/10Biofuels, e.g. bio-diesel

Definitions

  • This invention relates to the field of enzymatic peracid synthesis and in situ enzyme catalysis, At least one peroxycarboxy ⁇ c acid is produced at sufficient concentrations as to be efficacious for the disinfection or sanitization of surfaces, medical instrument sterilization, food processing equipment 15 sterilization, and suitable for use in textile and laundry care applications such as bleaching, destaining, deodorizing, disinfection or sanitization,
  • Peracid compositions have been reported to be effective antimicrobial 20 agents. Methods to clean, disinfect, and/or sanitize hard surfaces, meat products, living plant tissues, and medical devices against undesirable microbial growth have been described (e.g., U.S. Patent 6,545,047; U.S.
  • Peracids can be prepared by the chemical reaction of a carboxylic acid and hydrogen peroxide (see Organic Peroxides, Daniel Swern, ed., Vol. 1 , pp 30 313-516; Wiley Interscience, New York, 1971). The reaction is usually catalyzed by a strong inorganic acid, such as concentrated sulfuric acid. The reaction of hydrogen peroxide with a carboxylic acid is an equilibrium reaction, and the production of peracid is favored by the use of an excess concentration of peroxide and/or carboxylic acid, or by the removal of water.
  • Some peracid-based disinfectants or bleaching agents are comprised of an equilibrium mixture of peracid, hydrogen peroxide, and the corresponding carboxylic acid.
  • One disadvantage of these commercial peracid cleaning systems is that the peracid is oftentimes unstable in solution over time.
  • One way to overcome the stability problem is to generate the peracid prior to use by combining multiple reaction components that are individually stable for extended periods of time.
  • the individual reaction components are easy to store, relatively safe to handle, and capable of quickly producing an efficacious concentration of peracid upon mixing.
  • the CE-7 family of carbohydrate esterases has recently been reported to have perhydrolase activity. These "perhydrolase” enzymes have been demonstrated to be particularly effective for producing peracids from a variety of carboxylic acid ester substrates when combined with a source of peroxygen (See WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299 and 2008/176783 to DiCosimo et a/.; each herein incorporated by reference in their entireties).
  • Some members of the CE-7 family of carbohydrate esterases have been demonstrated to have perhydrolytic activity sufficient to produce 4000 - 5000 ppm peracetic acid from acetyl esters of alcohols, diois, and glycerols in 1 minute and up to 9000 ppm between 5 minutes and 30 minutes once the reaction components were mixed (DiCosimo et a/., U.S. Patent Application Publication No. 2009/0005590).
  • Organic solvents having a log P between two and four can be used on a case-by-case basis dependent on enzyme stability, and those having a log P > 4 are generally useful in organic phase systems.
  • a single-phase organic- aqueous solvent containing a low log P organic solvent usually has a negative effect on enzyme stability except in low organic solvent concentration applications.
  • Triacetin is reported to have a log P of 0.25 (Y. M. Gunning, et al., J. Agric. Food Chem.
  • the problem to be solved is to formulate a product using a mixture of a peracid-generating enzyme in an organic ester substrate employed for peracid production, where the enzyme retains significant perhydrolase activity even when stored in a mixture with the carboxylic acid ester substrate.
  • the stated problem has been solved by the discovery of a process for stabilizing the perhydrolysis activity of at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity when present in a formulation with a carboxylic acid ester. More specifically, the addition of at ieast one buffer to a formulation comprising a carboxylic acid ester and an enzyme powder comprising the CE-7 enzyme and at least one excipient enhances the stability of the perhydrolysis activity of the CE-7 enzyme stored in the formulation.
  • a process to stabilize the perhydrolysis activity of an enzyme when present in a formulation comprised of said enzyme and a carboxylic acid ester comprising:
  • a formulation used as a first component in a multi- component peracid generation system comprising a mixture of:
  • At least one carboxylic acid ester selected from the group consisting of monoacetin, diacetin, triacetin, monopropionin, dipropionin, tripropionin, monobutyrin, dibutyrin, tributyrin, and mixtures thereof;
  • an enzyme powder comprising a spray-dried formulation of at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity, at least one excipient, and optionally at least one surfactant;
  • a disinfectant system comprising a first component and a second component
  • said first component comprising the formulation described above
  • said second component comprising a source of peroxygen in water and optionally a hydrogen peroxide stabilizer
  • a process for enzymatically producing a peroxycarboxytic acid comprising;
  • a further aspect is for a process for treating an article of clothing or a textile for bleaching, stain removal, odor reduction, sanitization or disinfection using an enzymaticaliy-produced peroxycarboxylic acid composition, said process comprising:
  • step (d) contacting said article of clothing or textile fabric with the peroxycarboxyiic acid produced in step (b) or step (c); wherein said article of clothing or textile is cleaned, destained, deodorized, sanitized, disinfected, or a combination thereof.
  • SEQ ID NO:2 is the deduced amino acid sequence of a cephalosporin C deacetylase from B. subtilis ATCC ® 6633TM.
  • SEQ ID NO:3 is the deduced amino acid sequence of a cephalosporin C deacetylase from B, licheniformis ATCC ® 14580TM.
  • SEQ ID NO:4 is the deduced amino acid sequence of an acetyl xylan esterase from B. pumilus PS213.
  • SEQ ! D NO:5 is the deduced amino acid sequence of an acetyl xylan esterase from Clostridium thermocellum ATCC ® 27405TM.
  • SEQ ID NO:6 is the deduced amino acid sequence of an acetyl xyian esterase from Thermotoga neapolitana.
  • SEQ ID NO:7 is the deduced amino acid sequence of an acetyl xylan esterase from Thermotoga ma ⁇ tima MSB8.
  • SEQ ID NO:8 is the deduced amino acid sequence of an acetyl xyian esterase from Thermoanaerobacterium sp, JWVSL YS485.
  • SEQ ID NO:9 is the deduced amino acid sequence of a cephalosporin C deacetylase from Bacillus sp. NRRL B-14911. It should be noted that the nucleic acid sequence encoding the cephalosporin C deacetylase from Bacillus sp. NRRL B-1491 1 as reported in G ENBANK ® Accession number ZPJ31 168674 appears to encode a 15 amino acid N-terminal addition that is likely incorrect based on sequence alignments with other cephalosporin C deacetylases and a comparison of the reported length (340 amino acids) versus the observed length of other CAH enzymes (typically 318-325 amino acids in length; see co-owed, co-filed, and copending U.S. Patent Application under attorney docket number CL4205 US NA entitled "ENZYMATIC
  • SEQ ID NO:10 is the deduced amino acid sequence of a cephalosporin C deacetyiase from Bacillus halodurans C-125.
  • SEQ ID NO:11 is the deduced amino acid sequence of a cephalosporin
  • SEQ ID NO:12 is the deduced amino acid sequence of a Bacillus subtilis ATCC ® 29233TM cephalosporin C deacetyiase (CAH).
  • SEQ ID NO:13 is the deduced amino acid sequence of a Thermoanearobacterium saccharolytic ⁇ m cephalosporin C deacetyiase.
  • SEQ ID NO:14 is the deduced amino acid sequence of a Thermotoga lettingae acetyl xylan esterase.
  • SEQ ID NO:15 is the deduced amino acid sequence of a Thermotoga petrophila acetyl xylan esterase.
  • SEQ ID NO: 16 is the deduced amino acid sequence of a first acetyl xylan esterase from Thermotoga sp. RQ2 described herein as "RQ2(a)".
  • SEQ ID NO:17 is the deduced amino acid sequence of a second acetyl xylan esterase from Thermotoga sp. RQ2 described herein as n RQ2(b)".
  • SEQ ID NO:18 is the amino acid sequence of the region encompassing amino acids residues 1 18 through 299 of SEQ ID NO:1.
  • SEQ ID NO: 19 is the deduced amino acid sequence of a Thermotoga neapolitana acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA (incorporated herein by reference in its entirety), where the Xaa residue at position 277 is Ala, VaI, Ser, or Thr.
  • SEQ ID NO:20 is the deduced amino acid sequence of a Thermotoga maritima MSB8 acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA 1 where the Xaa residue at position 277 is AIa 1 VaI, Ser, or Thr.
  • SEQ ID NO:21 is the deduced amino acid sequence of a Thermotoga lettingae acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA 1 where the Xaa residue at position 277 is Ala, VaI, Ser, or Thr.
  • SEQ ID NO:22 is the deduced amino acid sequence of a Thermotoga petrophila acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA, where the Xaa residue at position 277 is Ala, VaI 1 Ser, or Thr.
  • SEQ ID NO:23 is the deduced amino acid sequence of a Thermotoga sp, RQ2 acetyl xylan esterase variant derived from"RQ2(a)" from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA, where the Xaa residue at position 277 is Ala, VaI, Ser, or Thr.
  • SEQ ID NO:24 is the deduced amino acid sequence of a Thermotoga sp. RQ2 acetyl xylan esterase variant derived from "RQ2(b) B from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA, where the Xaa residue at position 278 is Ala, VaI, Ser, or Thr.
  • SEQ ID NO:25 is the deduced amino acid sequence of a Thermoanaerobacte ⁇ um sp. JW/SL YS485 acetyl xylan esterase.
  • SEQ ID NO:26 is the coding region of a kanamycin resistance gene
  • SEQ ID NO:27 is plasmid pKD13, which contains the kanamycin resistance gene.
  • SEQ ID NO:28 is a forward primer used to clone katG from plasmid pKD13.
  • SEQ ID NO:29 is a reverse primer used to clone katG from plasmid pKD13.
  • SEQ ID NO:30 is the PCR product of the katG amplification from plasmid pKD13 using the primers of SEQ ID NO:28 and SEQ ID NO:29.
  • SEQ ID NO:31 is the coding region of the catalase-peroxidase gene
  • SEQ ID NO:32 is the deduced amino acid sequence of katG.
  • SEQ ID NO:33 is plasmid pKD46, which contains the ⁇ Red recombinase genes.
  • SEQ ID NO:34 is a forward primer used to confirm disruption of katG,
  • SEQ ID NO:35 is a reverse primer used to confirm disruption of katG
  • SEQ ID NO:36 is the temperature-sensitive plasmid pCP20, which contains the FLP recombinase.
  • SEQ ID NO:37 is a forward primer used to clone katE from plasmid pKD13.
  • SEQ ID NO:38 is a reverse primer used to done katE from plasmid pKD13.
  • SEQ ID NO: 39 is the PCR product of the katE amplification from plasmid pKD13 using the primers of SEQ ID NO:37 and SEQ ID NO:38.
  • SEQ ID NO:40 is the coding region of the catalase HPIl gene (katE).
  • SEQ ID NO:41 is the deduced amino acid sequence of katE.
  • SEQ ID NO:42 is a forward primer used to confirm disruption of katE.
  • SEQ ID NO:43 is a reverse primer used to confirm disruption of katE.
  • SEQ ID NO:44 is a coding region of a gene encoding acetyl xylan esterase from Thermotoga neapolitana as reported in GEN BANK ® (accession # AE000512).
  • SEQ ID NO:45 is a forward primer used to amplify the acetyl xylan esterase gene from Thermotoga neapolitana.
  • SEQ ID NO:46 is a reverse primer used to amplify the acetyl xylan esterase gene from Thermotoga neapolitana.
  • SEQ ID NO:47 is the PCR product of the acetyl xylan esterase amplification using the primers of SEQ ID NO:45 and SEQ ID NO:46.
  • SEQ ID NO:48 is a gene encoding acetyl xylan esterase from
  • Thermotoga maritima MSB8 as reported in GENBANK ® (accession # NP_227893.1).
  • SEQ ID NO:49 is a forward primer used to amplify the acetyl xylan esterase gene from Thermotoga maritima.
  • SEQ ID NO:50 is a reverse primer used to amplify the acetyl xyian esterase gene from Thermotoga maritima.
  • SEQ ID NO:51 is the PCR product of the acetyl xylan esterase amplification using the primers of SEQ ID NO:49 and SEQ ID NO:50.
  • Disclosed herein is a method for stabilization of the perhydrolase activity of a CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the formulation of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.
  • the term “comprising” means the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof.
  • the term “comprising” is intended to include embodiments encompassed by the terms “consisting essentially of and “consisting of. Similarly, the term “consisting essentially of is intended to include embodiments encompassed by the term “consisting of.
  • the term "about" modifying the quantity of an ingredient or reactant employed refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or use solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the compositions or carry out the methods; and the like.
  • the term “about” also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term “about”, the claims include equivalents to the quantities.
  • substrate As used herein, the terms “substrate”, “suitable substrate”, and “carboxylic acid ester substrate” interchangeably refer specifically to: (a) one or more esters having the structure
  • X is an ester group of the formula R 6 C(O)O;
  • Re is a C1 to C7 linear, branched or cyclic hydrocarbyt moiety, optionally substituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R 6 optionally comprises one or more ether linkages where R 6 is C2 to C7;
  • R 5 is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionally substituted with a hydroxy! group, wherein each carbon atom in R 5 individually comprises no more than one hydroxyl group or no more than one ester group, and wherein R 5 optionally comprises one or more ether linkages; m is 1 to the number of carbon atoms in Rs 1 said one or more esters having a solubility in water of at least 5 ppm at 25 0 C; or
  • R 1 is a C1 to C7 straight chain or branched chain alkyl optionally substituted with an hydroxyl or a C1 to C4 alkoxy group and R 3 and R 4 are individually H or R 1 C(O); or
  • Ri is a C1 to C7 straight chain or branched chain alky! optionally substituted with an hydroxyl or a C1 to C4 alkoxy group and R 2 is a C1 to C10 straight chain or branched chain alkyt, alkenyl, alkynyl, ary! t alkylaryl, alkylheteroaryl, heteroaryl, (CH 2 CH 2 O) n , or (CH 2 CH(CH 3 )-O) n H and ⁇ is 1 to 10; or
  • carboxylic acid ester substrate may include monoacetin; triacetin; monopropionin; dipropionin; tripropionin; monobutyrin; dibutyrin; tributyrin; glucose pe ⁇ taacetate; xylose tetraacetate; acetylated xylan; acetylated xylan fragments; ⁇ -D-ribofuranose-1 ,2,3,5-tetraacetate; tri-O- acetyl-D-galactal; tri-O-acety! ⁇ glucal; propylene glycol diacetate; ethylene glycol diacetate; monoesters or diesters of 1,2-ethanediol; 1,2-propanediol; 1 ,3-propanediol; 1 ,2-butanediol; 1 ,3-butanediol; 2,3-butanediol
  • peracid is synonymous with peroxyacid, peroxycarboxylic acid, peroxy acid, percarboxylic acid and peroxoic acid.
  • peracetic acid is abbreviated as "PAA” and is synonymous with peroxyacetic acid, ethaneperoxoic acid and all other synonyms of CAS Registry Number 79-21 -0.
  • monoacetin is synonymous with glycerol monoacetate, glycerin monoacetate, and glyceryl mo ⁇ oacetate.
  • diacetin is synonymous with glycerol diacetate; glycerin diacetate, glyceryl diacetate, and all other synonyms of CAS Registry Number 25395-31-7.
  • triacetin is synonymous with glycerin triacetate; glycerol triacetate; glyceryl triacetate, 1 ,2,3-triacetoxypropane; 1 ,2,3- propanetriol triacetate and all other synonyms of CAS Registry Number 102- 76-1.
  • mi ⁇ obutyrin is synonymous with glycerol monobutyrate, glycerin monobutyrate, and glyceryl monobutyrate.
  • dibutyrin is synonymous with glycerol dibutyrate and glyceryl dibutyrate.
  • tributyrin is synonymous with glycerol tributyrate, 1 ,2,3-tributyryigiycerol, and ail other synonyms of CAS Registry Number 60-01-5.
  • the term "monopropionin” is synonymous with glycerol monopropionate, glycerin monopropionate, and glyceryl monopropionate.
  • dipropionin is synonymous with glycerol dipropionate and glyceryl dipropionate.
  • tripropio ⁇ in is synonymous with glyceryl tripropionate, glycerol tripropionate, 1 ,2,3-tripropionylglycerol, and ail other synonyms of CAS Registry Number 139-45-7.
  • ethyl acetate is synonymous with acetic ether, acetoxyethane, ethyl ethanoate, acetic acid ethyl ester, ethanoic acid ethyl ester, ethyl acetic ester and all other synonyms of CAS Registry Number 141-78-6.
  • ethyl lactate is synonymous with lactic acid ethyl ester and all other synonyms of CAS Registry Number 97-64-3.
  • acetylated sugar and “acetylated saccharide” refer to mono-, di- and polysaccharides comprising at least one acetyl group.
  • Examples include, but are not limited to, glucose pentaacetate, xylose tetraacetate, acetylated xylan, acetylated xylan fragments, ⁇ -D- ribofuranose-1 ,2,3,5-tetraacetate, tri-O-acetyl ⁇ D-ga!actal, and tri-O-acetyl- glucal.
  • hydrocarbyl As used herein, the terms “hydrocarbyl”, “hydrocarbyl group”, and “hydrocarbyl moiety” is meant a straight chain, branched or cyclic arrangement of carbon atoms connected by single, double, or triple carbon to carbon bonds and/or by ether linkages, and substituted accordingly with hydrogen atoms. Such hydrocarbyl groups may be aliphatic and/or aromatic.
  • hydrocarbyi groups examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, pentyl, cyclopentyl, methylcyclopentyl, hexyl, cyclohexyl, benzyl, and phenyl.
  • the hydrocarbyl moiety is a straight chain, branched or cyclic arrangement of carbon atoms connected by single carbon to carbon bonds and/or by ether linkages, and substituted accordingly with hydrogen atoms.
  • the carboxylic acid ester substrate is selected from the group consisting of propylene glycol diacetate (PG)
  • propylene glycol diacetate is synonymous with 1 ,2-diacetoxypropane, propylene diacetate, 1,2-propanediol diacetate, and all other synonyms of CAS Registry Number 623-84-7.
  • ethylene glycol diacetate is synonymous with 1 ,2 ⁇ diacetoxyethane, ethylene diacetate, glycol diacetate, and all other synonyms of CAS Registry Number 111-55-7.
  • suitable enzymatic reaction mixture As used herein, the terms “suitable enzymatic reaction mixture”, “components suitable for in situ generation of a peracid”, “suitable reaction components”, and “suitable aqueous reaction mixture” refer to the materials and water in which the reactants and enzyme catalyst come into contact.
  • the components of the suitable aqueous reaction mixture are provided herein and those skilled in the art appreciate the range of component variations suitable for this process.
  • the suitable enzymatic reaction mixture produces peracid in situ upon combining the reaction components.
  • the reaction components may be provided as a multicompone ⁇ t system wherein one or more of the reaction components remains separated until use.
  • reaction components are first combined to form an aqueous solution of peracid which is subsequently contacted with the surface to be disinfected and/or bleached.
  • the design of systems and means for separating and combining multiple active components are known in the art and generally wii! depend upon the physical form of the individual reaction components.
  • multiple active fluids (liquid-liquid) systems typically use multi-chamber dispenser bottles or two-phase systems (e.g., U.S. Patent Application Publication No. 2005/0139608; U.S. Patent 5,398,846; U.S. Patent 5,624,634; U.S. Patent 6,391 ,840; E.P. Patent 0807156B1; U.S. Patent Application Publication No.
  • multi-component systems used to generate peracid may include, but are not limited to, those designed for one or more solid components or combinations of solid-liquid components, such as powders (e.g., U.S. Patent 5,1 16,575), multi- layered tablets (e.g., U.S. Patent 6,210,639), water dissolvable packets having multiple compartments (e.g., U.S. Patent 6,995,125) and solid agglomerates that react upon the addition of water (e.g., U.S. Patent 6,319,888).
  • powders e.g., U.S. Patent 5,1 16,575
  • multi- layered tablets e.g., U.S. Patent 6,210,639
  • water dissolvable packets having multiple compartments e.g., U.S. Patent 6,995,125
  • solid agglomerates that react upon the addition of water
  • a multicomponent formulation is provided as two individual components whereby an aqueous solution comprising a peroxycarboxylic acid is generated upon combining the two components.
  • a multicomponent formulation comprising: a) a first component comprising: i) an enzyme powder as disclosed herein; and ii) a carboxylic acid ester, said first component optionally comprising a further ingredient selected from the group consisting of an inorganic or organic buffer, a corrosion inhibitor, a wetting agent, and combinations thereof; and b) a second component comprising a source of peroxygen and water, said second component optionally comprising a hydrogen peroxide stabilizer.
  • the carboxylic acid ester in the first component is selected from the group consisting of mo ⁇ oacetin, diaceti ⁇ , triacetin, and combinations thereof.
  • the carboxyiic acid ester in the first component is an acetylated saccharide.
  • the enzyme catalyst in the first component is a particulate so ⁇ d.
  • the first reaction component is a solid tabiet or powder.
  • perhydroiysis is defined as the reaction of a selected substrate with peroxide to form a peracid. Typically, inorganic peroxide is reacted with the selected substrate in the presence of a catalyst to produce the peracid.
  • chemical perhydroiysis includes perhydroiysis reactions in which a substrate (a peracid precursor) is combined with a source of hydrogen peroxide wherein peracid is formed in the absence of an enzyme catalyst.
  • perhydrolase activity refers to the catalyst activity per unit mass (for example, milligram) of protein, dry cell weight, or immobilized catalyst weight.
  • one unit of enzyme activity or “one unit of activity” or
  • U is defined as the amount of perhydrolase activity required for the production of 1 ⁇ mol of peracid product per minute at a specified temperature.
  • enzyme catalyst and “perhydrolase catalyst” refer to a catalyst comprising an enzyme having perhydroiysis activity and may be in the form of a whole microbial cell, permeabilized microbial ceil(s), one or more celi components of a microbial cell extract, partially purified enzyme, or purified enzyme.
  • the enzyme catalyst may also be chemically modified (e.g., by pegylatio ⁇ or by reaction with cross-linking reagents).
  • the perhydrolase catalyst may also be immobilized on a soluble or insoluble support using methods well-known to those skilled in the art; see for example, Immobilization of Enzymes and Cells; Gordon F. Bickerstaff, Editor; Humana Press, Totowa, NJ, USA; 1997.
  • ail of the present enzymes having perhydroiysis activity are structurally members of the carbohydrate family esterase family 7 (CE-7 family) of enzymes (see Coutinho, P.M., He ⁇ rissat, B. "Carbohydrate-active enzymes: an integrated database approach" in Recent Advances in Carbohydrate Bioenqineering, H.J. Gilbert, G. Davies, B. Henrissat and B.
  • CE-7 The CE-7 family of enzymes has been demonstrated to be particularly effective for producing peracids from a variety of carboxylic acid ester substrates when combined with a source of peroxygen (See PCT publication No. WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299, 2008/176783, and 2009/0005590 to DiCosimo et al.; each herein incorporated by reference in their entireties).
  • CE-7 family include cephalosporin C deacetylases (CAHs; E.C. 3.11.41 ) and acetyl xylan esterases (AXEs; E.C. 3.1.1.72).
  • CAHs cephalosporin C deacetylases
  • AXEs acetyl xylan esterases
  • CE-7 esterase family share a conserved signature motif (Vincent et al., J, MoI. Biol., 330:593-606 (2003)).
  • Perhydrolases comprising the CE-7 signature motif and/or a substantially simiiar structure are suitable for use in the present invention. Means to identify substantially simiiar biological molecules are well known in the art (e.g., sequence alignment protocols, nucleic acid hybridizations, and/or the presence of a conserved signature motif).
  • the present perhydrolases include enzymes comprising the CE-7 signature motif and at least 30%, preferably at least 33%, more preferably at least 40%, even more preferably at least 42%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to the sequences provided herein.
  • the present perhydrolases include enzymes comprising the CE-7 signature motif and at least 30%, preferably at least 33%, more preferably at [east 40%, even more preferably at least 42%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to SEQ ID NO: 1 ,
  • the term "enzyme powder” refers to the spray-dried product of an aqueous formulation comprising (1) at least one enzyme structurally classified as a CE-7 carbohydrate esterase that has perhydrolysis activity, (2) at least one oligosaccharide excipient, and optionally at least one surfactant.
  • the at least one oligosaccharide excipient has a number average molecular weight of at least
  • cephalosporin C deacetylase and “cephalosporin C acetyl hydrolase” refer to an enzyme (E.C, 3.1.1.41) that catalyzes the deacetylation of cephalosporins such as cephalosporin C and 7- aminocephalosporanic acid (Mitsushima et a/., (1995) Appl. Env, Microbiol. 61 (6):2224-2229).
  • cephalosporin C deacetylases are provided herein having significant perhydroiysis activity.
  • acetyl xylan esterases refers to an enzyme (E.C. 3.1.1.72; AXEs) that catalyzes the deacetylation of acetySated xylans and other acetylated saccharides. As illustrated herein, several enzymes classified as acetyl xylan esterases are provided having significant perhydroiysis activity.
  • Bacillus subtilis ATCC ® 31954TM refers to a bacterial cell deposited to the American Type Culture Collection (ATCC ® ) having international depository accession number ATCC ® 31954TM.
  • Bacillus subtilis ATCC ® 31954TM has been reported to have an ester hydrolase ("diacetinase") activity capable of hydrolyzing glycerol esters having 2 to 8 carbon acyl groups, especially diacetin (U.S. patent 4,444,886; herein incorporated by reference in its entirety). As described herein, an enzyme having significant perhydrolase activity has been isolated from B. subtilis
  • Bacillus subtilis ATCC ® 29233TM refers to a strain of Bacillus subtilis deposited to the American Type Culture Collection (ATCC ® ) having international depository accession number ATCC ® 29233TM.
  • ATCC ® 29233TM an enzyme having significant perhydrotase activity has been isolated and sequenced from B. subtilis ATCC ® 29233TM and is provided as SEQ ID NO:12.
  • Clostridium thermocellum ATCC ® 27405TM refers to a strain of Clostridium thermocellum deposited to the American Type Culture Collection (ATCC ® ) having international depository accession number ATCC ® 27405TM.
  • the amino acid sequence of the enzyme having perhydrolase activity from C. thermocellum ATCC ® 27405TM is provided as SEQ ID NO;5.
  • Bacillus subtilis ATCC ® 6633TM refers to a bacterial eel! deposited to the American Type Culture Collection (ATCC ® ) having international depository accession number ATCC ® 6633TM.
  • Bacillus subtilis ATCC ® 6633TM has been reported to have cephalosporin acetylhydrolase activity (U.S. patent 6,465,233).
  • the amino acid sequence of the enzyme having perhydrolase activity from B. subtilis ATCC ® 6633TM is provided as SEQ ID NO;2.
  • Bacillus licheniformis ATCC ® 14580TM refers to a bacterial cell deposited to the American Type Culture Collection (ATCC ® ) having international depository accession number ATCC ® 14580TM. Bacillus licheniformis ATCC ® 14580TM has been reported to have cephalosporin acetyihydrolase activity. The amino acid sequence of the enzyme having perhydrolase activity from B. licheniformis ATCC ® 14580TM is provided as SEQ ID NO:3.
  • Bacillus pumilus PS213 refers to a bacterial cell reported to have acetyl xylan esterase activity (GENBANK ® AJ249957).
  • the amino acid sequence of the enzyme having perhydrolase activity from Bacillus pumilus PS213 is provided as SEQ ID NO:4.
  • Thermotoga neapolitana refers to a strain of Thermotoga neapolitana reported to have acetyl xylan esterase activity (GENBANK ® AAB70869).
  • the amino acid sequence of the enzyme having perhydrolase activity from Thermotoga neapolitana is provided as SEQ ID NO: 6.
  • Thermotoga maritime MSB8 refers to a bacterial cell reported to have acetyl xylan esterase activity (GENBANK ® NP_227893.1).
  • the amino acid sequence of the enzyme having perhydrolase activity from Thermotoga maritima MSB8 is provided as SEQ ID NO: 7.
  • Bacillus clausii KSM-K16 refers to a bacterial cell reported to have cephalospori ⁇ -C deacetylase activity (GENBANK ® YP__175265).
  • the amino acid sequence of the enzyme having perhydrolase activity from Bacillus clausii KSM-K16 is provided as SEQ ID NO: 1 1.
  • Thermoanearobacterium saccharolyticum refers to a bacterial strain reported to have acetyl xylan esterase activity (GENBANK ® S41858).
  • the amino acid sequence of the enzyme having perhydrolase activity from Thermoanearobacterium saccharolyticum is provided as SEQ ID NO: 13.
  • Thermotoga lettingae refers to a bacterial cell reported to have acetyl xylan esterase activity (GENBANK ® CP000812).
  • the deduced amino acid sequence of the enzyme having perhydrolase activity from Thermotoga lettingae is provided as SEQ ID NO: 14.
  • Thermotoga petrophila refers to a bacterial celi reported to have acetyl xylan esterase activity (GENBANK ® CP000702).
  • the deduced amino acid sequence of the enzyme having perhydrolase activity from Thermotoga lettingae is provided as SEQ ID NO: 15.
  • Thermotoga sp. RQ2 refers to a bacteria! cell reported to have acetyl xylan esterase activity (GENBANK ® CP000969). Two different acetyl xylan esterases have been identified from Thermotoga sp. RQ2 and are referred to herein as "RQ2(a)" (the deduced amino acid sequence provided as SEQ ID NO: 16) and B RQ2(b)" (the deduced amino acid sequence provided as SEQ ID NO: 17).
  • an "isolated nucleic acid molecule” and “isolated nucleic acid fragment” will be used interchangeably and refer to a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases.
  • An isolated nucleic acid molecule in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.
  • amino acid refers to the basic chemical structural unit of a protein or polypeptide.
  • the following abbreviations are used herein to identify specific amino acids: Three-Letter One-Letter
  • substantially similar refers to nucleic acid molecules wherein changes in one or more nucleotide bases results in the addition, substitution, or deletion of one or more amino acids, but does not affect the functional properties (i.e., perhydrolytic activity) of the protein encoded by the DNA sequence.
  • substantially similar also refers to an enzyme having an amino acid sequence that is at least 30%, preferably at least 33%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, yet even more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequences reported herein wherein the resulting enzyme retains the present functional properties (i.e., perhydroiytic activity).
  • “Substantially similar” may also refer to an enzyme having perhydroiytic activity encoded by nucleic acid molecules that hybridize under stringent conditions to the nucleic acid molecules reported herein. It is therefore understood that the invention encompasses more than the specific exemplary sequences.
  • a codon for the amino acid alanine, a hydrophobic amino acid may be substituted by a codon encoding another less hydrophobic residue (such as glycine) or a more hydrophobic residue (such as valine, leucine, or isoleucine).
  • a codon encoding another less hydrophobic residue such as glycine
  • a more hydrophobic residue such as valine, leucine, or isoleucine
  • changes which result in substitution of one negatively charged residue for another such as aspartic acid for glutamic acid
  • one positively charged residue for another such as lysine for arginine
  • substantially similar sequences are encompassed by the present invention.
  • substantially similar sequences are defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 65 0 C and washed with 2X SSC, 0.1% SDS followed by 0.1 X SSC 1 0.1% SDS, 65 0 C) with the sequences exemplified herein.
  • a nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single strand of the first molecule can anneal to the other molecule under appropriate conditions of temperature and solution ionic strength.
  • Hybridization and washing conditions are well known and exemplified in Sambrook, J. and Russell, D,, T. Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (2001). The conditions of temperature and ionic strength determine the "stringency" of the hybridization.
  • Stringency conditions can be adjusted to screen for moderateiy similar molecules, such as homologous sequences from distantly related organisms, to highly similar molecules, such as genes that duplicate functional enzymes from closely related organisms.
  • Post-hybridization washes typically determine stringency conditions.
  • One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45 0 C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50 0 C for 30 min.
  • a more preferred set of conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0,5% SDS was increased to 60 0 C.
  • compositions and methods employ an enzyme having perhydroiase activity encoded by isolated nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule encoding a polypeptide having perhydrolysis activity, said polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13; SEQ ID
  • Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible.
  • the appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences.
  • the relative stability (corresponding to higher Tm) of nucleic acid hybridizations decreases in the following order: RNA: RNA, DNA: RNA, DNA: DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating Tm have been derived (Sambrook and Russell, supra).
  • the length for a hybridizable nucleic acid is at least about 10 nucleotides.
  • a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides in length, more preferably at least about 20 nucleotides in length, even more preferably at least 30 nucleotides in length, even more preferably at least 300 nucleotides in length, and most preferably at least 800 nucleotides in length.
  • the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the probe.
  • the term “percent identity” is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
  • identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
  • Identity and “similarity” can be readily calculated by known methods, including but not limited to, methods described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputinq: informatics and Genome Projects (Smith, D.
  • Sequence alignments and percent identity caicuiations may be performed using the Megaiign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wl), the AlignX program of Vector NTI v. 7.0 (Informax, Inc., Bethesda, MD), or the EMBOSS Open Software Suite (EMBL-EBI; Rice et at., Trends in Genetics 16, (6):276-277 (2000)).
  • Multiple alignment of the sequences can be performed using the Clustal method (e.g., CLUSTALW; for example version 1.83) of alignment (Higgins and Sharp, CABIOS, 5:151-153 (1989); Higgins et al., Nucleic Acids Res.
  • matrix Gonnet (e.g. Gonnet250)
  • protein ENDGAP -1
  • a fast or slow alignment is used with the default settings where a slow alignment is preferred.
  • suitable isolated nucleic acid molecules encode a polypeptide having an amino acid sequence that is at least about 30%, preferably at least 33%, preferably at least 40%, preferably at least 50%, preferably at least 60%, more preferably at least 70%, more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences reported herein.
  • Suitable nucleic acid molecules not only have the above homologies, but also typically encode a polypeptide having about 300 to about 340 amino acids, more preferably about 310 to about 330 amino acids, and most preferably about 318 amino acids.
  • the terms "signature motif, "CE-7 signature motif, and "diagnostic motif” refer to conserved structures shared among a family of enzymes having a defined activity.
  • the signature motif can be used to define and/or identify the family of structurally related enzymes having similar enzymatic activity for a defined family of substrates.
  • the signature motif can be a single contiguous amino acid sequence or a coliection of discontiguous, conserved motifs that together form the signature motif.
  • the conserved motif(s) is represented by an amino acid sequence.
  • the present enzymes having perhydrolysis activity (“perhydrolases") belong to the family of CE-7 carbohydrate esterases (DiCosimo et a/., supra).
  • the phrase "enzyme is structurally classified as a CE-7 enzyme” or "CE-7 perhydrolase” will be used to refer to enzymes having perhydrolysis activity which are structurally classified as a CE-7 carbohydrate esterase.
  • This family of enzymes can be defined by the presence of a signature motif (Vincent et ai., supra).
  • the signature motif for CE-7 esterases comprises three conserved motifs (residue position numbering relative to reference sequence SEQ ID NO:1): a) Arg118-G!y119-Gln120; b) Gly179-Xaa180-Ser181-Gln182-Gly183; and c) His298-Glu299.
  • the Xaa at amino acid residue position 180 is glycine, alanine, proline, tryptophan, or threonine. Two of the three amino acid residues belonging to the catalytic triad are in bold. In one embodiment, the Xaa at amino acid residue position 180 is selected from the group consisting of glycine, alanine, proline, tryptophan, and threonine.
  • the conserved motifs within the CE-7 carbohydrate esterase family indicates the presence of an additional conserved motif (LXD at amino acid positions 267-269 of SEQ ID NO:1 ) that may be used to further define a perhydrolase belonging to the CE-7 carbohydrate esterase family.
  • the signature motif defined above includes a fourth conserved motif defined as: Leu267-Xaa268-Asp269.
  • the Xaa at amino acid residue position 268 is typically isoleucine, valine, or methionine.
  • the fourth motif includes the aspartic acid residue (bold) belonging to the catalytic triad (Ser181-Asp269-His298).
  • a number of well-known global alignment algorithms may be used to align two or more amino acid sequences representing enzymes having perhydrolase activity to determine if the enzyme is comprised of the present signature motif.
  • the aligned seque ⁇ ce(s) are compared to the reference sequence (SEQ ID NO:1) to determine the existence of the signature motif.
  • a CLUSTAL alignment (such as CLUSTALW) using a reference amino acid sequence (as used herein the perhydrolase sequence (SEQ ID NO:1) from the Bacillus subtilis ATCC ® 31954TM) is used to identify perhydrolases belonging to the CE-7 esterase family.
  • the relative numbering of the conserved amino acid residues is based on the residue numbering of the reference amino acid sequence to account for small insertions or deletions (for example, five amino acids of less) within the aligned sequence.
  • Examples of other suitable algorithms that may be used to identify sequences comprising the present signature motif (when compared to the reference sequence) include, but are not limited to, Needteman and Wunsch (J. MoI. Biol. 48, 443-453 (1970); a global alignment tool) and Smith-Waterman (J. MoI. Biol. 147: 195-197 (1981); a local alignment tool).
  • a Smith-Waterman alignment is implemented using default parameters.
  • suitable perhydrolases include enzymes comprising the CE-7 signature motif and at least 30%, preferably at least 33%, more preferably at least 40%, even more preferably at least 42%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to SEQ ID NO: 1.
  • a contiguous amino acid sequence comprising the region encompassing the conserved motifs may also be used to identify CE-7 family members.
  • cognate degeneracy refers to the nature of the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. Accordingly, the present invention relates to any nucleic acid molecule that encodes all or a substantial portion of the amino acid sequences encoding the present microbial polypeptide.
  • the skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.
  • codon optimized refers to genes or coding regions of nucleic acid molecules for transformation of various hosts, refers to the alteration of codons in the gene or coding regions of the nucleic acid molecules to reflect the typical codon usage of the host organism without altering the polypeptide for which the DNA codes.
  • “synthetic genes” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments that are then enzymatically assembled to construct the entire gene.
  • “Chemically synthesized”, as pertaining to a DNA sequence means that the component nucleotides were assembled in vitro. Manual chemical synthesis of DNA may be accomplished using well- established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the genes can be tailored for optima! gene expression based on optimization of nucleotide sequences to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.
  • gene refers to a nucleic acid molecule that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence.
  • “Native gene” refers to a gene as found in nature with its own regulatory sequences.
  • “Chimeric gene” refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different from that found in nature.
  • Endogenous gene refers to a native gene in its natural location in the genome of an organism.
  • a “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer.
  • Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes.
  • a “transgene” is a gene that has been introduced into the genome by a transformation procedure.
  • coding sequence refers to a DNA sequence that codes for a specific amino acid sequence.
  • Suitable regulatory sequences refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, RNA processing site, effector binding site and stem-loop structure.
  • promoter refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA.
  • a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed at most times are commonly referred to as “constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.
  • the "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenytation recognition sequences (normally limited to eukaryotes) and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression.
  • the polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts (normally limited to eukaryotes) to the 3' end of the mRNA precursor.
  • operably linked refers to the association of nucleic acid sequences on a single nucleic acid molecule so that the function of one is affected by the other.
  • a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence, i.e., that the coding sequence is under the transcriptional control of the promoter.
  • Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.
  • the term "expression” refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid molecule of the invention. Expression may also refer to translation of mRNA into a polypeptide.
  • transformation refers to the transfer of a nucleic acid molecule into the genome of a host organism, resulting in genetically stable inheritance.
  • the host cell's genome includes chromosomal and extrachromosoma! (e.g. plasmid) genes.
  • Host organisms containing the transformed nucleic acid molecules are referred to as “transgenic” or “recombinant” or “transformed” organisms.
  • plasmid refers to an extrachromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular doubie- stranded DNA molecules.
  • Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell.
  • Transformation cassette refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell.
  • Expression cassette refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
  • sequence analysis software refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences.
  • Sequence analysis software may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to, the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wl), BLASTP 1 BLASTN, BLASTX (Altschu! et al., J. MoI. Biol. 215:403-410 (1990), and DNASTAR (DNASTAR, Inc. 1228 S. Park St.
  • default values will mean any set of values or parameters set by the software manufacturer that originally load with the software when first initialized.
  • biological contaminants refers to one or more unwanted and/or pathogenic biological entities including, but not limited to, microorganisms, spores, viruses, prions, and mixtures thereof.
  • the process produces an efficacious concentration of at least one percarboxylic acid useful to reduce and/or eliminate the presence of the viable biologica! contaminants.
  • the biological contaminant is a viable pathogenic microorganism.
  • the term “disinfect” refers to the process of destruction of or prevention of the growth of biological contaminants
  • the term “disinfectant” refers to an agent that disinfects by destroying, neutralizing, or inhibiting the growth of biological contaminants. Typically, disinfectants are used to treat inanimate objects or surfaces.
  • the term “disinfect” refers to the process of destruction of or prevention of the growth of biological contaminants.
  • the term “disinfectant” refers to an agent that disinfects by destroying, neutralizing, or inhibiting the growth of biological contaminants. Typically, disinfectants are used to treat inanimate objects or surfaces.
  • disinfection refers to the act or process of disinfecting.
  • antiseptic refers to a chemical agent that inhibits the growth of disease- carrying microorganisms. In one aspect, the biological contaminants are pathogenic microorganisms.
  • sanitary means of or relating to the restoration or preservation of health, typically by removing, preventing or controlling an agent that may be injurious to health.
  • sanitize means to make sanitary.
  • sanitizer refers to a sanitizing agent.
  • cleaning refers to the act or process of sanitizing.
  • virucide refers to an agent that inhibits or destroys viruses, and is synonymous with "viricide”.
  • An agent that exhibits the ability to inhibit or destroy viruses is described as having "virucidal” activity.
  • Peracids can have virucidal activity.
  • Typical alternative virucides known in the art which may be suitable for use with the present invention include, for example, alcohols, ethers, chloroform, formaldehyde, phenols, beta propiolactone, iodine, chlorine, mercury salts, hydroxylamine, ethylene oxide, ethylene glycol, quaternary ammonium compounds, enzymes, and detergents.
  • biocide refers to a chemical agent, typically broad spectrum, which inactivates or destroys microorganisms.
  • a chemical agent that exhibits the ability to inactivate or destroy microorganisms is described as having "biocidal” activity.
  • Peracids can have biocidal activity.
  • Typical alternative biocides known in the art, which may be suitable for use in the present invention include, for example, chlorine, chlorine dioxide, chloroisocyanurates, hypochlorites, ozone, acrolein, amines, chlorinated phenoiics, copper salts, orga ⁇ o-sufphur compounds, and quaternary ammonium salts.
  • the phrase "minimum biocidal concentration” refers to the minimum concentration of a biocidal agent that, for a specific contact time, will produce a desired lethal, irreversible reduction in the viable population of the targeted microorganisms.
  • the effectiveness can be measured by the iog 10 reduction in viable microorganisms after treatment
  • the targeted reduction in viable microorganisms after treatment is at least a 3-log reduction, more preferably at least a 4-log reduction, and most preferably at least a 5-iog reduction.
  • the minimum biocidal concentration is at least a 6-log reduction in viable microbial cells.
  • peroxygen source and “source of peroxygen” refer to compounds capable of providing hydrogen peroxide at a concentration of about 1 mM or more when in an aqueous solution including, but not limited to, hydrogen peroxide, hydrogen peroxide adducts (e.g., urea- hydrogen peroxide adduct (carbamide peroxide)), perborates, and percarbonates.
  • concentration of the hydrogen peroxide provided by the peroxygen compound in the aqueous reaction formulation is initially at least 1 mM or more upon combining the reaction components. In one embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is at least 10 mM.
  • the hydrogen peroxide concentration in the aqueous reaction formulation is at ieast 100 mM. In another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is at least 200 mM. In another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is 500 mM or more. In yet another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is 1000 mM or more.
  • the molar ratio of the hydrogen peroxide to enzyme substrate, e.g. triglyceride, (H ⁇ O ⁇ : substrate) in the aqueous reaction formulation may be from about 0.002 to 20, preferably about 0.1 to 10, and most preferably about 0.5 to 5.
  • oligosaccharide compounds containing between 2 and at least 24 monosaccharide units linked by glycosidic linkages.
  • the term “monosaccharide” refers to a compound of empirical formula (CH 2 O) n , where n>3, the carbon skeleton is unbranched, each carbon atom except one contains a hydroxyl group, and the remaining carbon atom is an aldehyde or ketone at carbon atom 2.
  • the term “monosaccharide” also refers to intracellular cyclic hemiaceta! or hemiketal forms.
  • the term “excipient” refers to an inactive substance used to stabilize the active ingredient in a formulation, such as the storage stability of the active ingredient. Excipients are also sometimes used to bulk up formulations that contain active ingredients.
  • the "active ingredient” is an enzyme catalyst comprising at least one enzyme having perhydrolysis activity. In one embodiment, the active ingredient is at least one CE-7 carbohydrate esterase having perhydrolysis activity.
  • oligosaccharide excipient means an oligosaccharide that, when added to an aqueous enzyme solution, improves recovery/retention of active enzyme ⁇ i.e., perhydrolase activity) after spray drying and/or improves storage stability of the resulting spray-dried enzyme powder or a formulation of the enzyme powder and a carboxylic acid ester.
  • the addition of the oligosaccharide excipient prior to spray drying improves the storage stability of the enzyme when stored in the carboxylic acid ester (/.e., a storage mixture substantially free of water).
  • the carboxylic acid ester may contain a very low concentration of water, for example, triacetin typically has between 180 ppm and 300 ppm of water.
  • the phrase "substantially free of water” will refer to a concentration of water in a mixture of the enzyme powder and the carboxylic acid ester that does not adversely impact the storage stability of enzyme powder when present in the carboxylic acid ester.
  • "substantially free of water” may mean less than 2000 ppm, preferably less than 1000 ppm, more preferably less than 500 ppm, and even more preferably less than 250 ppm of water in the formulation comprising the enzyme powder and the carboxylic acid ester.
  • an enzyme powder comprising a formulation of at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity, at least one excipient, and optionally at least one surfactant.
  • the enzyme powder is formed by spray drying.
  • the at least one excipient is an oligosaccharide excipient has a number average molecular weight of at least about 1250 and a weight average molecular weight of at feast about 9000.
  • the at least one enzyme can be any of the CE-7 carbohydrate esterases described herein or can be any of the CE-7 carbohydrate esterases described in co-owned, copending Published U.S. Patent Application Nos. 2008/0176299 and 2009/0005590 (each incorporated herein by reference in its entirety).
  • the at least one enzyme is selected from the group consisting of SEQ ID NOs: 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, and 25.
  • the at least one enzyme is present in the spray-dried formulation in an amount in a range of from about 5 wt % to about 75 wt% based on the dry weight of the spray-dried formulation.
  • a preferred wt % range of enzyme in the spray-dried formulation is from about 10 wt% to 50 wt%, and a more preferred wt % range of enzyme in the spray-dried formulation is from about 20 wt% to 33 wt%
  • the spray-dried formulation further comprises at least one oligosaccharide excipient.
  • the at least one oligosaccharide excipient has a number average molecular weight of at least about 1250 and a weight average molecular weight of at least about 9000.
  • the oligosaccharide excipient has a number average molecular weight of at least about 1700 and a weight average molecular weight of at least about 15000.
  • oligosaccharides useful in the present invention include, but are not limited to, maltodextrin, xylan, ma ⁇ nan, fucoidan, galactoma ⁇ nan, chitosan, raffi ⁇ ose, stachyose, pectin, inuli ⁇ , levan, grami ⁇ an, and amyiopecti ⁇ , sucrose, lactulose, lactose, maltose, trehalose, cellobiose, nigerotriose, maltotriose, melezitose, maltotriuiose, raffi ⁇ ose, kestose, and mixtures thereof.
  • Oligosaccharide-based excipie ⁇ ts useful in the present invention include, but are not limited to, water-soluble non-ionic cellulose ethers, such as hydroxymethyl-cellulose and hydroxypropylmethylcellulose, and mixtures thereof.
  • the excipient is present in the formulation in an amount in a range of from about 95 wt% to about 25 wt% based on the dry weight of the spray-dried formulation.
  • a preferred wt % range of excipient in the spray-dried formulation is from about 90 wt% to 50 wt%, and a more preferred wt % range of excipient in the spray-dried formulation is from about 80 wt% to 67 wt%.
  • the formulation further comprises at least one surfactant.
  • useful surfactants include, but are not limited to, ionic and no ⁇ ionic surfactants or wetting agents, such as ethoxyiated castor oil, poiygiycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or ethoxyiated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, sodium docusate, sodium laurylsulfate, cholic acid or derivatives thereof, lecithins, phospholipids, block copolymers of ethylene glycol and propylene glycol, and non-ionic organosilicones.
  • the surfactant is a polyoxyethyiene sorbitan fatty ester, with polysorbate 80 being more preferred.
  • the surfactant is present in an amount in a range of from about 5 wt% to 0.1 wt% based on the weight of protein present in the spray dried formulation, preferably from about 2 wt% to 0.5 wt% based on the weight of protein present in the spray dried formulation.
  • the spray dried formulation may additionally comprise one or more buffers (such as sodium and/or potassium salts of bicarbonate, citrate, acetate, phosphate, pyrophosphate, methylphosphonate, succinate, maiate, fumarate, tartrate, or maleate), and an enzyme stabilizer (e.g., ethyie ⁇ ediaminetetraacetic acid, (i-hydroxyethylidene)bisphosphonic acid).
  • buffers such as sodium and/or potassium salts of bicarbonate, citrate, acetate, phosphate, pyrophosphate, methylphosphonate, succinate, maiate, fumarate, tartrate, or maleate
  • an enzyme stabilizer e.g., ethyie ⁇ ediaminetetraacetic acid, (i-hydroxyethylidene)bisphosphonic acid.
  • spray drying consists of bringing together a highly dispersed liquid and a sufficient volume of hot air to produce evaporation and drying of the liquid droplets.
  • feed is sprayed into a current of warm filtered air that evaporates the solvent and conveys the dried product to a collector.
  • the spent air is then exhausted with the solvent.
  • apparatus may be used to provide the desired product. For example, commercial spray dryers manufactured by Buchi Ltd. (Postfach, Switzerland) or GEA Niro Corp. (Copenhagen, Denmark) will effectively produce particles of desired size.
  • these spray dryers may be modified or customized for specialized applications, such as the simultaneous spraying of two solutions using a double nozzle technique. More specifically, a water-in-oil emulsion can be atomized from one nozzle and a solution containing an anti- adherent such as mannito! can be co-atomized from a second nozzle. In other cases it may be desirable to push the feed solution though a custom designed nozzle using a high pressure liquid chromatography (HPLC) pump.
  • HPLC high pressure liquid chromatography
  • the temperature of both the inlet and outlet of the gas used to dry the sprayed material is such that it does not cause degradation of the enzyme in the sprayed material.
  • Such temperatures are typically determined experimentally, although generally, the inlet temperature will range from about 50 0 C to about 225 0 C 1 while the outlet temperature will range from about 30 0 C to about 150 0 C.
  • Preferred parameters include atomization pressures ranging from about 20-150 psi (0.14 MPa - 1.03 MPa), and preferably from about 30- 40 to 100 psi (0.21-0.28 MPa to 0.69 MPa).
  • the atomization pressure employed will be one of the following (MPa) 0.14, 0.21, 0.28, 0.34, 0.41 , 0.48, 0.55, 0.62, 0.69, 0.76, 0.83 or above.
  • the enzyme powder or a formulation of the enzyme powder in carboxylic acid ester substantially retains its enzymatic activity for an extended period of time when stored at ambient temperature.
  • the enzyme powder or a formulation of the spray-dried enzyme powder in carboxylic acid ester substantially retains its enzymatic activity at elevated temperatures for short periods of time.
  • substantially retains its enzymatic activity is meant that the spray-dried enzyme powder or a formulation of the spray-dried enzyme powder in carboxylic acid ester retains at least about 75 percent of the enzyme activity of the enzyme in the spray-dried enzyme powder or a formulation of the spray-dried enzyme powder after an extended storage period at ambient temperature and/or after a short storage period at an elevated temperature (above ambient temperature) in a formulation comprised of a carboxylic acid ester and the enzyme powder as compared to the initial enzyme activity of the enzyme powder prior to the preparation of a formulation comprised of the carboxy ⁇ c acid ester and the enzyme powder.
  • the extended storage period is a period of time of from about one year to about two years at ambient temperature
  • the short storage period is at an elevated temperature for a period of time of from when the formulation comprised of a carboxylic acid ester and the enzyme powder is produced at 40 0 C to about eight weeks at 40 0 C.
  • the elevated temperature is in a range of from about 30 °C to about 52 0 C. In a preferred embodiment, the elevated temperature is in a range of from about 30 0 C to about 40 0 C.
  • the spray-dried enzyme powder has at least 75 percent of the enzyme activity of the at least one enzyme after eight weeks storage at 40 °C in a formulation comprised of a carboxylic acid ester and the enzyme powder as compared to the initial enzyme activity of the enzyme powder prior to the preparation of a formulation comprised of the carboxyiic acid ester and the enzyme powder at 40 0 C.
  • the enzyme powder has at least 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent of the enzyme activity of the at least one enzyme after eight weeks storage at 40 0 C in a formulation comprised of a carboxylic acid ester and the enzyme powder as compared to the initial enzyme activity of the enzyme powder prior to the preparation of a formulation comprised of the carboxylic acid ester and the enzyme powder at 40 0 C.
  • perhydrolysis activity is measured as described in Example 8-13, infra, but any method of measuring perhydrolysis activity can be used in the practice of the present invention.
  • a buffer having a buffering capacity in a pH range of from about 5.5 to about 9.5 to the formulation comprised of the carboxylic acid ester and the spray-dried enzyme powder.
  • Suitable buffer for use in the formuiation may include, but is not iimited to, sodium sa!t, potassium salt, or mixtures of sodium or potassium salts of bicarbonate, pyrophosphate, phosphate, methyiphosphonate, citrate, acetate, malate, fumarate, tartrate maleate or succinate.
  • Preferred buffers for use in the formulation comprised of the carboxylic acid ester and the spray-dried enzyme powder include the sodium salt, potassium salt, or mixtures of sodium or potassium salts of bicarbonate, phosphate, methyiphosphonate, or citrate.
  • the buffer may be present in an amount in a range of from about 0.01 wt% to about 50 wt% based on the weight of carboxylic acid ester in the formulation comprised of carboxylic acid ester and enzyme powder.
  • the buffer may be present in a more preferred range of from about 0.10 % to about 10 % based on the weight of carboxylic acid ester in the formulation comprised of carboxylic acid ester and enzyme powder.
  • the comparison between perhydrolysis activities of the enzyme is determined as between (a) an enzyme powder which retains at least 75 percent of the perhydrolysis activity of the at least one enzyme after eight weeks storage at 40 0 C in a formulation comprised of a carboxylic acid ester, a buffer having a buffering capacity in a pH range of from about 5.5 to about 9.5, and the enzyme powder and (b) the initial perhydrolysis activity of the enzyme powder prior to the preparation of a formuiation comprised of the carboxyiic acid ester, the buffer having a buffering capacity in a pH range of from about 5.5 to about 9.5, and the enzyme powder.
  • the enzyme powder be stored as a formulation in the organic compound that is a substrate for the at least one enzyme, such as triacetin.
  • triacetin is normally hydroiyzed in aqueous solution by a CE-7 carbohydrate esterase to produce diacetin and acetic acid, and the production of acetic acid results in a decrease in the pH of the reaction mixture.
  • One requirement for long term storage stability of the enzyme in triacetin is that there not be significant reaction of the triacetin with any water that might be present in the triacetin; the specification for water content in one commercial triacetin (supplied by Tessenderlo Group, Brussels, Belgium) is 0.03 wt% water (300 ppm).
  • any hydrolysis of triacetin that occurs during storage of the enzyme in triacetin would produce acetic acid, which could result in a decrease in activity or inactivation of the perhydrolysis activity of the CE-7 carbohydrate esterases; the perhydrolase activity of the CE-7 carbohydrate esterases is typically inactivated at or below a pH of 5.0 (see U.S. Patent Application No. 12/539,025 to DiCosimo, R., et a/.).
  • the oligosaccharide excipient selected for use in the present application must provide stability of the enzyme in the organic substrate for the enzyme under conditions where acetic acid might be generated due to the presence of low concentrations of water in the formuiation.
  • a process is provided to produce an aqueous formulation comprising a peracid by reacting one or more carboxylic acid esters with source of peroxygen (hydrogen peroxide, sodium perborate or sodium percarbonate) in the presence of an enzyme catalyst having perhydrolysis activity.
  • the enzyme catalyst comprises at ⁇ east one enzyme having perhydrolysis activity, wherein said enzyme is structurally classified as a member of the CE-7 carbohydrate esterase family (CE-7; see Coutinho, P.M., Henrissat, B., supra).
  • the perhydrolase catalyst is structurally classified as a cephalosporin C deacetylase.
  • the perhydrolase catalyst is structurally classified as an acetyl xylan esterase.
  • the perhydrolase catalyst comprises an enzyme having perhydrolysis activity and a signature motif comprising: a) an RGQ motif as amino acid residues 1 18-120; b) a GXSQG motif at amino acid residues 179-183; and c) an HE motif as amino acid residues 298-299 when aligned to reference sequence SEQ ID NO:1 using CLUSTALW.
  • the signature motif additional comprises a fourth conserved motif defined as an LXD motif at amino acid residues 267- 269 when aligned to reference sequence SEQ ID NO:1 using CLUSTALW,
  • the perhydroiase catalyst comprises an enzyme having the present signature motif and at least 30% amino acid to SEQ ID NO:1.
  • the perhydroiase catalyst comprises an enzyme having perhydroiase activity selected from the group consisting of SEQ ID NOs: 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 19, 20, 21 , 22, 23, 24, and 25.
  • the perhydroiase catalyst comprises an enzyme having at least 40% amino acid identity to a contiguous signature motif defined as SEQ ID NO: 18 wherein the conserved motifs described above (i.e., RGQ, GXSQG, and HE, and optionally, LXD) are conserved.
  • the perhydroiase catalyst comprises an enzyme having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21 , 22, 23, 24, and 25, wherein said enzyme may have one or more additions, deletions, or substitutions so long as the signature motif is conserved and perhydroiase activity is retained.
  • Suitable carboxylic acid ester substrates may include esters provided by the following formula:
  • X an ester group of the formula R 6 C(O)O
  • R 5 a C1 to C6 linear, branched or cyclic hydrocarbyl moiety optionally substituted with hydroxy!
  • suitable substrates may also include esters of the formula:
  • suitable carboxylic acid ester substrates may include glycerides of the formula:
  • R 1 C1 to C7 straight chain or branched chain alkyl optionaily substituted with a hydroxy! or a C1 to C4 alkoxy group and R3 and R 4 are individually H or R 1 C(O).
  • Rg is C1 to C7 linear hydrocarbyl moiety, optionally substituted with hydroxy! groups or C1 to C4 alkoxy groups, optionally comprising one or more ether linkages.
  • R 6 is C2 to C7 linear hydrocarbyl moiety, optionally substituted with hydroxy! groups, and/or optionally comprising one or more ether linkages.
  • suitable carboxyiic acid ester substrates may also include acetylated saccharides selected from the group consisting of acetylated mono-, di-, and polysaccharides. In preferred embodiments, the acetylated saccharides include acetylated mono- , di-, and polysaccharides.
  • the acetylated saccharides are selected from the group consisting of acetylated xylan, fragments of acetyiated xylan, acetylated xylose(such as xylose tetraacetate), acetylated glucose (such as glucose pentaacetate), ⁇ -D-ribofuranose-1 ,2,3,5-tetraacetate, tri-O-acetyl-D-galactal, tri-O-acetyl-D-glucal, and acetylated cellulose.
  • the acetylated saccharide is selected from the group consisting of ⁇ -D- ribofuranose-1 ,2,3,5-tetraacetate, tri-O-acetyl-D-gaiactal, tri-O-acetyl-D-glucai, and acetylated cellulose.
  • acetylated carbohydrates may be suitable substrates for generating percarboxylic acids using the present methods and systems (Ae., in the presence of a peroxygen source).
  • the carboxyiic acid ester substrate may be monoacetin; triacetin; monopropionin; dipropionin; tripropionin; monobutyrin; dibutyrin; tributyrin; glucose pentaacetate; xylose tetraacetate; acetylated xyian; acetylated xylan fragments; ⁇ -D-ribofuranose-1 ,2,3,5-tetraacetate; tri-O- acetyl-D-galactal; tri-O-acetyl-glucal; propylene glycol diacetate; ethylene glycol diacetate; monoesters or diesters of 1 ,2-ethanediol; 1 ,2-propanediol; 1 ,3-propanediol; 1 ,2-butanediol; 1 ,3-butanediol; 2,3-butanediol; 1 ,4
  • the substrate comprises triacetin.
  • the carboxyiic acid ester is present in the reaction formulation at a concentration sufficient to produce the desired concentration of peracid upon enzyme-catalyzed perhydrolysis.
  • the carboxyiic acid ester need not be completely soluble in the reaction formulation, but has sufficient solubility to permit conversion of the ester by the perhydrolase catalyst to the corresponding peracid.
  • the carboxyiic acid ester is present in the reaction formulation at a concentration of 0.05 wt % to 40 wt % of the reaction formulation, preferably at a concentration of 0.1 wt % to 20 wt % of the reaction formulation, and more preferably at a concentration of 0.5 wt % to 10 wt % of the reaction formulation.
  • the peroxygen source may include, but is not limited to, hydrogen peroxide, hydrogen peroxide adducts (e.g., urea-hydrogen peroxide adduct (carbamide peroxide) ⁇ perborate salts and percarbonate salts.
  • the concentration of peroxygen compound in the reaction formulation may range from 0.0033 wt % to about 50 wt %, preferably from 0,033 wt % to about 40 wt %, more preferably from 0.33 wt % to about 30 wt %,
  • perhydrolase catalysts whole cells, permeabilized whole cells, and partially purified whole cell extracts
  • catalase activity EC 1.1 1.1.6
  • Catalases catalyze the conversion of hydrogen peroxide into oxygen and water.
  • the perhydrolysis catalyst lacks catalase activity.
  • a catalase inhibitor is added to the reaction formulation. Examples of catalase inhibitors include, but are not limited to, sodium azide and hydroxylamine sulfate.
  • One of skill in the art can adjust the concentration of catalase inhibitor as needed.
  • the concentration of the catalase inhibitor typically ranges from 0.1 mM to about 1 M; preferably about 1 mM to about 50 mM; more preferably from about 1 mM to about 20 mM.
  • sodium azide concentration typically ranges from about 20 m M to about 60 mM whife hydroxylamine sulfate is concentration is typically about 0.5 mM to about 30 mM, preferably about 10 mM.
  • the enzyme catalyst lacks significant catalase activity or is engineered to decrease or eliminate catalase activity.
  • the catalase activity in a host cell can be down-regulated or eliminated by disrupting expression of the gene(s) responsible for the catalase activity using well known techniques including, but not limited to, transposon mutagenesis, RNA antisense expression, targeted mutagenesis, and random mutagenesis.
  • the gene(s) encoding the endogenous catalase activity are down-reguiated or disrupted (i.e. knocked-out).
  • a "disrupted" gene is one where the activity and/or function of the protein encoded by the modified gene is no longer present.
  • Means to disrupt a gene are weli-known in the art and may include, but are not limited to, insertions, deletions, or mutations to the gene so long as the activity and/or function of the corresponding protein is no longer present.
  • the production host is an E. coli production host comprising a disrupted catalase gene selected from the group consisting of katG and katE (see Published U.S. Patent Application No. 20080176299).
  • the production host is an E. coli strain comprising a down-regulation and/or disruption in both /cafcji and a katE catalase genes.
  • the concentration of the catalyst in the aqueous reaction formulation depends on the specific catalytic activity of the catalyst, and is chosen to obtain the desired rate of reaction.
  • the weight of catalyst in perhydrolysis reactions typically ranges from 0.0001 mg to 10 mg per mL of total reaction volume, preferably from 0.001 mg to 2.0 mg per mL.
  • the catalyst may also be immobilized on a soluble or insoluble support using methods well-known to those skilled in the art; see for example, Immobijization.pf Enzymes and Cells; Gordon F. Bickerstaff, Editor; Humana Press, Totowa, NJ, USA; 1997.
  • the use of immobilized catalysts permits the recovery and reuse of the catalyst in subsequent reactions.
  • the enzyme catalyst may be in the form of whole microbial cells, permeabilized microbial cells, microbial cell extracts, partially- purified or purified enzymes, and mixtures thereof.
  • the concentration of peracid generated by the combination of chemical perhydrolysis and enzymatic perhydrolysis of the carboxylic acid ester is sufficient to provide an effective concentration of peracid for bleaching or disinfection at a desired pH.
  • the present methods provide combinations of enzymes and enzyme substrates to produce the desired effective concentration of peracid, where, in the absence of added enzyme, there is a significantly lower concentration of peracid produced. Although there may in some cases be substantia!
  • the concentration of peracid generated (such as peracetic acid) by the perhydrolysis of at least one carboxylic acid ester is at least about 20 ppm, preferably at least 100 ppm, more preferably at least about 200 ppm peracid, more preferably at least 300 ppm, more preferably at feast 500 ppm, more preferably at least 700 ppm, more preferably at least about 1000 ppm peracid, most preferably at least 2000 ppm peracid within 10 minutes, preferably within 5 minutes, more preferably within 1 minute of initiating the perhydrolysis reaction.
  • the product formulation comprising the peracid may be optionally diluted with water, or a solution predominantly comprised of water, to produce a formulation with the desired lower concentration of peracid.
  • the reaction time required to produce the desired concentration of peracid is not greater than about two hours, preferably not greater than about 30 minutes, more preferably not greater than about 10 minutes, and most preferably in about 5 minutes or less.
  • a hard surface or inanimate object contaminated with a biological contaminant(s) is contacted with the peracid formed in accordance with the processes described herein within about 5 minutes to about 168 hours of combining said reaction components, or within about 5 minutes to about 48 hours, or within about 5 minutes to 2 hours of combining said reaction components, or any such time interval therein.
  • the peroxycarboxylic acid formed in accordance with the processes describe herein is used in a laundry care application wherein the peroxycarboxylic acid is contacted with at least one article of clothing or textile to provide a benefit, such as disinfecting, bleaching, destaining, sanitizing, deodorizing or a combination thereof.
  • the peroxycarboxylic acid may be used in a variety of laundry care products including, but not limited to, textile pre- wash treatments, laundry detergents, stain removers, bleaching compositions, deodorizing compositions, and rinsing agents.
  • the present process to produce a peroxycarboxyiic acid for a target surface is conducted in situ.
  • the term "contacting an article of clothing or textile” means that the article of clothing or textile is exposed to a formulation disclosed herein.
  • the formulation may be used to treat fabric including, but not limited to, liquid, solids, gel, paste, bars, tablets, spray, foam, powder, or granules and can be delivered via hand dosing, unit dosing, dosing from a substrate, spraying and automatic dosing from a laundry washing or drying machine.
  • Granular compositions can also be in compact form; liquid compositions can also be in a concentrated form.
  • the formulation can further contain components typical to laundry detergents.
  • typical components included, but are not limited to, surfactants, bleaching agents, bleach activators, additional enzymes, suds suppressors, dtspersants, lime-soap dispersants, soil suspension and anti-redeposition agents, softening agents, corrosion inhibitors, tarnish inhibitors, germicides, pH adjusting agents, non-builder alkalinity sources, chelating agents, organic and/or inorganic fillers, solvents, hydrotropes, optical brighteners, dyes, and perfumes.
  • formulations disclosed herein can also be used as detergent additive products in solid or liquid form. Such additive products are intended to supplement or boost the performance of conventional detergent compositions and can be added at any stage of the cleaning process.
  • the concentration of peracid generated (e.g., peracetic acid) by the perhydrolysis of at least one carboxylic acid ester may be at least about 2 ppm, preferably at least 20 ppm, preferably at least 100 ppm, and more preferably at least about 200 ppm peracid.
  • the concentration of peracid generated (e.g., peracetic acid) by the perhydrolysis of at least one carboxyiic acid ester may be at ieast about 2 ppm, more preferably at ieast 20 ppm, more preferably at least 200 ppm, more preferably at least 500 ppm, more preferably at least 700 ppm, more preferably at least about 1000 ppm peracid, most preferably at least 2000 ppm peracid within 10 minutes, preferably within 5 minutes, and most preferably within 1 minute of initiating the perhydrolysis reaction.
  • the product mixture comprising the peracid may be optionally diluted with water, or a solution predominantly comprised of water, to produce a mixture with the desired lower concentration of peracid.
  • the reaction time required to produce the desired concentration of peracid is not greater than about two hours, preferably not greater than about 30 minutes, more preferably not greater than about 10 minutes, even more preferably not greater than about 5 minutes, and most preferably in about
  • the temperature of the reaction is chosen to control both the reaction rate and the stability of the enzyme catalyst activity.
  • the temperature of the reaction may range from just above the freezing point of the reaction formulation (approximately 0 0 C) to about 95 0 C, with a preferred range of reaction temperature of from about 5 0 C to about 55 0 C.
  • the pH of the final reaction formulation containing peracid is from about
  • the pH of the reaction formulation is acidic (pH ⁇ 7).
  • the pH of the reaction, and of the final reaction formulation may optionally be controlled by the addition of a suitable buffer, including, but not limited to, bicarbonate, pyrophosphate, phosphate, methylphosphonate, citrate, acetate, malate, fumarate, tartrate maleate or succinate.
  • the concentration of buffer, when employed, is typically from 0.1 mM to 1.0 M, preferably from 1 mM to 300 mM, most preferably from 10 mM to 10O mM.
  • the enzymatic perhydrolysis reaction formulation may contain an organic solvent that acts as a dispersant to enhance the rate of dissolution of the carboxyiic acid ester in the reaction formulation.
  • organic solvents include, but are not limited to, propylene glycol methy! ether, acetone, cyclohexanone, diethylene glycol butyl ether, tripropylene glycol methy! ether, diethylene glycol methyl ether, propylene glycol butyl ether, di propylene glycol methyl ether, cyclohexanol, benzyl alcohol, isopropanol, ethanol, propylene glycol, and mixtures thereof.
  • the enzymatic perhydrolysis product may contain additional components that provide desirable functionality.
  • additional components include, but are not limited to, buffers, detergent builders, thickening agents, emulsifiers, surfactants, wetting agents, corrosion inhibitors (such as benzotriazoie), enzyme stabilizers, and peroxide stabilizers (e.g., metal ion chelating agents).
  • corrosion inhibitors such as benzotriazoie
  • enzyme stabilizers such as enzyme stabilizers
  • peroxide stabilizers e.g., metal ion chelating agents.
  • emulsifiers include, but are not limited to polyvinyl alcohol or polyvinylpyrrolidone.
  • thickening agents include, but are not limited to, LAPONITE ® RD, corn starch, PVP,
  • buffering systems include, but are not limited to, sodium phosphate monobasic/sodium phosphate dibasic; sulfamic acid/triethanolamine; citric acid/triethanolamine; tartaric actd/triethanolamine; succinic acid/triethanolamine; and acetic acid/triethanolamine.
  • surfactants include, but are not limited to, a) non-ionic surfactants such as block copolymers of ethylene oxide or propylene oxide, ethoxylated or propoxylated linear and branched primary and secondary alcohols, and aliphatic phosphine oxides; b) cationic surfactants such as quaternary ammonium compounds, particularly quaternary ammonium compounds having a C8-C20 alkyl group bound to a nitrogen atom additionally bound to three C1- C2 alky!
  • non-ionic surfactants such as block copolymers of ethylene oxide or propylene oxide, ethoxylated or propoxylated linear and branched primary and secondary alcohols, and aliphatic phosphine oxides
  • cationic surfactants such as quaternary ammonium compounds, particularly quaternary ammonium compounds having a C8-C20 alkyl group bound to a nitrogen atom additionally bound to three C1- C2 alky!
  • anionic surfactants such as alkane carboxylic acids (e.g., C8-C20 fatty acids), alkyl phosphonates, alkane sulfonates (e.g., sodium dodecylsulphate "SDS") or linear or branched alkyl benzene sulfonates, aikene sulfonates; and d) amphoteric and zwttterionic surfactants, such as aminocarboxylic acids, aminodicarboxylic acids, alkybetaines, and mixtures thereof.
  • anionic surfactants such as alkane carboxylic acids (e.g., C8-C20 fatty acids), alkyl phosphonates, alkane sulfonates (e.g., sodium dodecylsulphate "SDS") or linear or branched alkyl benzene sulfonates, aikene sulfonates
  • Additional components may include fragrances, dyes, stabilizers of hydrogen peroxide (e.g., metal chelators such as 1-hydroxyethylidene -1 ,1- diphosphonic acid (DEQUEST ® 201 O 1 Soiutia Inc., St. Louis, MO and ethyienediaminetetraacetic acid (EDTA)), TURPINAL ® SL (CAS# 2809-21-4), DEQUEST ® 0520, DEQUEST ® 0531 , stabilizers of enzyme activity (e.g., polyethylene glycol (PEG)), and detergent builders.
  • metal chelators such as 1-hydroxyethylidene -1 ,1- diphosphonic acid (DEQUEST ® 201 O 1 Soiutia Inc., St. Louis, MO and ethyienediaminetetraacetic acid (EDTA)
  • TURPINAL ® SL CAS# 2809-21-4
  • DEQUEST ® 0520 DEQUEST
  • Cephalosporin C deacetylases (E. C. 3.1.1.41 ; systematic name cephalosporin C acetylhjdrolases; CAHs) are enzymes having the ability to hydrolyze the acetyl ester bond on cephalosporins such as cephalosporin C, 7- aminocephalosporanic acid, and 7-(thiophene ⁇ 2-acetamido)cepha!osporanic acid (Abbott, B. and Fukuda, D., Appl. Microbiol. 30(3):413-419 (1975)).
  • CAHs belong to a larger family of structurally related enzymes referred to as the carbohydrate esterase family seven ("CE-7 n ; Coutinho, P.M., Henrissat, B., supra).
  • the CE-7 carbohydrate esterase family includes both CAHs and acetyl xylan esterases (AXEs; E. C. 3.1.1.72).
  • CE-7 family members share a common structural motif and are quite unusual in that they typically exhibit ester hydrolysis activity for both acetyiated xylooligosaccharides and acetySated cephalosporin C, suggesting that the CE-7 family represents a single class of proteins with a multifunctional deacetyiase activity against a range of small substrates (Vincent et a/., supra). Vincent et a/, describes the structural similarity among the members of this family and defines a signature sequence motif characteristic of the CE-7 family.
  • CE-7 Members of the CE-7 family are found in plants, fungi (e.g., Cephalosporidium acremonium), yeasts (e.g., Rhodosporidium toruloides, Rhodotorula glutinis), and bacteria such as Thermoanaerobacterium sp.; Norcardia lactamdurans, and various members of the genus Bacillus (Politino et at., Appl, Environ. Microbiol., 63(12):4807-4811 (1997); Sakai et al., J. Ferment. Bioeng. 85:53-57 (1998); Lorenz, W. and Wiegel, J., J.
  • fungi e.g., Cephalosporidium acremonium
  • yeasts e.g., Rhodosporidium toruloides, Rhodotorula glutinis
  • bacteria such as Thermoanaerobacterium sp.
  • WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299 and 2008/176783 to DiCosimo et a/ disclose various enzymes structurally classified as CE-7 enzymes that have perhydrolysis activity suitable for producing efficacious concentrations of peracids from a variety of carboxylic acid ester substrates when combined with a source of peroxygen.
  • Variant CE- 7 enzymes having improved perhydrolysis activity are also described in a co- fiied, co-owned, and copending U.S. Patent Application (Attorney Docket No, CL4392 US NA, incorporated herein by reference in its entirety).
  • the present method produces industrially-useful, efficacious concentrations of peracids in situ under aqueous reaction conditions using the perhydroiase activity of an enzyme belonging to the CE-7 family of carbohydrate esterases.
  • a variety of analytical methods can be used in the present methods to analyze the reactants and products including, but not limited to, titration, high performance liquid chromatography (HPLC), gas chromatography (GC), mass spectroscopy (MS), capillary electrophoresis (CE), the analytical procedure described by U. Karst et a/., (Anal. Chem., 69(17):3623-3627 (1997)), and the 2,2'-azino-bis (3-ethy!benzothazoline)-6-sulfonate (ABTS) assay (S. Minning, et al., Analytica Chimica Acta 378:293-298 (1999) and WO 2004/058961 A1) as described in the present examples.
  • HPLC high performance liquid chromatography
  • GC gas chromatography
  • MS mass spectroscopy
  • CE capillary electrophoresis
  • the method described by J. Gabrielson, et al, can be employed for determination of the Minimum Biocidai Concentration (MBC) of peracids, or of hydrogen peroxide and enzyme substrates.
  • MCC Minimum Biocidai Concentration
  • the assay method is based on XTT reduction inhibition, where XTT ⁇ -bisp-methoxy ⁇ -nitro- ⁇ -sulfophenyiJ-S-Ifphe ⁇ yiami ⁇ oJcarbo ⁇ ylj ⁇ H- tetrazolium, inner salt, monosodium salt) is a redox dye that indicates microbial respiratory activity by a change in optical density (OD) measured at 490 nm or 450 nm.
  • OD optical density
  • the enzyme catalyst-generated peroxycarboxyiic acid produced according to the present method can be used in a variety of hard surface/inanimate object applications for reduction of concentrations of biological contaminants, such as decontamination of medical instruments (e.g., endoscopes), textiles (e.g., garments, carpets), food preparation surfaces, food storage and food-packaging equipment, materials used for the packaging of food products, chicken hatcheries and grow-out facilities, animal enclosures, and spent process waters that have microbial and/or virucidal activity.
  • medical instruments e.g., endoscopes
  • textiles e.g., garments, carpets
  • food preparation surfaces e.g., food preparation surfaces
  • food storage and food-packaging equipment e.g., materials used for the packaging of food products, chicken hatcheries and grow-out facilities, animal enclosures, and spent process waters that have microbial and/or virucidal activity.
  • the enzyme-generated peroxycarboxyfic acids may be used in formulations designed to inactivate prions (e.g., certain proteases) to additionally provide biocida! activity.
  • the present peroxycarboxyiic acid compositions are particularly useful as a disinfecting agent for non- autoclavable medical instruments and food packaging equipment.
  • the peroxycarboxyiic acid-containing formulation may be prepared using GRAS or food-grade components (enzyme, enzyme substrate, hydrogen peroxide, and buffer), the enzyme-generated peroxycarboxyiic acid may also be used for decontamination of animal carcasses, meat, fruits and vegetables, or for decontamination of prepared foods.
  • the enzyme-generated peroxycarboxyiic acid may be incorporated into a product whose final form is a powder, liquid, gel, film, solid or aerosol.
  • the enzyme-generated peroxycarboxyiic acid may be diluted to a concentration that still provides an efficacious decontamination.
  • compositions comprising an efficacious concentration of peroxycarboxyiic acid can be used to disinfect surfaces and/or objects contaminated (or suspected of being contaminated) with biological contaminants by contacting the surface or object with the products produced by the present processes.
  • contacting refers to placing a disinfecting composition comprising an effective concentration of peroxycarboxyiic acid in contact with the surface or inanimate object suspected of contamination with a biological contaminant for a period of time sufficient to clean and disinfect.
  • Contacting includes spraying, treating, immersing, flushing, pouring on or in, mixing, combining, painting, coating, applying, affixing to and otherwise communicating a peroxycarboxyiic acid solution or composition comprising an efficacious concentration of peroxycarboxyiic acid, or a solution or composition that forms an efficacious concentration of peroxycarboxyiic acid, with the surface or inanimate object suspected of being contaminated with a concentration of a biological contaminant
  • the disinfectant compositions may be combined with a cleaning composition to provide both cleaning and disinfection.
  • a cleaning agent e.g., a surfactant or detergent
  • compositions comprising an efficacious concentration of peroxycarboxyiic acid can also contain at least one additional antimicrobial agent, combinations of prion-degradi ⁇ g proteases, a virucide, a sporicide, or a biocide. Combinations of these agents with the peroxycarboxyiic acid produced by the claimed processes can provide for increased and/or synergistic effects when used to clean and disinfect surfaces and/or objects contaminated (or suspected of being contaminated) with biological contaminants.
  • Suitable antimicrobial agents include carboxylic esters (e.g., p ⁇ hydroxy alkyi be ⁇ zoates and alky!
  • sulfonic acids e.g., dodecylbenzene sulfonic acid
  • iodo-compounds or active halogen compounds e.g., elemental halogens, halogen oxides (e.g., NaOCi, HOCI, HOBr, CIO 2 ), iodine, interhalides (e.g., iodine monochloride, iodine dichloride, iodine trichloride, iodine tetrachloride, bromine chloride, iodine monobromide, or iodine dibromide), polyhalides, hypochlorite salts, hypochlorous acid, hypobromite salts, hypobromous acid, chloro- and bromo-hydantoins, chlorine dioxide, and sodium chlorite); organic peroxides including benzoyl peroxide, alkyi benzoyl peroxides
  • Effective amounts of antimicrobial agents include about 0.001 wt% to about 60 wt% antimicrobial agent, about 0.01 wt% to about 15 wt% antimicrobial agent, or about 0.08 wt% to about 2,5 wt% antimicrobial agent.
  • the peroxycarboxylic acids formed by the present process can be used to reduce the concentration of viable biological contaminants (such as a viable microbial population) when applied on and/or at a locus.
  • a locus comprises part or all of a target surface suitable for disinfecting or bleaching. Target surfaces include all surfaces that can potentially be contaminated with biological contaminants.
  • Non-limiting examples include equipment surfaces found in the food or beverage industry (such as tanks, conveyors, floors, drains, coolers, freezers, equipment surfaces, walls, valves, belts, pipes, drains, joints, crevasses, combinations thereof, and the like); building surfaces (such as walls, floors and windows); non-food-industry related pipes and drains, including water treatment facilities, pools and spas, and fermentation tanks; hospital or veterinary surfaces (such as wails, floors, beds, equipment (such as endoscopes), clothing worn in hospital/veterinary or other healthcare settings, including clothing, scrubs, shoes, and other hospital or veterinary surfaces); restaurant surfaces; bathroom surfaces; toilets; clothes and shoes; surfaces of barns or stables for livestock, such as poultry, cattle, dairy cows, goats, horses and pigs; hatcheries for poultry or for shrimp; and pharmaceutical or biopharmaceutical surfaces (e.g., pharmaceutical or biopharmaceutical manufacturing equipment, pharmaceutical or biopharmaceutical ingredients, pharmaceutical or biopharmaceutical excipients).
  • building surfaces such as
  • Additional hard surfaces also include food products, such as beef, poultry, pork, vegetables, fruits, seafood, combinations thereof, and the like.
  • the locus can also include water absorbent materials such as infected linens or other textiles.
  • the locus also includes harvested plants or plant products including seeds, corms, tubers, fruit, and vegetables, growing plants, and especially crop growing plants, including cereals, leaf vegetables and salad crops, root vegetables, legumes, berried fruits, citrus fruits and hard fruits.
  • Non-limiting examples of hard surface materials are metals (e.g., steel, stainless steel, chrome, titanium, iron, copper, brass, aluminum, and alloys thereof), minerals (e.g., concrete), polymers and plastics (e.g., polyolefins, such as polyethylene, polypropylene, polystyrene, poly(meth)acrylate, polyacrylonitrile, polybutadiene, poly(acrylonitrile, butadiene, styrene), poly(acrylonitrile, butadiene), acrylonitrile butadiene; polyesters such as polyethylene terephthalate; and polyamides such as nylon).
  • Additional surfaces include brick, tile, ceramic, porcelain, wood, vinyl, linoleum, and carpet.
  • the peroxycarboxylic acids formed by the present process may be used to provide a benefit to an article of clothing or textile including, but not limited to, bleaching, destaining, sanitizing, disinfecting, and deodorizing.
  • the peroxycarboxylic acids formed by the present process may be used in any number of laundry care products including, but not limited to, textile pre-wash treatments, laundry detergents, stain removers, bleaching compositions, deodorizing compositions, and rinsing agents.
  • the genes and gene products of the instant sequences may be produced in heterologous host cells, particularly in the cells of microbial hosts.
  • Preferred heterologous host cells for expression of the instant genes and nucleic acid molecules are microbial hosts that can be found within the fungal or bacterial families and which grow over a wide range of temperature, pH values, and solvent tolerances.
  • any of bacteria, yeast, and filamentous fungi may suitably host the expression of the present nucleic acid molecules.
  • the perhydrolase may be expressed intracellular ⁇ , extracellulariy, or a combination of both intracellularly and extracellularly, where extracellular expression renders recovery of the desired protein from a fermentation product more facile than methods for recovery of protein produced by intracellular expression.
  • host strains include, but are not limited to, bacterial, fungal or yeast species such as Aspergillus, Trichoderma, Saccharomyces, Pichia, Phaffia, Kluyveromyces, Candida, Hansenula, Yarrowia, Salmonella, Bacillus, Acinetobacter, Zymomonas, Agrobacterium, Erythrobacter, Chlorobium, Chromatium, Flavobacterium, Cytophaga, Rhodobacter, Rhodococcus, Streptomyces, Brevibacterium, Corynebacteria, Mycobacterium, Deinococcus, Escherichia, Erwinia, Pantoea, Pseudomonas, Sphingomonas, Methylomonas, Methylobacter, Methylococcus, Me
  • Large-scale microbial growth and functional gene expression may use a wide range of simple or complex carbohydrates, organic acids and alcohols or saturated hydrocarbons, such as methane or carbon dioxide in the case of photosynthetic or chemoautotrophic hosts, the form and amount of nitrogen, phosphorous, sulfur, oxygen, carbon or any trace micronutrient including small inorganic ions.
  • the regulation of growth rate may be affected by the addition, or not, of specific regulatory molecules to the culture and which are not typically considered nutrient or energy sources.
  • Vectors or cassettes useful for the transformation of suitable host cells are well known in the art. Typically the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration.
  • Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell and/or native to the production host, although such control regions need not be so derived. Initiation control regions or promoters, which are useful to drive expression of the present cephalosporin C deacetyiase coding region in the desired host celi are numerous and familiar to those skilled in the art.
  • Virtually any promoter capable of driving these genes is suitable for the present invention including, but not limited to, CYC1, HIS3, GAL1, GAL10, ADH1, PGK 1 PH05, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI (useful for expression in Saccharomyces); A0X1 (useful for expression in Pichia); and lac, araB, tet, trp, Pj_, IPR, Tl, tac, and trc (useful for expression in Escherichia coli) as well as the amy, apr, npr promoters and various phage promoters useful for expression in Bacillus.
  • Termination control regions may also be derived from various genes native to the preferred host cell. In one embodiment, the inclusion of a termination control region is optional. In another embodiment, the chimeric gene includes a termination control region derived from the preferred host cell.
  • a variety of culture methodologies may be applied to produce the perhydrolase catalyst.
  • large-scale production of a specific gene product overexpressed from a recombinant microbial host may be produced by batch, fed-batch, and continuous culture methodologies.
  • Batch and fed-batch cuituring methods are common and well known in the art and examples may be found in Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989) and Deshpande, Mukund V., Appl. Biochem. Biotechnol., 36:227 (1992).
  • Continuous cultures are an open system where a defined culture media is added continuously to a btoreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous cultures generally maintain the cells at a constant high liquid phase density where cells are primarily in iog phase growth.
  • continuous culture may be practiced with immobilized ceils where carbon and nutrients are continuously added and valuable products, by- products or waste products are continuously removed from the ceil mass. Cell immobilization may be performed using a wide range of solid supports composed of natural and/or synthetic materials.
  • Recovery of the desired perhydrolase catalysts from a batch fermentation, fed-batch fermentation, or continuous culture may be accomplished by any of the methods that are known to those skilled in the art.
  • the cell paste is separated from the culture medium by centrifugatio ⁇ or membrane filtration, optionally washed with water or an aqueous buffer at a desired pH, then a suspension of the cell paste in an aqueous buffer at a desired pH is homogenized to produce a cell extract containing the desired enzyme catalyst.
  • the cell extract may optionally be filtered through an appropriate filter aid such as celite or silica to remove eel! debris prior to a heat-treatment step to precipitate undesired protein from the enzyme catalyst solution.
  • the solution containing the desired enzyme catalyst may then be separated from the precipitated cell debris and protein by membrane filtration or centrifugation, and the resulting partially-purified enzyme catalyst solution concentrated by additional membrane filtration, then optionally mixed with an appropriate carrier (for example, maltodextrin, phosphate buffer, citrate buffer, or mixtures thereof) and spray-dried to produce a solid powder comprising the desired enzyme catalyst.
  • an appropriate carrier for example, maltodextrin, phosphate buffer, citrate buffer, or mixtures thereof
  • the coding region of the kanamycin resistance gene was amplified from the plasmid pKD13 (SEQ ID NO: 27) by PCR (0.5 min at 94 0 C, 0.5 min at 55 0 C, 1 min at 70 0 C, 30 cycles) using primers identified as SEQ ID NO: 28 and SEQ ID NO: 29 to generate the PCR product identified as SEQ ID NO: 30.
  • the katG nucleic acid sequence is provided as SEQ ID NO: 31 and the corresponding amino acid sequence is SEQ ID NO: 32.
  • colt MG1655 (ATCC ® 47076TM) was transformed with the temperature- sensitive plasmid pKD46 (SEQ ID NO: 33), which contains the ⁇ Red recombi ⁇ ase genes (Datsenko and Wanner, (2000), PNAS USA 97:6640 » 6645), and selected on LB-amp plates for 24 h at 30 0 C.
  • MG1655/pKD46 was transformed with 50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0.2 cm cuvette, 2.5 kV, 200 W, 25 ⁇ F), and selected on LB-kan plates for 24 h at 37 0 C.
  • the kanamycj ⁇ resistance gene (SEQ ID NO:26) was amplified from the plasmid pKD13 (SEQ ID NO:27) by PCR (0.5 min at 94 0 C, 0.5 mi ⁇ at 55 0 C, 1 mi ⁇ at 70 0 C, 30 cycles) using primers identified as SEQ ID NO:37 and SEQ ID NO:38 to generate the PCR product identified as SEQ ID NO:39.
  • the katE nucleic acid sequence is provided as SEQ ID NO:40 and the corresponding amino acid sequence is SEQ ID NO:41.
  • E coli MG 1655 (ATCC ® 47076TM) was transformed with the temperature-sensitive plasmid pKD46 (SEQ ID NO:33), which contains the ⁇ -Red recombinase genes, and selected on LB- amp plates for 24 h at 30 0 C.
  • MG1655/pKD46 was transformed with 50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0,2 cm cuvette, 2.5 kV, 200 W, 25 ⁇ F), and selected on LB-kan plates for 24 h at 37 0 C.
  • Several colonies were streaked onto LB-kan plates and incubated overnight at 42 0 C to cure the pKD46 plasmid.
  • Genomic DNA was isolated from several colonies using the PUREGENE ® DNA purification system, and checked by PCR to confirm disruption of the katE gene using primers identified as SEQ ID NO:42 and SEQ ID NO:43.
  • Several /cafE-disrupted strains were transformed with the temperature-sensitive plasmid pCP20 (SEQ ID NO:36), which contains the FLP recombinase, used to excise the kan gene, and selected on LB-amp plates for 24 h at 37 0 C.
  • Several colonies were streaked onto LB plates and incubated overnight at 42 0 C to cure the pCP20 plasmid. Two colonies were checked to confirm a phenotype of kanS/ampS, and called MG 1655 KatE1 and MG 1655 KatE2.
  • the kanamycin resistance gene (SEQ ID NO:26) was amplified from the piasmid pKD13 (SEQ ID NO:27) by PCR (0.5 mi ⁇ at 94 0 C 1 0.5 min at 55 0 C 1 1 min at 70 0 C, 30 cycles) using primers identified as SEQ ID NO:37 and SEQ ID NO:38 to generate the PCR product identified as SEQ ID NO:39.
  • E. coll MG 1655 KatG1 (EXAMPLE 1) was transformed with the temperature-sensitive pfasmid pKD46 (SEQ ID NO:33), which contains the ⁇ -Red recombinase genes, and selected on LB-amp plates for 24 h at 30 0 C.
  • MG1655 KatG1/pKD46 was transformed with 50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0.2 cm cuvette, 2.5 kV, 200 W, 25 ⁇ F), and selected on LB-kan plates for 24 h at 37 0 C. Several colonies were streaked onto LB-kan plates and incubated overnight at 42 0 C to cure the pKD46 plasmid. Colonies were checked to confirm a phenotype of kanR/ampS. Genomic DNA was isolated from several colonies using the PUREGENE ® DNA purification system, and checked by PCR to confirm disruption of the katE. gene using primers identified as SEQ ID NO:42 and SEQ ID NO:43.
  • ⁇ katE Several /ca ⁇ E-disrupted strains ( ⁇ katE) were transformed with the temperature-sensitive plasmid pCP20 (SEQ ID NO:36), which contains the FLP recombtnase, used to excise the kan gene, and selected on LB-amp plates for 24 h at 37 0 C. Several colonies were streaked onto LB plates and incubated overnight at 42 0 C to cure the pCP20 plasmid. Two colonies were checked to confirm a phenotype of kanS/ampS, and called MG1655 KatG1 KatE18.1 and MG1655 KatG1 KatE23. MG1655 KatG1 KatE18.1 is designated E. coli KLP18.
  • the coding region of the gene encoding acetyl xylan esterase from Thermotoga neapolitana as reported in GENBANK ® was synthesized using codons optimized for expression in E. coli (DNA 2.0, Menlo Park, CA).
  • the coding region of the gene was subsequently amplified by PCR (0.5 min at 94 0 C, 0.5 mtn at 55 0 C, 1 min at 70 D C, 30 cycles) using primers identified as SEQ ID NO:45 and SEQ ID NO:46.
  • the resulting nucleic acid product (SEQ ID NO:47) was subcloned into pTrcHis2-TOPO ® to generate the plasmid identified as pSW196.
  • the plasmid pSW196 was used to transform E. coli KLP 18 (EXAMPLE 3) to generate the strain KLP18/pSW196.
  • the coding region of the gene encoding acety! xylan esterase from Thermotoga maritima MSB8 as reported in GENBANK ® was synthesized (DNA 2.0, Menlo Park, CA).
  • the coding region of the gene was subsequently amplified by PCR (0.5 min @ 94 0 C, 0.5 min @ 55 0 C, 1 min @ 70 0 C, 30 cycles) using primers identified as SEQ ID NO:49 and SEQ ID NO:50.
  • the resulting nucleic acid product (SEQ ID NO:51) was cut with restriction enzymes Pstl and Xbal and subcloned between the Pst ⁇ and Xba ⁇ sites in pUC19 to generate the plasmid identified as pSW207.
  • the plasmid pSW207 was used to transform E. coli KLP18 (EXAMPLE 3) to generate the strain identified as KLP18/pSW207.
  • a fermentor seed culture was prepared by charging a 2-L shake flask with 0.5 L seed medium containing yeast extract (Amberex 695, 5.0 g/L), K 2 HPO 4 (10.0 g/L), KH 2 PO 4 (7.0 g/L), sodium citrate dihydrate (1.0 g/L), (NH 4 J 2 SO 4 (4.0 g/L), MgSO 4 heptahydrate (1.0 g/L) and ferric ammonium citrate (0.10 g/L). The pH of the medium was adjusted to 6.8 and the medium was sterilized in the fiask. Post sterilization additions included glucose (50 wt %, 10.0 mL) and 1 mL ampiciili ⁇ (25 mg/mL) stock solution.
  • yeast extract Amberex 695, 5.0 g/L
  • K 2 HPO 4 (10.0 g/L)
  • KH 2 PO 4 7.0 g/L
  • sodium citrate dihydrate 1.0 g/L
  • the seed medium was inoculated with a 1-mL culture of E. coli KLP18/pSW196 or E. coli KLP18/pSW207 in 20% glycerol, and cultivated at 35 0 C and 300 rpm.
  • the seed culture was transferred at ca.
  • the trace elements solution contained citric acid monohydrate (10 g/L), MnSO 4 hydrate (2 g/L), NaCi (2 g/L), FeSO 4 heptahydrate (0.5 g/L), ZnSO 4 heptahydrate (0.2 g/L), CuSO 4 pentahydrate (0.02 g/L) and NaMoO 4 dihydrate (0.02 g/L).
  • Post sterilization additions included glucose solution (50% w/w, 80.0 g) and ampicillin (25 mg/mL) stock solution (16.00 mL).
  • Glucose solution (50% w/w) was used for fed batch.
  • Glucose feed was initiated when glucose concentration decreased to 0.5 g/L, starting at 0.31 g feed/mi ⁇ and increasing progressively each hour to 0.36, 0.42, 0.49, 0.57, 0.66, 0.77, 0.90, 1.04, 1.21, 1.41 , and 1.63 g/min respectively; the rate remained constant afterwards.
  • Glucose concentration in the medium was monitored and if the concentration exceeded 0.1 g/L the feed rate was decreased or stopped temporarily.
  • the dissolved oxygen (DO) concentration was controlled at 25% of air saturation.
  • the DO was controlled first by impeller agitation rate (400 to 1400 rpm) and later by aeration rate (2 to 10 slpm).
  • the pH was controlled at 6.8.
  • NH 4 OH (29% w/w) and H 2 SO 4 (20% w/v) were used for pH control.
  • the head pressure was 0.5 bars.
  • the cells were harvested by ce ⁇ trifugation 16 h post IPTG addition.
  • Thermotoga neapolitana (KLP18/pSW196) or Thermotoga maritima MSB8 (KLP18/pSW207) was prepared by passing a suspension of cell paste (20 wt % wet cell weight) in 0.05 M potassium phosphate buffer (pH 7.0) containing dithiothreitol (1 mM) twice through a French press having a working pressure of 16,000 psi (-110 MPa). The crude extract was then centrifuged at 20,000 x g to remove cellular debris, producing a clarified cell extract that was assayed for total soluble protein (Bicinchoninic Acid Kit for Protein Determination, Sigma Aidrich catalog # BCA1-KT).
  • the clarified Thermotoga maritima MSB8 or Thermotoga neapolitana perhydrolase-containing extract was heated for 20 min at 75 0 C, followed immediately by cooling in an ice/water bath to 5 0 C.
  • the resulting mixture was centrifuged to remove precipitated protein, and the supernatant collected and assayed for total soluble protein as before.
  • SDS- PAGE of the heat-treated supernatant indicated that the perhydrolase constituted at least ca. 90 % of the total soluble protein present in the supernatant.
  • Table 1 Composition of protein/excipient solutions used to produce T. neapolitana perhydrolase/trehaiose spray-dried enzyme powders, and Tg of corresponding powders.
  • the spray-dried enzyme powders were stored in sealed vials at 40 0 C and sampled at one-week intervals, and the samples assayed for the concentration of peracetic acid produced in 5 minutes in reactions containing T. neapolitana perhydrolase (50 ⁇ g protein/ml_), H 2 O 2 (100 imM), triacetin (100 mM) and TURPINAL ® SL (500 ppm) in sodium bicarbonate buffer (50 mM, pH 7.2) at 25 0 C, and analyzed for production of peracetic acid using a modification of the analytical method reported by Karst et a!, (beiow).
  • a sample (0.040 ml_) of the reaction mixture was removed at a predetermined time (5 min) and immediately mixed with 0.960 ml_ of 5 mM phosphoric acid in water to terminate the reaction by adjusting the pH of the diluted sample to less than pH 4.
  • the resulting solution was filtered using an ULTRAFREE ® MC-filter unit (30,000 Normal Molecular Weight Limit (NMWL), MiHi pore Corp., Billerica, MA, cat # UFC3LKT 00) by centrifugation for 2 min at 12,000 rpm.
  • Enzyme Powders in a Mixture of Enzyme Powder and Triacetin The spray-dried enzyme powders prepared as described in Example 8 were evaluated for stability when stored for eight weeks at 40 0 C as a mixture of the spray-dried powder in triacetin. Spray-dried enzyme powders were added to triacetin to produce a mixture containing 0.200 g of protein in 87.2 g of triacetin.
  • aqueous mixture was prepared containing heat-treated cell extract protein of E. coll KLP18/pSW196 (34 g protein/L, > 90 % T. neapolitana perhydrolase by PAGE) and maltodextrin (66.7 g/L MALTRIN ® M100 maltodextrin, 14.7 g/L MALTRIN ® M250, 14.7 g/L MALTRIN ® M040, Grain Processing Corporation, Muscatine, IA) as excipient in 50 mM sodium bicarbonate (pH 8.1).
  • E. coll KLP18/pSW196 34 g protein/L, > 90 % T. neapolitana perhydrolase by PAGE
  • maltodextrin 66.7 g/L MALTRIN ® M100 maltodextrin, 14.7 g/L MALTRIN ® M250, 14.7 g/L MALTRIN ® M040, Grain Processing Corporation, Muscatine, I
  • This solution was spray-dried to produce a powder that was then tested for stability during storage at 40 0 C for 9 weeks.
  • the spray-dried enzyme powder (stored at 40 °C) was sampled at one-week intervals and assayed for activity using 50 ⁇ g protein/mL of T. neapolitana perhydrolase, H 2 O 2 (100 mM), triacetin (100 mM) and TURPINAL ® SL (500 ppm) in 50 mM bicarbonate buffer (pH 7.2) at 25°C, and analyzed for production of peracetic acid using a modification of the analytical method reported by Karst et a/., supra.
  • the perhydroiytic activity of the T. neapolitana perhydroiase/maltodextrin spray-dried powder was stable over eight weeks of storage at 40 0 C (Table 5).
  • the spray-dried enzyme powder prepared as described in Example 10 was evaluated for stability when stored for twenty-one weeks at 40 °C as a mixture of the spray-dried powder in triacetin.
  • the spray-dried enzyme powder (1.235 g, 20.3 wt % protein) was added to 109 g of triacetin.
  • the resulting mixture was stored at 40 0 C, and a 2.19 g sample of the weli-stirred mixture assayed in duplicate at 25 0 C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPINAL ® SL (500 ppm) in 50 mM sodium bicarbonate buffer at pH 7.2, where the resulting concentration of triacetin and protein was 100 mM and 50 ⁇ g/mL, respectively.
  • the spray-dried enzyme powder prepared as described in Example 10 was evaluated for stability when stored for 21 weeks at 40 0 C as a mixture of the spray-dried powder in a mixture of triacetin and sodium bicarbonate.
  • the spray-dried enzyme powder (0.988 g, 20.3 wt % protein) was added to a mixture of 87.2 g of triacetin and 16.8 g of sodium bicarbonate (Grade 3DF (powder), Church & Dwight).
  • neapolitana perhydrolase/ma ⁇ todextrin spray- dried enzyme powders when stored for twenty-one weeks at 40 0 C as a mixture with triacetin and solid sodium bicarbonate is improved when compared to the stability of T. neapolitana perhydrolase/maltodextrtn spray- dried enzyme powders when stored for twenty-one weeks at 40 0 C as a mixture with triacetin alone.
  • the perhydrolase still retains ca. 100 % of initial activity in a mixture of triacetin and sodium bicarbonate.
  • aqueous mixture was prepared containing heat-treated cell extract protein of E. coli KLP 18/pSW207 (21 g protein/L, > 90% T. maritima perhydrolase by PAGE) and maitodextrin (31 g/L maltodextrin DE 13-17 and 31 g/L maltodextrin DE 4-7, Aldrich) as excipient in 50 mM sodium bicarbonate (pH 8.1).
  • the spray-dried enzyme powder (stored at 40 0 C) was sampled at one-week intervals and assayed for activity using 50 ⁇ g protein/mL of T. maritima perhydrolase, H ⁇ O ⁇ (H 2 O 2 (100 mM)), triacetin (100 mM) and TURPINAL ® SL (500 ppm) in 50 mM bicarbonate buffer (pH 7.2) at 25 0 C, and analyzed for production of peracetic acid using a modification of the analytical method reported by Karst et at,, supra.
  • the perhydrolytic activity of the T. maritima perhydroiase/maltodextrin spray-dried powder was stable over seven weeks of storage at 40 0 C (Table 8).
  • the spray-dried enzyme powder prepared as described in Example 13 was evaluated for stability when stored for seven weeks at 40 D C as a mixture of the spray-dried powder in triacetin.
  • the spray-dried enzyme powder (0.556 g, 18.0 wt % protein) was added to 43.6 g of triacetin.
  • the resulting mixture was stored at 40 0 C 1 and a 2.21 g sample of the well-stirred mixture assayed in duplicate at 25 °C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPINAL ® SL (500 ppm) in 50 mM sodium bicarbonate buffer at pH 7.2, where the resulting concentration of triacetin and protein was 100 mM and 50 ⁇ g/mL, respectively.
  • the spray-dried enzyme powder prepared as described in Example 13 was evaluated for stability when stored for seven weeks at 40 0 C as a mixture of the spray-dried powder in a mixture of triacetin and sodium bicarbonate.
  • the spray-dried enzyme powder (0.556 g, 18.0 wt % protein) was added to 43.6 g of triacetin and 8.4 g of sodium bicarbonate (Grade 3DF (powder), Church & Dwight).
  • the resulting mixture was stored at 40 °C ; and a 2.63 g sample of the weli-stirred mixture assayed in duplicate at 25 0 C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPI NAL ® SL (500 ppm), where the resulting concentrations of triacetin, sodium bicarbonate buffer (pH 7.2) and protein were 100 mM, 50 mM and 50 ⁇ g/mL, respectively.
  • Table 10 Comparison of the data in Table 10 with the data in Example 14, Table 9, demonstrates the improved stability of T, maritima perhydrolase/maltodextrin spray-dried enzyme powders when stored for five, six and seven weeks at 40 0 C as a mixture with triacetin and solid sodium bicarbonate when compared to the stability of T. neapoiitana perhydrolase/maltodextrin spray-dried enzyme powders when stored for five, six and seven weeks at 40 0 C as a mixture with triacetin alone.
  • Table 10 Temperature stability of T. maritima perhydrolase/maltodextrin spray- dried enzyme powder during storage in a mixture of enzyme powder, sodium bicarbonate and triacetin at 40 0 C.
  • PAA ppm produced in 5 min at 25 0 C by reaction of triacetin (100 mM) and H 2 O 2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T, maritima perhydrolase (50 ⁇ g protein/mL) and TURPINAL ® SL (500 ppm).
  • Bacillus subtilis ATCC ® 31954TM was prepared from a suspension of cell paste (20 wt % wet cell weight) in 0.05 M potassium phosphate buffer (pH 7.0) containing dithiothreitol (1 mM). The crude homogenate was centrifuged to remove cellular debris, producing a clarified cell extract that was heat-treated at 65 0 C for 30 min.
  • the resulting mixture was centrifuged, and the heat-treated supernatant concentrated on a 3OK MWCO (molecular weight cutoff) membrane to a concentration of 32 mg/mL total dissolved solids; a SDS-PAGE of the clarified, heat-treated cell extract indicated that the perhydroiase was at least 85-90 % pure.
  • To this concentrate was then added 2.06 grams of NaH 2 PO 4 and 1.17 grams Na 2 HPO 4 per gram of soiids was added to this concentrate to produce an approximate 3:1 ratio (wt/wt) of phosphate buffer to heat-treated cell extract protein.
  • This solution was diluted by 30 wt% with deionized water, then spray-dried (180 °C iniet temperature, 70 0 C exit temperature) using a Buchi B-290 laboratory spray dryer); the resulting spray-dried powder contained 25.5 wt % protein (Bradford protein assay) and was 94.3 wt % dry soiids.
  • the reactions were sampled at 1 , 5, and 30 minutes and the samples analyzed for peracetic acid using the Karst derivatization protocol (Karst et al., supra); aiiquots (0.040 ml_) of the reaction mixture were removed and mixed with 0.960 ml_ of 5 mM phosphoric acid in water; adjustment of the pH of the diluted sample to less than pH 4 immediately terminated the reaction.
  • the resulting solution was filtered using an ULTRAFREE ® MC-f ⁇ lter unit (30,000 Normal Molecular Weight Limit (NMWL), M ⁇ lipore cat # UFC3LKT 00) by centrifugation for 2 min at 12,000 rpm.
  • PAA Peracetic acid
  • PGDA propylene glycol diacetate
  • EGDA ethylene glycol diacetate
  • hydrogen peroxide 100 mM
  • sodium bicarbonate buffer 50 mM, initial pH 7.2
  • heat-treated extract protein from E. coli KLP18/pSW194 ⁇ Bacillus subtilis ATCC ® 31954TM perhydrolase
  • the lysed cells were centrifuged for 30 minutes at 12,000 x g, producing a clarified cell extract that was assayed for total soluble protein (Bradford assay).
  • the supernatant was heated at 75 D C for 20 minutes, followed by quenching in an ice bath for 2 minutes. Precipitated protein was removed by centrifugation for 10 minutes at 1 1 ,000 x g.
  • SDS-PAGE of the resulting heat-treated extract protein supernatant indicated that the CE-7 enzyme comprised approximately 85-90% of the total protein in the preparation.
  • the heat-treated extract protein supernatant was frozen in dry ice and stored at -80 °C until use.
  • a first set of reactions (10 ml_ total volume) were run at 20 0 C in 10 mM sodium bicarbonate buffer (initial pH 8.1) containing propylene glycol diacetate (PGDA) or ethylene glycol diacetate (EGDA) (100 mM), hydrogen peroxide (100 mM) and 25 ⁇ g/mL of heat-treated extract protein from one of E coli KLP18/pSW196 (Thermotoga neapolitana wild-type perhydroiase), E coli KLP18/pSW196/C277S ⁇ Thermotoga neapolitana C277S variant perhydroiase), E.
  • E coli KLP18/pSW196 Thermotoga neapolitana wild-type perhydroiase
  • E coli KLP18/pSW196/C277S ⁇ Thermotoga neapolitana C277S variant perhydroiase
  • coli KLP18/pSW196/C277T Thermotoga neapolitana C277T variant perhydroiase
  • E. coli KLP18/pSW228 Thermotoga maritime wild-type perhydroiase
  • E coli KLP18/pSW228/C277S Thermotoga maritime C277S variant perhydroiase
  • E. coli KLP18/pSW228/C277T Thermotoga maritime C277T variant perhydroiase
  • PAA Peracetic acid
  • Table 12 Peracetic acid (PAA) concentration produced utilizing T. maritima and T neapolitana wild-type and variant perhydroiases in reactions at 20 0 C in sodium bicarbonate buffer (10 mM, initial pH 8.1 ) containing propylene glycol diacetate (PGDA) (100 mM) or ethylene glycol diacetate (EGDA) (100 mM), hydrogen peroxide (100 mM) and 25 ⁇ g/mL of heat-treated extract protein.
  • a second set of reactions (10 ml. total volume) were run at 20 0 C in 10 mM sodium bicarbonate buffer (initial pH 8.1) containing propylene glycol diacetate (PGDA) or ethylene glycol diacetate (EGDA) (2 mM), hydrogen peroxide (10 mM) and 10 ⁇ g/mL of heat-treated extract protein from one of E. coli KLP18/pSW196 (Thermotoga neapolitana wild-type perhydrolase), E.
  • PGDA propylene glycol diacetate
  • EGDA ethylene glycol diacetate
  • coli KLP18/pSW196/C277S (Thermotoga neapolitana C277S variant perhydrolase), E coli KLP18/pSW196/C277T (Thermotoga neapolitana C277T variant perhydroiase), E. coli KLP18/pSW228 (Thermotoga maritima wild-type perhydrolase), E colt KLP18/pSW228/C277S (Thermotoga maritima C277S variant perhydrolase), and E. coli KLP18/pSW228/C277T (Thermotoga maritima C277T variant perhydroiase) (prepared as described above).
  • PAA Peracetic acid
  • Table 13 Peracetic acid (PAA) concentration produced utilizing T, maritima and T. neapolitana wild-type and variant perhydrolases in reactions at 20 0 C in sodium bicarbonate buffer (10 mM, initial pH 8.1) containing propylene glycol diacetate (PGDA) (2 mM) or ethylene glycol diacetate (EGDA) (2 mM), hydrogen peroxide (10 mM) and 10 ⁇ g/mL of heat-treated extract protein.
  • PGDA propylene glycol diacetate
  • EGDA ethylene glycol diacetate

Abstract

Disclosed herein is a method for stabilization of the perhydrolase activity of the CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the mixture of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant and laundry care formulations comprising the peracids produced by the processes described herein are provided.

Description

TITLE
STABILIZATION OF PERHYDROLASES IN A FORMULATION WITH A CARBOXYLIC ACID ESTER
CROSS REFERENCE TQ RELATED APPLlCATiONS
5 This application claims the benefit of U.S. Provisional Application Nos.
61/102,505; 61/102,512; 61/102,514; 61/102,520; 61/102,531 ; and 61/102,539; each filed October 3, 2008, each of which incorporated by reference herein in their entireties.
10 FIELD OF THE INVENTION
This invention relates to the field of enzymatic peracid synthesis and in situ enzyme catalysis, At feast one peroxycarboxyϋc acid is produced at sufficient concentrations as to be efficacious for the disinfection or sanitization of surfaces, medical instrument sterilization, food processing equipment 15 sterilization, and suitable for use in textile and laundry care applications such as bleaching, destaining, deodorizing, disinfection or sanitization,
BACKGROUND OF THE INVENTION
Peracid compositions have been reported to be effective antimicrobial 20 agents. Methods to clean, disinfect, and/or sanitize hard surfaces, meat products, living plant tissues, and medical devices against undesirable microbial growth have been described (e.g., U.S. Patent 6,545,047; U.S.
Patent 6,183,807; U.S. Patent 6,518,307; U.S. Patent 5,683,724; and U.S.
Patent Application Publication No. 2003/0026846). Peracids have also been 25 reported to be useful in preparing bleaching compositions for laundry detergent applications (U.S. Patent 3,974,082; U.S. Patent 5,296,161 ; and U.S. Patent
5,364,554).
Peracids can be prepared by the chemical reaction of a carboxylic acid and hydrogen peroxide (see Organic Peroxides, Daniel Swern, ed., Vol. 1 , pp 30 313-516; Wiley Interscience, New York, 1971). The reaction is usually catalyzed by a strong inorganic acid, such as concentrated sulfuric acid. The reaction of hydrogen peroxide with a carboxylic acid is an equilibrium reaction, and the production of peracid is favored by the use of an excess concentration of peroxide and/or carboxylic acid, or by the removal of water.
Some peracid-based disinfectants or bleaching agents are comprised of an equilibrium mixture of peracid, hydrogen peroxide, and the corresponding carboxylic acid. One disadvantage of these commercial peracid cleaning systems is that the peracid is oftentimes unstable in solution over time. One way to overcome the stability problem is to generate the peracid prior to use by combining multiple reaction components that are individually stable for extended periods of time. Preferably, the individual reaction components are easy to store, relatively safe to handle, and capable of quickly producing an efficacious concentration of peracid upon mixing.
The CE-7 family of carbohydrate esterases has recently been reported to have perhydrolase activity. These "perhydrolase" enzymes have been demonstrated to be particularly effective for producing peracids from a variety of carboxylic acid ester substrates when combined with a source of peroxygen (See WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299 and 2008/176783 to DiCosimo et a/.; each herein incorporated by reference in their entireties). Some members of the CE-7 family of carbohydrate esterases have been demonstrated to have perhydrolytic activity sufficient to produce 4000 - 5000 ppm peracetic acid from acetyl esters of alcohols, diois, and glycerols in 1 minute and up to 9000 ppm between 5 minutes and 30 minutes once the reaction components were mixed (DiCosimo et a/., U.S. Patent Application Publication No. 2009/0005590).
The enzymatic peracid generation system described by U.S. 2009/0005590 to DiCosimo er a/, is typically based on the use of multiple reaction components that remain separated until the peracid solution is needed. Using this approach overcomes the peracid instability issues associated with storage of many peracid-based disinfectants and bleaching agents. However, specific formulations that provide long term stability of perhydrolase activity when using multicomponent formulations comprising CE- 7 carbohydrate esterases remains to be addressed. Of particular concern is the long term storage stability of a CE-7 enzyme having perhydrolysis activity when stored in an organic liquid or solvent having a log P {i.e., the logarithm of the partition coefficient of a substance between octanol and water, where P equals [so!ute]octaπof/[soiute]water) of iess than two. Several of the organic ester substrates previous described by DiCosimo et al. have log P values of less than two. Organic liquids or solvents can be deleterious to the activity of enzymes, either when enzymes are suspended directly in organic liquids or solvents, or when miscible organic/aqueous single phase liquids or solvents are employed. Two literature publications that review the effects of organic solvents on enzyme activity and structure are: (a) C. Laane et at., Biotechnot. Bioeng. 30:81 -87 (1987) and (b) Cowan, DA and Plant, A., Biocatalysis in Organic Phase Systems., Ch. 7 in Biocatalvsis at Extreme Temperatures, Kelly, R.VV.W. and Adams, M., eds., Amer. Chem. Soc. Symposium Series, Oxford University Press, New York, NY, pp 86-107 (1992). Cowan and Plant, supra, note (on page 87) that the art generally recognizes that there is little or no value in using organic solvents having a log P < 2 to stabilize intracellular enzymes in an organic phase system. Organic solvents having a log P between two and four can be used on a case-by-case basis dependent on enzyme stability, and those having a log P > 4 are generally useful in organic phase systems. Cowan and Plant, supra, further note (on page 91) that the effect of direct exposure of an enzyme dissolved in a single-phase organic-aqueous solvent depends on solvent concentration, solvent/enzyme surface group interactions, and solvent/enzyme hydration shell interactions. Because a solvent's log P value must be sufficiently low so that the solvent is fully miscible with the aqueous phase to produce a single-phase, a single-phase organic- aqueous solvent containing a low log P organic solvent usually has a negative effect on enzyme stability except in low organic solvent concentration applications. Triacetin is reported to have a log P of 0.25 (Y. M. Gunning, et al., J. Agric. Food Chem. 48:395-399 (2000)), similar to that of ethanol (log P - 0.26) and isopropanol (log P 0.15) (Cowan and Plant); therefore the storage of enzyme powder in triacetin would be expected to result in unacceptable loss of enzyme activity, as would the use of additional cosolvents with log P < 2 (e.g., cyclohexanone, log P = 0.94) (Cowan and Plant); 1 ,2-propanediol, log P - - 1.41 (Gunning, et al.); 1 ,3-propanediol, log P = -1.3 (S-J. Kuo, et al., J. Am. Oil Chem. Soc. 73:1427-1433 (1996); diethylene glyco! butyl ether, log P = 0.56 (N. Funasaki, et al., J. Phys, Chem. 88:5786-5790 (1984); triethyleneglycol, log P = -1.75 (L Braeken, et al., ChemPhysChem 6:1606-1612 (2005)). Thus, the problem to be solved is to formulate a product using a mixture of a peracid-generating enzyme in an organic ester substrate employed for peracid production, where the enzyme retains significant perhydrolase activity even when stored in a mixture with the carboxylic acid ester substrate.
SUMMARY QF THE INVENTION
The stated problem has been solved by the discovery of a process for stabilizing the perhydrolysis activity of at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity when present in a formulation with a carboxylic acid ester. More specifically, the addition of at ieast one buffer to a formulation comprising a carboxylic acid ester and an enzyme powder comprising the CE-7 enzyme and at least one excipient enhances the stability of the perhydrolysis activity of the CE-7 enzyme stored in the formulation.
In one aspect, a process to stabilize the perhydrolysis activity of an enzyme when present in a formulation comprised of said enzyme and a carboxylic acid ester is provided, the process comprising:
(a) providing an aqueous formulation comprising at least one enzyme structurally classified as a CE-7 enzyme having perhydrolysis activity, at least one excipient, and optionally at least one surfactant;
(b) spray-drying the aqueous formulation of (a) to produce an enzyme powder comprising said at least one enzyme, said at ieast one oligosaccharide excipient, and optionally said at ieast one surfactant; and (c) combining the enzyme powder of (b) with at least one buffer and a carboxylic acid ester to form a formulation, wherein the addition of the at least one buffer to the formulation enhances the stability of the perhyclrolysis activity of said at least one enzyme when stored in said formulation.
In another aspect, a formulation used as a first component in a multi- component peracid generation system is provided, said formulation comprising a mixture of:
(a) at least one carboxylic acid ester selected from the group consisting of monoacetin, diacetin, triacetin, monopropionin, dipropionin, tripropionin, monobutyrin, dibutyrin, tributyrin, and mixtures thereof; (b) an enzyme powder comprising a spray-dried formulation of at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity, at least one excipient, and optionally at least one surfactant; and
(c) at least one buffer; wherein said at least one buffer enhances the stability of said at least one enzyme when present in said formulation,
In a further aspect, a disinfectant system comprising a first component and a second component is provided, said first component comprising the formulation described above and said second component comprising a source of peroxygen in water and optionally a hydrogen peroxide stabilizer.
In an additional aspect, a process for enzymatically producing a peroxycarboxytic acid is provided comprising;
(a) providing a set of reaction components, said components comprising: (1) the formulation described above; and
(2) a source of peroxygen in water; and
(b) combining said reaction components whereby a peroxycarboxylic acid is produced. in another aspect, a process to disinfect or sanitize a hard surface or inanimate object using an enzymatically-produced peroxycarboxylic acid composition is provided, said process comprising:
(a) providing a set of reaction components, said components comprising: (1) the formulation described above; and
(2) a source of peroxygen in water;
(b) combining said reaction components whereby a peroxycarboxylic acid product is produced; (c) optionally diluting said peroxycarboxylic acid product; and
(d) contacting said hard surface or inanimate object with the peroxycarboxylic acid produced in step (b) or step (c) whereby said surface or said inanimate object is disinfected. A further aspect is for a process for treating an article of clothing or a textile for bleaching, stain removal, odor reduction, sanitization or disinfection using an enzymaticaliy-produced peroxycarboxylic acid composition, said process comprising:
(a) providing a set of reaction components, said components comprising; (1 ) a formulation comprising
(i) the formulation describe above; and (ii) a carboxylic acid ester; and (2) a source of peroxygen;
(b) combining said reaction components under suitable aqueous reaction conditions whereby a peroxycarboxylic acid product is formed;
(c) optionally diluting said peroxycarboxyiic acid product; and
(d) contacting said article of clothing or textile fabric with the peroxycarboxyiic acid produced in step (b) or step (c); wherein said article of clothing or textile is cleaned, destained, deodorized, sanitized, disinfected, or a combination thereof.
BRIEF DESCRIPTION OF THE BIOLOGICAL SEQUENCES The following sequences comply with 37 C.F.R. §§ 1.821-1.825 ("Requirements for Patent Applications Containing Nucleotide Sequences and/or Amino Acid Sequence Disclosures - the Sequence Rules") and are consistent with World intellectual Property Organization (WIPO) Standard ST.25 (1998) and the sequence listing requirements of the European Patent Convention (EPC) and the Patent Cooperation Treaty (PCT) Rules 5.2 and 49.5(a-bis), and Section 208 and Annex C of the Administrative Instructions. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 CF. R. § 1.822. SEQ ID NO:1 is the deduced amino acid sequence of a cephalosporin C deacetylase from Bacillus subtilis ATCC® 31954™.
SEQ ID NO:2 is the deduced amino acid sequence of a cephalosporin C deacetylase from B. subtilis ATCC® 6633™.
SEQ ID NO:3 is the deduced amino acid sequence of a cephalosporin C deacetylase from B, licheniformis ATCC® 14580™.
SEQ ID NO:4 is the deduced amino acid sequence of an acetyl xylan esterase from B. pumilus PS213.
SEQ ! D NO:5 is the deduced amino acid sequence of an acetyl xylan esterase from Clostridium thermocellum ATCC® 27405™. SEQ ID NO:6 is the deduced amino acid sequence of an acetyl xyian esterase from Thermotoga neapolitana.
SEQ ID NO:7 is the deduced amino acid sequence of an acetyl xylan esterase from Thermotoga maήtima MSB8.
SEQ ID NO:8 is the deduced amino acid sequence of an acetyl xyian esterase from Thermoanaerobacterium sp, JWVSL YS485.
SEQ ID NO:9 is the deduced amino acid sequence of a cephalosporin C deacetylase from Bacillus sp. NRRL B-14911. It should be noted that the nucleic acid sequence encoding the cephalosporin C deacetylase from Bacillus sp. NRRL B-1491 1 as reported in G ENBANK® Accession number ZPJ31 168674 appears to encode a 15 amino acid N-terminal addition that is likely incorrect based on sequence alignments with other cephalosporin C deacetylases and a comparison of the reported length (340 amino acids) versus the observed length of other CAH enzymes (typically 318-325 amino acids in length; see co-owed, co-filed, and copending U.S. Patent Application under attorney docket number CL4205 US NA entitled "ENZYMATIC
PERACiD PRODUCTION USING A COSOLVENT"; herein incorporated by reference) . As such, the deduced amino acid sequence reported herein for the cephalosporin C deacetylase sequence from Bacillus sp. NRRL B-14911 does not include the the N-terminai 15 amino acids as reported under GENBANK® Accession number ZP_01168674.
SEQ ID NO:10 is the deduced amino acid sequence of a cephalosporin C deacetyiase from Bacillus halodurans C-125. SEQ ID NO:11 is the deduced amino acid sequence of a cephalosporin
C deacetyiase from Bacillus clausii KSM-K16.
SEQ ID NO:12 is the deduced amino acid sequence of a Bacillus subtilis ATCC® 29233™ cephalosporin C deacetyiase (CAH).
SEQ ID NO:13 is the deduced amino acid sequence of a Thermoanearobacterium saccharolyticυm cephalosporin C deacetyiase.
SEQ ID NO:14 is the deduced amino acid sequence of a Thermotoga lettingae acetyl xylan esterase.
SEQ ID NO:15 is the deduced amino acid sequence of a Thermotoga petrophila acetyl xylan esterase. SEQ ID NO: 16 is the deduced amino acid sequence of a first acetyl xylan esterase from Thermotoga sp. RQ2 described herein as "RQ2(a)".
SEQ ID NO:17 is the deduced amino acid sequence of a second acetyl xylan esterase from Thermotoga sp. RQ2 described herein as nRQ2(b)".
SEQ ID NO:18 is the amino acid sequence of the region encompassing amino acids residues 1 18 through 299 of SEQ ID NO:1.
SEQ ID NO: 19 is the deduced amino acid sequence of a Thermotoga neapolitana acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA (incorporated herein by reference in its entirety), where the Xaa residue at position 277 is Ala, VaI, Ser, or Thr.
SEQ ID NO:20 is the deduced amino acid sequence of a Thermotoga maritima MSB8 acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA1 where the Xaa residue at position 277 is AIa1 VaI, Ser, or Thr. SEQ ID NO:21 is the deduced amino acid sequence of a Thermotoga lettingae acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA1 where the Xaa residue at position 277 is Ala, VaI, Ser, or Thr. SEQ ID NO:22 is the deduced amino acid sequence of a Thermotoga petrophila acetyl xylan esterase variant from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA, where the Xaa residue at position 277 is Ala, VaI1 Ser, or Thr. SEQ ID NO:23 is the deduced amino acid sequence of a Thermotoga sp, RQ2 acetyl xylan esterase variant derived from"RQ2(a)" from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA, where the Xaa residue at position 277 is Ala, VaI, Ser, or Thr.
SEQ ID NO:24 is the deduced amino acid sequence of a Thermotoga sp. RQ2 acetyl xylan esterase variant derived from "RQ2(b)B from co-owned, co-filed, and copending U.S. Patent Application Attorney Docket No. CL4392 US NA, where the Xaa residue at position 278 is Ala, VaI, Ser, or Thr.
SEQ ID NO:25 is the deduced amino acid sequence of a Thermoanaerobacteήum sp. JW/SL YS485 acetyl xylan esterase. SEQ ID NO:26 is the coding region of a kanamycin resistance gene
(kan) from Streptomyces kanamyceticus.
SEQ ID NO:27 is plasmid pKD13, which contains the kanamycin resistance gene.
SEQ ID NO:28 is a forward primer used to clone katG from plasmid pKD13.
SEQ ID NO:29 is a reverse primer used to clone katG from plasmid pKD13.
SEQ ID NO:30 is the PCR product of the katG amplification from plasmid pKD13 using the primers of SEQ ID NO:28 and SEQ ID NO:29. SEQ ID NO:31 is the coding region of the catalase-peroxidase gene
(katG).
SEQ ID NO:32 is the deduced amino acid sequence of katG.
SEQ ID NO:33 is plasmid pKD46, which contains the λ~Red recombinase genes. SEQ ID NO:34 is a forward primer used to confirm disruption of katG,
SEQ ID NO:35 is a reverse primer used to confirm disruption of katG,
SEQ ID NO:36 is the temperature-sensitive plasmid pCP20, which contains the FLP recombinase. SEQ ID NO:37 is a forward primer used to clone katE from plasmid pKD13.
SEQ ID NO:38 is a reverse primer used to done katE from plasmid pKD13. SEQ ID NO: 39 is the PCR product of the katE amplification from plasmid pKD13 using the primers of SEQ ID NO:37 and SEQ ID NO:38.
SEQ ID NO:40 is the coding region of the catalase HPIl gene (katE).
SEQ ID NO:41 is the deduced amino acid sequence of katE.
SEQ ID NO:42 is a forward primer used to confirm disruption of katE. SEQ ID NO:43 is a reverse primer used to confirm disruption of katE.
SEQ ID NO:44 is a coding region of a gene encoding acetyl xylan esterase from Thermotoga neapolitana as reported in GEN BANK® (accession # AE000512).
SEQ ID NO:45 is a forward primer used to amplify the acetyl xylan esterase gene from Thermotoga neapolitana.
SEQ ID NO:46 is a reverse primer used to amplify the acetyl xylan esterase gene from Thermotoga neapolitana.
SEQ ID NO:47 is the PCR product of the acetyl xylan esterase amplification using the primers of SEQ ID NO:45 and SEQ ID NO:46. SEQ ID NO:48 is a gene encoding acetyl xylan esterase from
Thermotoga maritima MSB8 as reported in GENBANK® (accession # NP_227893.1).
SEQ ID NO:49 is a forward primer used to amplify the acetyl xylan esterase gene from Thermotoga maritima. SEQ ID NO:50 is a reverse primer used to amplify the acetyl xyian esterase gene from Thermotoga maritima.
SEQ ID NO:51 is the PCR product of the acetyl xylan esterase amplification using the primers of SEQ ID NO:49 and SEQ ID NO:50.
DETAILED DESCRIPTION QF THE INVENTION
Disclosed herein is a method for stabilization of the perhydrolase activity of a CE-7 esterase in a formulation with a carboxylic acid ester that employs the addition of a buffering agent, substantially undissolved, to the formulation of the CE-7 esterase and the carboxylic acid ester. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided.
In this disclosure, a number of terms and abbreviations are used. The following definitions apply unless specifically stated otherwise.
As used herein, the articles "a", "an", and "the" preceding an element or component of the invention are intended to be n on restrictive regarding the number of instances {i.e., occurrences) of the element or component. Therefore "a", "an" and "the" should be read to include one or at least one, and the singular word form of the element or component also includes the plural unless the number is obviously meant to be singular.
As used hereint the term "comprising" means the presence of the stated features, integers, steps, or components as referred to in the claims, but that it does not preclude the presence or addition of one or more other features, integers, steps, components or groups thereof. The term "comprising" is intended to include embodiments encompassed by the terms "consisting essentially of and "consisting of. Similarly, the term "consisting essentially of is intended to include embodiments encompassed by the term "consisting of. As used herein, the term "about" modifying the quantity of an ingredient or reactant employed refers to variation in the numerical quantity that can occur, for example, through typical measuring and liquid handling procedures used for making concentrates or use solutions in the real world; through inadvertent error in these procedures; through differences in the manufacture, source, or purity of the ingredients employed to make the compositions or carry out the methods; and the like. The term "about" also encompasses amounts that differ due to different equilibrium conditions for a composition resulting from a particular initial mixture. Whether or not modified by the term "about", the claims include equivalents to the quantities.
Where present, all ranges are inclusive and combinabfe. For example, when a range of "1 to 5" is recited, the recited range should be construed as including ranges "1 to 4", "1 to 3", "1-2", "1-2 & 4-5", "1-3 & 5", and the like.
As used herein, the terms "substrate", "suitable substrate", and "carboxylic acid ester substrate" interchangeably refer specifically to: (a) one or more esters having the structure
[X]mR5
wherein
X is an ester group of the formula R6C(O)O; Re is a C1 to C7 linear, branched or cyclic hydrocarbyt moiety, optionally substituted with a hydroxyl group or C1 to C4 alkoxy group, wherein R6 optionally comprises one or more ether linkages where R6 is C2 to C7;
R5 is a C1 to C6 linear, branched, or cyclic hydrocarbyl moiety optionally substituted with a hydroxy! group, wherein each carbon atom in R5 individually comprises no more than one hydroxyl group or no more than one ester group, and wherein R5 optionally comprises one or more ether linkages; m is 1 to the number of carbon atoms in Rs1 said one or more esters having a solubility in water of at least 5 ppm at 25 0C; or
(b) one or more glycerides having the structure
Figure imgf000013_0001
wherein R1 is a C1 to C7 straight chain or branched chain alkyl optionally substituted with an hydroxyl or a C1 to C4 alkoxy group and R3 and R4 are individually H or R1C(O); or
(c) one or more esters of the formula
Figure imgf000014_0001
wherein Ri is a C1 to C7 straight chain or branched chain alky! optionally substituted with an hydroxyl or a C1 to C4 alkoxy group and R2 is a C1 to C10 straight chain or branched chain alkyt, alkenyl, alkynyl, ary!t alkylaryl, alkylheteroaryl, heteroaryl, (CH2CH2O)n, or (CH2CH(CH3)-O)nH and π is 1 to 10; or
(d) one or more acetylated monosaccharides, acetyiated disaccharides, or acetylated polysaccharides; or
(e) any combination of (a) through (d). Examples of said carboxylic acid ester substrate may include monoacetin; triacetin; monopropionin; dipropionin; tripropionin; monobutyrin; dibutyrin; tributyrin; glucose peπtaacetate; xylose tetraacetate; acetylated xylan; acetylated xylan fragments; β-D-ribofuranose-1 ,2,3,5-tetraacetate; tri-O- acetyl-D-galactal; tri-O-acety!~glucal; propylene glycol diacetate; ethylene glycol diacetate; monoesters or diesters of 1,2-ethanediol; 1,2-propanediol; 1 ,3-propanediol; 1 ,2-butanediol; 1 ,3-butanediol; 2,3-butanediol; 1 ,4-butanediol; 1 ,2-pentanediol; 2,5-pentaπediol; 1 ,6-pentanediol, 1 ,2-hexanediol; 2,5- hexanediol; 1 ,6-hexanediol; or any combination thereof.
As used herein, the term "peracid" is synonymous with peroxyacid, peroxycarboxylic acid, peroxy acid, percarboxylic acid and peroxoic acid.
As used herein, the term "peracetic acid" is abbreviated as "PAA" and is synonymous with peroxyacetic acid, ethaneperoxoic acid and all other synonyms of CAS Registry Number 79-21 -0.
As used herein, the term "monoacetin" is synonymous with glycerol monoacetate, glycerin monoacetate, and glyceryl moπoacetate.
As used herein, the term "diacetin" is synonymous with glycerol diacetate; glycerin diacetate, glyceryl diacetate, and all other synonyms of CAS Registry Number 25395-31-7. As used herein, the term "triacetin" is synonymous with glycerin triacetate; glycerol triacetate; glyceryl triacetate, 1 ,2,3-triacetoxypropane; 1 ,2,3- propanetriol triacetate and all other synonyms of CAS Registry Number 102- 76-1. As used herein, the term "moπobutyrin" is synonymous with glycerol monobutyrate, glycerin monobutyrate, and glyceryl monobutyrate.
As used herein, the term "dibutyrin" is synonymous with glycerol dibutyrate and glyceryl dibutyrate.
As used herein, the term "tributyrin" is synonymous with glycerol tributyrate, 1 ,2,3-tributyryigiycerol, and ail other synonyms of CAS Registry Number 60-01-5.
As used herein, the term "monopropionin" is synonymous with glycerol monopropionate, glycerin monopropionate, and glyceryl monopropionate. As used herein, the term "dipropionin" is synonymous with glycerol dipropionate and glyceryl dipropionate.
As used herein, the term "tripropioπin" is synonymous with glyceryl tripropionate, glycerol tripropionate, 1 ,2,3-tripropionylglycerol, and ail other synonyms of CAS Registry Number 139-45-7.
As used herein, the term "ethyl acetate" is synonymous with acetic ether, acetoxyethane, ethyl ethanoate, acetic acid ethyl ester, ethanoic acid ethyl ester, ethyl acetic ester and all other synonyms of CAS Registry Number 141-78-6.
As used herein, the term "ethyl lactate" is synonymous with lactic acid ethyl ester and all other synonyms of CAS Registry Number 97-64-3. As used herein, the terms "acetylated sugar" and "acetylated saccharide" refer to mono-, di- and polysaccharides comprising at least one acetyl group. Examples include, but are not limited to, glucose pentaacetate, xylose tetraacetate, acetylated xylan, acetylated xylan fragments, β-D- ribofuranose-1 ,2,3,5-tetraacetate, tri-O-acetyl~D-ga!actal, and tri-O-acetyl- glucal.
As used herein, the terms "hydrocarbyl", "hydrocarbyl group", and "hydrocarbyl moiety" is meant a straight chain, branched or cyclic arrangement of carbon atoms connected by single, double, or triple carbon to carbon bonds and/or by ether linkages, and substituted accordingly with hydrogen atoms. Such hydrocarbyl groups may be aliphatic and/or aromatic. Examples of hydrocarbyi groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, cyclopropyl, cyclobutyl, pentyl, cyclopentyl, methylcyclopentyl, hexyl, cyclohexyl, benzyl, and phenyl. In a preferred embodiment, the hydrocarbyl moiety is a straight chain, branched or cyclic arrangement of carbon atoms connected by single carbon to carbon bonds and/or by ether linkages, and substituted accordingly with hydrogen atoms.
As used herein, the terms "monoesters" and "diesters" of 1 ,2-ethanediol; 1 ,2-propanediol; 1 ,3-propanediol; 1 ,2-butanediol; 1 ,3-butanediol; 2,3- butanediol; 1 ,4-butanedioi; 1,2-pentanediol; 2,5-pentanediol; 1 ,6-pentanediol; 1 ,2-hexanediol; 2,5-hexanediol; 1,6-hexanediol; and mixtures thereof, refer to said compounds comprising at least one ester group of the formula RC(O)O, wherein R is a C1 to C7 linear hydrocarbyl moiety. In one embodiment, the carboxylic acid ester substrate is selected from the group consisting of propylene glycol diacetate (PGDA), ethylene glycoi diacetate (EDGA), and mixtures thereof.
As used herein, the term "propylene glycol diacetate" is synonymous with 1 ,2-diacetoxypropane, propylene diacetate, 1,2-propanediol diacetate, and all other synonyms of CAS Registry Number 623-84-7.
As used herein, the term "ethylene glycol diacetate" is synonymous with 1 ,2~diacetoxyethane, ethylene diacetate, glycol diacetate, and all other synonyms of CAS Registry Number 111-55-7.
As used herein, the terms "suitable enzymatic reaction mixture", "components suitable for in situ generation of a peracid", "suitable reaction components", and "suitable aqueous reaction mixture" refer to the materials and water in which the reactants and enzyme catalyst come into contact. The components of the suitable aqueous reaction mixture are provided herein and those skilled in the art appreciate the range of component variations suitable for this process. In one embodiment, the suitable enzymatic reaction mixture produces peracid in situ upon combining the reaction components. As such, the reaction components may be provided as a multicomponeπt system wherein one or more of the reaction components remains separated until use. In another embodiment, the reaction components are first combined to form an aqueous solution of peracid which is subsequently contacted with the surface to be disinfected and/or bleached. The design of systems and means for separating and combining multiple active components are known in the art and generally wii! depend upon the physical form of the individual reaction components. For example, multiple active fluids (liquid-liquid) systems typically use multi-chamber dispenser bottles or two-phase systems (e.g., U.S. Patent Application Publication No. 2005/0139608; U.S. Patent 5,398,846; U.S. Patent 5,624,634; U.S. Patent 6,391 ,840; E.P. Patent 0807156B1; U.S. Patent Application Publication No. 2005/0008526; and PCT Publication No. WO 00/61713) such as found in some bleaching applications wherein the desired bleaching agent is produced upon mixing the reactive fluids. Other forms of multi-component systems used to generate peracid may include, but are not limited to, those designed for one or more solid components or combinations of solid-liquid components, such as powders (e.g., U.S. Patent 5,1 16,575), multi- layered tablets (e.g., U.S. Patent 6,210,639), water dissolvable packets having multiple compartments (e.g., U.S. Patent 6,995,125) and solid agglomerates that react upon the addition of water (e.g., U.S. Patent 6,319,888). In one embodiment, a multicomponent formulation is provided as two individual components whereby an aqueous solution comprising a peroxycarboxylic acid is generated upon combining the two components. In another embodiment, a multicomponent formulation is provided comprising: a) a first component comprising: i) an enzyme powder as disclosed herein; and ii) a carboxylic acid ester, said first component optionally comprising a further ingredient selected from the group consisting of an inorganic or organic buffer, a corrosion inhibitor, a wetting agent, and combinations thereof; and b) a second component comprising a source of peroxygen and water, said second component optionally comprising a hydrogen peroxide stabilizer.
In another embodiment, the carboxylic acid ester in the first component is selected from the group consisting of moπoacetin, diacetiπ, triacetin, and combinations thereof. In another embodiment, the carboxyiic acid ester in the first component is an acetylated saccharide. In another embodiment, the enzyme catalyst in the first component is a particulate soϋd. In another embodiment, the first reaction component is a solid tabiet or powder As used herein, the term "perhydroiysis" is defined as the reaction of a selected substrate with peroxide to form a peracid. Typically, inorganic peroxide is reacted with the selected substrate in the presence of a catalyst to produce the peracid. As used herein, the term "chemical perhydroiysis" includes perhydroiysis reactions in which a substrate (a peracid precursor) is combined with a source of hydrogen peroxide wherein peracid is formed in the absence of an enzyme catalyst.
As used herein, the term "perhydrolase activity" refers to the catalyst activity per unit mass (for example, milligram) of protein, dry cell weight, or immobilized catalyst weight. As used herein, "one unit of enzyme activity" or "one unit of activity" or
"U" is defined as the amount of perhydrolase activity required for the production of 1 μmol of peracid product per minute at a specified temperature. As used herein, the terms "enzyme catalyst" and "perhydrolase catalyst" refer to a catalyst comprising an enzyme having perhydroiysis activity and may be in the form of a whole microbial cell, permeabilized microbial ceil(s), one or more celi components of a microbial cell extract, partially purified enzyme, or purified enzyme. The enzyme catalyst may also be chemically modified (e.g., by pegylatioπ or by reaction with cross-linking reagents). The perhydrolase catalyst may also be immobilized on a soluble or insoluble support using methods well-known to those skilled in the art; see for example, Immobilization of Enzymes and Cells; Gordon F. Bickerstaff, Editor; Humana Press, Totowa, NJ, USA; 1997. As described herein, ail of the present enzymes having perhydroiysis activity are structurally members of the carbohydrate family esterase family 7 (CE-7 family) of enzymes (see Coutinho, P.M., Heπrissat, B. "Carbohydrate-active enzymes: an integrated database approach" in Recent Advances in Carbohydrate Bioenqineering, H.J. Gilbert, G. Davies, B. Henrissat and B. Svensson eds., (1999) The Royal Society of Chemistry, Cambridge, pp. 3-12.). The CE-7 family of enzymes has been demonstrated to be particularly effective for producing peracids from a variety of carboxylic acid ester substrates when combined with a source of peroxygen (See PCT publication No. WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299, 2008/176783, and 2009/0005590 to DiCosimo et al.; each herein incorporated by reference in their entireties).
Members of the CE-7 family include cephalosporin C deacetylases (CAHs; E.C. 3.11.41 ) and acetyl xylan esterases (AXEs; E.C. 3.1.1.72). Members of the CE-7 esterase family share a conserved signature motif (Vincent et al., J, MoI. Biol., 330:593-606 (2003)). Perhydrolases comprising the CE-7 signature motif and/or a substantially simiiar structure are suitable for use in the present invention. Means to identify substantially simiiar biological molecules are well known in the art (e.g., sequence alignment protocols, nucleic acid hybridizations, and/or the presence of a conserved signature motif). In one aspect, the present perhydrolases include enzymes comprising the CE-7 signature motif and at least 30%, preferably at least 33%, more preferably at least 40%, even more preferably at least 42%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to the sequences provided herein. In a further aspect, the present perhydrolases include enzymes comprising the CE-7 signature motif and at least 30%, preferably at least 33%, more preferably at [east 40%, even more preferably at least 42%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to SEQ ID NO: 1 , As used herein, the term "enzyme powder" refers to the spray-dried product of an aqueous formulation comprising (1) at least one enzyme structurally classified as a CE-7 carbohydrate esterase that has perhydrolysis activity, (2) at least one oligosaccharide excipient, and optionally at least one surfactant. In some embodiments, the at least one oligosaccharide excipient has a number average molecular weight of at least about 1250 and a weight average molecular weight of at least about 9000,
As used herein, the terms "cephalosporin C deacetylase" and "cephalosporin C acetyl hydrolase" refer to an enzyme (E.C, 3.1.1.41) that catalyzes the deacetylation of cephalosporins such as cephalosporin C and 7- aminocephalosporanic acid (Mitsushima et a/., (1995) Appl. Env, Microbiol. 61 (6):2224-2229). Several cephalosporin C deacetylases are provided herein having significant perhydroiysis activity.
As used herein, "acetyl xylan esterases" refers to an enzyme (E.C. 3.1.1.72; AXEs) that catalyzes the deacetylation of acetySated xylans and other acetylated saccharides. As illustrated herein, several enzymes classified as acetyl xylan esterases are provided having significant perhydroiysis activity. As used herein, the term "Bacillus subtilis ATCC® 31954™" refers to a bacterial cell deposited to the American Type Culture Collection (ATCC®) having international depository accession number ATCC® 31954™. Bacillus subtilis ATCC® 31954™ has been reported to have an ester hydrolase ("diacetinase") activity capable of hydrolyzing glycerol esters having 2 to 8 carbon acyl groups, especially diacetin (U.S. patent 4,444,886; herein incorporated by reference in its entirety). As described herein, an enzyme having significant perhydrolase activity has been isolated from B. subtilis
ATCC® 31954™ and is provided as SEQ ID NO:1. The amino acid sequence of the isolated enzyme has 100% amino acid identity to the cephalosporin C deacetylase provided by GENBAN K® Accession No. BAA01729.1 (Mitsushima et al., supra). As used herein, the term "Bacillus subtilis ATCC® 29233™" refers to a strain of Bacillus subtilis deposited to the American Type Culture Collection (ATCC®) having international depository accession number ATCC® 29233™. As described herein, an enzyme having significant perhydrotase activity has been isolated and sequenced from B. subtilis ATCC® 29233™ and is provided as SEQ ID NO:12.
As used herein, the term "Clostridium thermocellum ATCC® 27405™" refers to a strain of Clostridium thermocellum deposited to the American Type Culture Collection (ATCC®) having international depository accession number ATCC® 27405™. The amino acid sequence of the enzyme having perhydrolase activity from C. thermocellum ATCC® 27405™ is provided as SEQ ID NO;5.
As used herein, the term "Bacillus subtilis ATCC® 6633™" refers to a bacterial eel! deposited to the American Type Culture Collection (ATCC®) having international depository accession number ATCC® 6633™. Bacillus subtilis ATCC® 6633™ has been reported to have cephalosporin acetylhydrolase activity (U.S. patent 6,465,233). The amino acid sequence of the enzyme having perhydrolase activity from B. subtilis ATCC® 6633™ is provided as SEQ ID NO;2.
As used herein, the term "Bacillus licheniformis ATCC® 14580™" refers to a bacterial cell deposited to the American Type Culture Collection (ATCC®) having international depository accession number ATCC® 14580™. Bacillus licheniformis ATCC® 14580™ has been reported to have cephalosporin acetyihydrolase activity. The amino acid sequence of the enzyme having perhydrolase activity from B. licheniformis ATCC® 14580™ is provided as SEQ ID NO:3.
As used herein, the term "Bacillus pumilus PS213" refers to a bacterial cell reported to have acetyl xylan esterase activity (GENBANK® AJ249957). The amino acid sequence of the enzyme having perhydrolase activity from Bacillus pumilus PS213 is provided as SEQ ID NO:4.
As used herein, the term "Thermotoga neapolitana " refers to a strain of Thermotoga neapolitana reported to have acetyl xylan esterase activity (GENBANK® AAB70869). The amino acid sequence of the enzyme having perhydrolase activity from Thermotoga neapolitana is provided as SEQ ID NO: 6.
As used herein, the term "Thermotoga maritime MSB8" refers to a bacterial cell reported to have acetyl xylan esterase activity (GENBANK® NP_227893.1). The amino acid sequence of the enzyme having perhydrolase activity from Thermotoga maritima MSB8 is provided as SEQ ID NO: 7.
As used herein, the term "Bacillus clausii KSM-K16" refers to a bacterial cell reported to have cephalosporiπ-C deacetylase activity (GENBANK® YP__175265). The amino acid sequence of the enzyme having perhydrolase activity from Bacillus clausii KSM-K16 is provided as SEQ ID NO: 1 1.
As used herein, the term "Thermoanearobacterium saccharolyticum" refers to a bacterial strain reported to have acetyl xylan esterase activity (GENBANK® S41858). The amino acid sequence of the enzyme having perhydrolase activity from Thermoanearobacterium saccharolyticum is provided as SEQ ID NO: 13.
As used herein, the term "Thermotoga lettingae" refers to a bacterial cell reported to have acetyl xylan esterase activity (GENBANK® CP000812). The deduced amino acid sequence of the enzyme having perhydrolase activity from Thermotoga lettingae is provided as SEQ ID NO: 14.
As used herein, the term "Thermotoga petrophila" refers to a bacterial celi reported to have acetyl xylan esterase activity (GENBANK® CP000702). The deduced amino acid sequence of the enzyme having perhydrolase activity from Thermotoga lettingae is provided as SEQ ID NO: 15.
As used herein, the term "Thermotoga sp. RQ2" refers to a bacteria! cell reported to have acetyl xylan esterase activity (GENBANK® CP000969). Two different acetyl xylan esterases have been identified from Thermotoga sp. RQ2 and are referred to herein as "RQ2(a)" (the deduced amino acid sequence provided as SEQ ID NO: 16) and BRQ2(b)" (the deduced amino acid sequence provided as SEQ ID NO: 17).
As used herein, an "isolated nucleic acid molecule" and "isolated nucleic acid fragment" will be used interchangeably and refer to a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid molecule in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA or synthetic DNA.
The term "amino acid" refers to the basic chemical structural unit of a protein or polypeptide. The following abbreviations are used herein to identify specific amino acids: Three-Letter One-Letter
Amino Acid Abbreviation Abbreviation
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamine GIn Q
Glutamic acid GIu E
Glycine GIy G
Histidine His H lsoleucine lie I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine VaI V
Any amino acid or as defined herein Xaa X
As used herein, "substantially similar" refers to nucleic acid molecules wherein changes in one or more nucleotide bases results in the addition, substitution, or deletion of one or more amino acids, but does not affect the functional properties (i.e., perhydrolytic activity) of the protein encoded by the DNA sequence. As used herein, "substantially similar" also refers to an enzyme having an amino acid sequence that is at least 30%, preferably at least 33%, more preferably at least 40%, more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, yet even more preferably at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequences reported herein wherein the resulting enzyme retains the present functional properties (i.e., perhydroiytic activity). "Substantially similar" may also refer to an enzyme having perhydroiytic activity encoded by nucleic acid molecules that hybridize under stringent conditions to the nucleic acid molecules reported herein. It is therefore understood that the invention encompasses more than the specific exemplary sequences.
For example, it is well known in the art that alterations in a gene which result in the production of a chemically equivalent amino acid at a given site, but do not affect the functional properties of the encoded protein are common. For the purposes of the present invention substitutions are defined as exchanges within one of the following five groups:
1. Small aliphatic, nonpolar or slightly polar residues: Ala, Ser, Thr
(Pro, GIy); 2. Polar, negatively charged residues and their amides: Asp, Asn, Giu,
GIn;
3. Polar, positively charged residues: His, Arg, Lys;
4. Large aliphatic, nonpolar residues: Met, Leu, lie, VaI (Cys); and
5. Large aromatic residues: Phe, Tyr, and Trp. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue (such as glycine) or a more hydrophobic residue (such as valine, leucine, or isoleucine). Similarly, changes which result in substitution of one negatively charged residue for another (such as aspartic acid for glutamic acid) or one positively charged residue for another (such as lysine for arginine) can also be expected to produce a functionally equivalent product. In many cases, nucleotide changes which result in alteration of the N-terminai and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Moreover, the skilled artisan recognizes that substantially similar sequences are encompassed by the present invention. In one embodiment, substantially similar sequences are defined by their ability to hybridize, under stringent conditions (0.1X SSC, 0.1% SDS, 650C and washed with 2X SSC, 0.1% SDS followed by 0.1 X SSC1 0.1% SDS, 650C) with the sequences exemplified herein. As used herein, a nucleic acid molecule is "hybridizable" to another nucleic acid molecule, such as a cDNA, genomic DNA, or RNA, when a single strand of the first molecule can anneal to the other molecule under appropriate conditions of temperature and solution ionic strength. Hybridization and washing conditions are well known and exemplified in Sambrook, J. and Russell, D,, T. Molecular Cloning: A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor (2001). The conditions of temperature and ionic strength determine the "stringency" of the hybridization. Stringency conditions can be adjusted to screen for moderateiy similar molecules, such as homologous sequences from distantly related organisms, to highly similar molecules, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes typically determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 450C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 500C for 30 min. A more preferred set of conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0,5% SDS was increased to 600C. Another preferred set of stringent hybridization conditions is 0.1 X SSC, 0.1% SDS1 650C and washed with 2X SSC, 0.1 % SDS followed by a final wash of 0.1 X SSC, 0.1 % SDS, 65°C with the sequences exemplified herein, in a further embodiment, the present compositions and methods employ an enzyme having perhydroiase activity encoded by isolated nucleic acid molecule that hybridizes under stringent conditions to a nucleic acid molecule encoding a polypeptide having perhydrolysis activity, said polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1 , SEQ ID NO: 2, SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 , SEQ ID NO: 12, SEQ ID NO: 13; SEQ ID NO: 14; SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ SD NO: 20, SEQ ID NO: 21 , SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, and SEQ ID NO: 25.
Hybridization requires that the two nucleic acids contain complementary sequences, although depending on the stringency of the hybridization, mismatches between bases are possible. The appropriate stringency for hybridizing nucleic acids depends on the length of the nucleic acids and the degree of complementation, variables well known in the art. The greater the degree of similarity or homology between two nucleotide sequences, the greater the value of Tm for hybrids of nucleic acids having those sequences. The relative stability (corresponding to higher Tm) of nucleic acid hybridizations decreases in the following order: RNA: RNA, DNA: RNA, DNA: DNA. For hybrids of greater than 100 nucleotides in length, equations for calculating Tm have been derived (Sambrook and Russell, supra). For hybridizations with shorter nucleic acids, i.e., oligonucleotides, the position of mismatches becomes more important, and the length of the oligonucleotide determines its specificity (Sambrook and Russell, supra). In one aspect, the length for a hybridizable nucleic acid is at least about 10 nucleotides. Preferably, a minimum length for a hybridizable nucleic acid is at least about 15 nucleotides in length, more preferably at least about 20 nucleotides in length, even more preferably at least 30 nucleotides in length, even more preferably at least 300 nucleotides in length, and most preferably at least 800 nucleotides in length. Furthermore, the skilled artisan will recognize that the temperature and wash solution salt concentration may be adjusted as necessary according to factors such as length of the probe.
As used herein, the term "percent identity" is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to, methods described in: Computational Molecular Biology (Lesk, A. M., ed.) Oxford University Press, NY (1988); Biocomputinq: informatics and Genome Projects (Smith, D. W., ed.) Academic Press, NY (1993); Computer Analysis of Sequence Data, Part i (Griffin, A. M., and Griffin, H. G., eds.) Humana Press, NJ (1994); Sequence Analysis in Molecular Biology (von Heinje, G., ed.) Academic Press (1987); and Sequence Analysis Primer (Gribskov, M. and Devereux, J., eds.) Stockton Press, NY (1991). Methods to determine identity and similarity are codified in publicly available computer programs. Sequence alignments and percent identity caicuiations may be performed using the Megaiign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, Wl), the AlignX program of Vector NTI v. 7.0 (Informax, Inc., Bethesda, MD), or the EMBOSS Open Software Suite (EMBL-EBI; Rice et at., Trends in Genetics 16, (6):276-277 (2000)). Multiple alignment of the sequences can be performed using the Clustal method (e.g., CLUSTALW; for example version 1.83) of alignment (Higgins and Sharp, CABIOS, 5:151-153 (1989); Higgins et al., Nucleic Acids Res. 22:4673-4680 (1994); and Chenna et a/., Nucleic Acids Res 31 (13):3497-500 (2003)), available from the European Molecular Biology Laboratory via the European Bioinformatics Institute) with the default parameters. Suitable parameters for CLUSTALW protein alignments include GAP Existence penalty=15, GAP extension =0.2, matrix = Gonnet (e.g. Gonnet250), protein ENDGAP = -1 , Protein GAPDlST=4, and KTUPLE=L In one embodiment, a fast or slow alignment is used with the default settings where a slow alignment is preferred. Alternatively, the parameters using the CLUSTALW method (version 1.83) may be modified to also use KTUPLE =1, GAP PENALTY=I O, GAP extension =1 , matrix = BLOSUM (e.g. BLOSUM64), WlNDOW=S, and TOP DIAGONALS SAVED=S.
In one aspect, suitable isolated nucleic acid molecules encode a polypeptide having an amino acid sequence that is at least about 30%, preferably at least 33%, preferably at least 40%, preferably at least 50%, preferably at least 60%, more preferably at least 70%, more preferably at least 80%, even more preferably at least 85%, even more preferably at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequences reported herein. Suitable nucleic acid molecules not only have the above homologies, but also typically encode a polypeptide having about 300 to about 340 amino acids, more preferably about 310 to about 330 amino acids, and most preferably about 318 amino acids.
As used herein, the terms "signature motif, "CE-7 signature motif, and "diagnostic motif refer to conserved structures shared among a family of enzymes having a defined activity. The signature motif can be used to define and/or identify the family of structurally related enzymes having similar enzymatic activity for a defined family of substrates. The signature motif can be a single contiguous amino acid sequence or a coliection of discontiguous, conserved motifs that together form the signature motif. Typically, the conserved motif(s) is represented by an amino acid sequence. As described herein, the present enzymes having perhydrolysis activity ("perhydrolases") belong to the family of CE-7 carbohydrate esterases (DiCosimo et a/., supra). As used herein, the phrase "enzyme is structurally classified as a CE-7 enzyme" or "CE-7 perhydrolase" will be used to refer to enzymes having perhydrolysis activity which are structurally classified as a CE-7 carbohydrate esterase. This family of enzymes can be defined by the presence of a signature motif (Vincent et ai., supra). As defined herein, the signature motif for CE-7 esterases comprises three conserved motifs (residue position numbering relative to reference sequence SEQ ID NO:1): a) Arg118-G!y119-Gln120; b) Gly179-Xaa180-Ser181-Gln182-Gly183; and c) His298-Glu299.
Typically, the Xaa at amino acid residue position 180 is glycine, alanine, proline, tryptophan, or threonine. Two of the three amino acid residues belonging to the catalytic triad are in bold. In one embodiment, the Xaa at amino acid residue position 180 is selected from the group consisting of glycine, alanine, proline, tryptophan, and threonine.
Further analysis of the conserved motifs within the CE-7 carbohydrate esterase family indicates the presence of an additional conserved motif (LXD at amino acid positions 267-269 of SEQ ID NO:1 ) that may be used to further define a perhydrolase belonging to the CE-7 carbohydrate esterase family. In a further embodiment, the signature motif defined above includes a fourth conserved motif defined as: Leu267-Xaa268-Asp269.
The Xaa at amino acid residue position 268 is typically isoleucine, valine, or methionine. The fourth motif includes the aspartic acid residue (bold) belonging to the catalytic triad (Ser181-Asp269-His298). A number of well-known global alignment algorithms may be used to align two or more amino acid sequences representing enzymes having perhydrolase activity to determine if the enzyme is comprised of the present signature motif. The aligned sequeπce(s) are compared to the reference sequence (SEQ ID NO:1) to determine the existence of the signature motif. In one embodiment, a CLUSTAL alignment (such as CLUSTALW) using a reference amino acid sequence (as used herein the perhydrolase sequence (SEQ ID NO:1) from the Bacillus subtilis ATCC® 31954™) is used to identify perhydrolases belonging to the CE-7 esterase family. The relative numbering of the conserved amino acid residues is based on the residue numbering of the reference amino acid sequence to account for small insertions or deletions (for example, five amino acids of less) within the aligned sequence.
Examples of other suitable algorithms that may be used to identify sequences comprising the present signature motif (when compared to the reference sequence) include, but are not limited to, Needteman and Wunsch (J. MoI. Biol. 48, 443-453 (1970); a global alignment tool) and Smith-Waterman (J. MoI. Biol. 147: 195-197 (1981); a local alignment tool). In one embodiment, a Smith-Waterman alignment is implemented using default parameters. An example of suitable default parameters include the use of a BLOSUM62 scoring matrix with GAP open penalty = 10 and a GAP extension penalty = 0.5. A comparison of the overall percent identity among perhydrolases exemplified herein indicates that enzymes having as little as 33% identity to SEQ ID NO:1 (while retaining the signature motif) exhibit significant perhydrolase activity and are structurally classified as CE-7 carbohydrate esterases, in one embodiment, suitable perhydrolases include enzymes comprising the CE-7 signature motif and at least 30%, preferably at least 33%, more preferably at least 40%, even more preferably at least 42%, even more preferably at least 50%, even more preferably at least 60%, even more preferably at least 70%, even more preferably at least 80%, even more preferably at least 90%, and most preferably at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% amino acid identity to SEQ ID NO: 1.
Alternatively, a contiguous amino acid sequence comprising the region encompassing the conserved motifs may also be used to identify CE-7 family members.
As used herein, "codon degeneracy" refers to the nature of the genetic code permitting variation of the nucleotide sequence without affecting the amino acid sequence of an encoded polypeptide. Accordingly, the present invention relates to any nucleic acid molecule that encodes all or a substantial portion of the amino acid sequences encoding the present microbial polypeptide. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.
As used herein, the term "codon optimized", as it refers to genes or coding regions of nucleic acid molecules for transformation of various hosts, refers to the alteration of codons in the gene or coding regions of the nucleic acid molecules to reflect the typical codon usage of the host organism without altering the polypeptide for which the DNA codes.
As used herein, "synthetic genes" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments that are then enzymatically assembled to construct the entire gene. "Chemically synthesized", as pertaining to a DNA sequence, means that the component nucleotides were assembled in vitro. Manual chemical synthesis of DNA may be accomplished using well- established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the genes can be tailored for optima! gene expression based on optimization of nucleotide sequences to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.
As used herein, "gene" refers to a nucleic acid molecule that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different from that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.
As used herein, "coding sequence" refers to a DNA sequence that codes for a specific amino acid sequence. "Suitable regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, RNA processing site, effector binding site and stem-loop structure.
As used herein, "promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. in general, a coding sequence is located 3' to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene at different stages of development, or in response to different environmental or physiological conditions. Promoters that cause a gene to be expressed at most times are commonly referred to as "constitutive promoters". It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.
As used herein, the "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenytation recognition sequences (normally limited to eukaryotes) and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts (normally limited to eukaryotes) to the 3' end of the mRNA precursor.
As used herein, the term "operably linked" refers to the association of nucleic acid sequences on a single nucleic acid molecule so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence, i.e., that the coding sequence is under the transcriptional control of the promoter. Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.
As used herein, the term "expression" refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid molecule of the invention. Expression may also refer to translation of mRNA into a polypeptide. As used herein, "transformation" refers to the transfer of a nucleic acid molecule into the genome of a host organism, resulting in genetically stable inheritance. In the present invention, the host cell's genome includes chromosomal and extrachromosoma! (e.g. plasmid) genes. Host organisms containing the transformed nucleic acid molecules are referred to as "transgenic" or "recombinant" or "transformed" organisms.
As used herein, the terms "plasmid", "vector" and "cassette" refer to an extrachromosomal element often carrying genes which are not part of the central metabolism of the cell, and usually in the form of circular doubie- stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. "Transformation cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that facilitate transformation of a particular host cell. "Expression cassette" refers to a specific vector containing a foreign gene and having elements in addition to the foreign gene that allow for enhanced expression of that gene in a foreign host.
As used herein, the term "sequence analysis software" refers to any computer algorithm or software program that is useful for the analysis of nucleotide or amino acid sequences. "Sequence analysis software" may be commercially available or independently developed. Typical sequence analysis software will include, but is not limited to, the GCG suite of programs (Wisconsin Package Version 9.0, Genetics Computer Group (GCG), Madison, Wl), BLASTP1 BLASTN, BLASTX (Altschu! et al., J. MoI. Biol. 215:403-410 (1990), and DNASTAR (DNASTAR, Inc. 1228 S. Park St. Madison, Wl 53715 USA), CLUSTALW (for example, version 1.83; Thompson et a/., Nucleic Acids Research, 22(22):4673-4680 (1994), and the FASTA program incorporating the Smith-Waterman algorithm (W. R. Pearson, Comput. Methods Genome Res., [Proc. Int. Symp.] (1994), Meeting Date 1992, 111-20. Editor(s): Suhai, Sandor. Publisher: Plenum, New York, NY), Vector NTI (Informax, Bethesda, MD) and Sequeπcher v. 4.05. Within the context of this application it will be understood that where sequence analysis software is used for analysis, that the results of the analysis will be based on the "default values" of the program referenced, unless otherwise specified. As used herein "default values" will mean any set of values or parameters set by the software manufacturer that originally load with the software when first initialized.
As used herein, the term "biological contaminants" refers to one or more unwanted and/or pathogenic biological entities including, but not limited to, microorganisms, spores, viruses, prions, and mixtures thereof. The process produces an efficacious concentration of at least one percarboxylic acid useful to reduce and/or eliminate the presence of the viable biologica! contaminants. In a preferred embodiment, the biological contaminant is a viable pathogenic microorganism.
As used herein, the term "disinfect" refers to the process of destruction of or prevention of the growth of biological contaminants, As used herein, the term "disinfectant" refers to an agent that disinfects by destroying, neutralizing, or inhibiting the growth of biological contaminants. Typically, disinfectants are used to treat inanimate objects or surfaces. As used herein, the term
"disinfection" refers to the act or process of disinfecting. As used herein, the term "antiseptic" refers to a chemical agent that inhibits the growth of disease- carrying microorganisms. In one aspect, the biological contaminants are pathogenic microorganisms. As used herein, the term "sanitary" means of or relating to the restoration or preservation of health, typically by removing, preventing or controlling an agent that may be injurious to health. As used herein, the term "sanitize" means to make sanitary. As used herein, the term "sanitizer" refers to a sanitizing agent. As used herein the term "sanitization" refers to the act or process of sanitizing.
As used herein, the term "virucide" refers to an agent that inhibits or destroys viruses, and is synonymous with "viricide". An agent that exhibits the ability to inhibit or destroy viruses is described as having "virucidal" activity. Peracids can have virucidal activity. Typical alternative virucides known in the art which may be suitable for use with the present invention include, for example, alcohols, ethers, chloroform, formaldehyde, phenols, beta propiolactone, iodine, chlorine, mercury salts, hydroxylamine, ethylene oxide, ethylene glycol, quaternary ammonium compounds, enzymes, and detergents. As used herein, the term "biocide" refers to a chemical agent, typically broad spectrum, which inactivates or destroys microorganisms. A chemical agent that exhibits the ability to inactivate or destroy microorganisms is described as having "biocidal" activity. Peracids can have biocidal activity. Typical alternative biocides known in the art, which may be suitable for use in the present invention include, for example, chlorine, chlorine dioxide, chloroisocyanurates, hypochlorites, ozone, acrolein, amines, chlorinated phenoiics, copper salts, orgaπo-sufphur compounds, and quaternary ammonium salts. As used herein, the phrase "minimum biocidal concentration" refers to the minimum concentration of a biocidal agent that, for a specific contact time, will produce a desired lethal, irreversible reduction in the viable population of the targeted microorganisms. The effectiveness can be measured by the iog10 reduction in viable microorganisms after treatment In one aspect, the targeted reduction in viable microorganisms after treatment is at least a 3-log reduction, more preferably at least a 4-log reduction, and most preferably at least a 5-iog reduction. In another aspect, the minimum biocidal concentration is at least a 6-log reduction in viable microbial cells.
As used herein, the terms "peroxygen source" and "source of peroxygen" refer to compounds capable of providing hydrogen peroxide at a concentration of about 1 mM or more when in an aqueous solution including, but not limited to, hydrogen peroxide, hydrogen peroxide adducts (e.g., urea- hydrogen peroxide adduct (carbamide peroxide)), perborates, and percarbonates. As described herein, the concentration of the hydrogen peroxide provided by the peroxygen compound in the aqueous reaction formulation is initially at least 1 mM or more upon combining the reaction components. In one embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is at least 10 mM. In another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is at ieast 100 mM. In another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is at least 200 mM. In another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is 500 mM or more. In yet another embodiment, the hydrogen peroxide concentration in the aqueous reaction formulation is 1000 mM or more. The molar ratio of the hydrogen peroxide to enzyme substrate, e.g. triglyceride, (H ≥O≥: substrate) in the aqueous reaction formulation may be from about 0.002 to 20, preferably about 0.1 to 10, and most preferably about 0.5 to 5. By "oligosaccharide" is meant compounds containing between 2 and at least 24 monosaccharide units linked by glycosidic linkages. The term "monosaccharide" refers to a compound of empirical formula (CH2O)n, where n>3, the carbon skeleton is unbranched, each carbon atom except one contains a hydroxyl group, and the remaining carbon atom is an aldehyde or ketone at carbon atom 2. The term "monosaccharide" also refers to intracellular cyclic hemiaceta! or hemiketal forms.
As used herein, the term "excipient" refers to an inactive substance used to stabilize the active ingredient in a formulation, such as the storage stability of the active ingredient. Excipients are also sometimes used to bulk up formulations that contain active ingredients. As described herein, the "active ingredient" is an enzyme catalyst comprising at least one enzyme having perhydrolysis activity. In one embodiment, the active ingredient is at least one CE-7 carbohydrate esterase having perhydrolysis activity. As used herein, the term "oligosaccharide excipient" means an oligosaccharide that, when added to an aqueous enzyme solution, improves recovery/retention of active enzyme {i.e., perhydrolase activity) after spray drying and/or improves storage stability of the resulting spray-dried enzyme powder or a formulation of the enzyme powder and a carboxylic acid ester. In one embodiment, the addition of the oligosaccharide excipient prior to spray drying improves the storage stability of the enzyme when stored in the carboxylic acid ester (/.e., a storage mixture substantially free of water). The carboxylic acid ester may contain a very low concentration of water, for example, triacetin typically has between 180 ppm and 300 ppm of water. As used herein, the phrase "substantially free of water" will refer to a concentration of water in a mixture of the enzyme powder and the carboxylic acid ester that does not adversely impact the storage stability of enzyme powder when present in the carboxylic acid ester. In a further embodiment, "substantially free of water" may mean less than 2000 ppm, preferably less than 1000 ppm, more preferably less than 500 ppm, and even more preferably less than 250 ppm of water in the formulation comprising the enzyme powder and the carboxylic acid ester. Enzyme Powder
One aspect is for an enzyme powder comprising a formulation of at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity, at least one excipient, and optionally at least one surfactant. In one embodiment, the enzyme powder is formed by spray drying. In some embodiments, the at least one excipient is an oligosaccharide excipient has a number average molecular weight of at least about 1250 and a weight average molecular weight of at feast about 9000.
The at least one enzyme can be any of the CE-7 carbohydrate esterases described herein or can be any of the CE-7 carbohydrate esterases described in co-owned, copending Published U.S. Patent Application Nos. 2008/0176299 and 2009/0005590 (each incorporated herein by reference in its entirety). In some embodiments, the at least one enzyme is selected from the group consisting of SEQ ID NOs: 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, and 25.
The at least one enzyme is present in the spray-dried formulation in an amount in a range of from about 5 wt % to about 75 wt% based on the dry weight of the spray-dried formulation. A preferred wt % range of enzyme in the spray-dried formulation is from about 10 wt% to 50 wt%, and a more preferred wt % range of enzyme in the spray-dried formulation is from about 20 wt% to 33 wt%
The spray-dried formulation further comprises at least one oligosaccharide excipient. In some embodiments, the at least one oligosaccharide excipient has a number average molecular weight of at least about 1250 and a weight average molecular weight of at least about 9000. In some embodiments, the oligosaccharide excipient has a number average molecular weight of at least about 1700 and a weight average molecular weight of at least about 15000. Specific oligosaccharides useful in the present invention include, but are not limited to, maltodextrin, xylan, maπnan, fucoidan, galactomaπnan, chitosan, raffiπose, stachyose, pectin, inuliπ, levan, gramiπan, and amyiopectiπ, sucrose, lactulose, lactose, maltose, trehalose, cellobiose, nigerotriose, maltotriose, melezitose, maltotriuiose, raffiπose, kestose, and mixtures thereof. Oligosaccharide-based excipieπts useful in the present invention include, but are not limited to, water-soluble non-ionic cellulose ethers, such as hydroxymethyl-cellulose and hydroxypropylmethylcellulose, and mixtures thereof.
The excipient is present in the formulation in an amount in a range of from about 95 wt% to about 25 wt% based on the dry weight of the spray-dried formulation. A preferred wt % range of excipient in the spray-dried formulation is from about 90 wt% to 50 wt%, and a more preferred wt % range of excipient in the spray-dried formulation is from about 80 wt% to 67 wt%.
In some embodiments, the formulation further comprises at least one surfactant. Useful surfactants include, but are not limited to, ionic and noπionic surfactants or wetting agents, such as ethoxyiated castor oil, poiygiycolyzed glycerides, acetylated monoglycerides, sorbitan fatty acid esters, poloxamers, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene derivatives, monoglycerides or ethoxyiated derivatives thereof, diglycerides or polyoxyethylene derivatives thereof, sodium docusate, sodium laurylsulfate, cholic acid or derivatives thereof, lecithins, phospholipids, block copolymers of ethylene glycol and propylene glycol, and non-ionic organosilicones. Preferably, the surfactant is a polyoxyethyiene sorbitan fatty ester, with polysorbate 80 being more preferred, When part of the formulation, the surfactant is present in an amount in a range of from about 5 wt% to 0.1 wt% based on the weight of protein present in the spray dried formulation, preferably from about 2 wt% to 0.5 wt% based on the weight of protein present in the spray dried formulation.
The spray dried formulation may additionally comprise one or more buffers (such as sodium and/or potassium salts of bicarbonate, citrate, acetate, phosphate, pyrophosphate, methylphosphonate, succinate, maiate, fumarate, tartrate, or maleate), and an enzyme stabilizer (e.g., ethyieπediaminetetraacetic acid, (i-hydroxyethylidene)bisphosphonic acid). Spray drying of the formulation of at least one enzyme, at least one oligosaccharide excipient, and optionally at least one surfactant is carried out, for example, as described generally in the SpXay^D^ing^Handboo^ 5th ed., K. Masters, John Wiley & Sons, Inc., NY, N.Y. (1991), and in PCT Patent Publication Nos. WO 97/41833 (1997) and WO 96/32149 (1996) to Plate, R., et a/..
In general spray drying consists of bringing together a highly dispersed liquid and a sufficient volume of hot air to produce evaporation and drying of the liquid droplets. Typically the feed is sprayed into a current of warm filtered air that evaporates the solvent and conveys the dried product to a collector. The spent air is then exhausted with the solvent. Those skilled in the art wil! appreciate that several different types of apparatus may be used to provide the desired product. For example, commercial spray dryers manufactured by Buchi Ltd. (Postfach, Switzerland) or GEA Niro Corp. (Copenhagen, Denmark) will effectively produce particles of desired size. It will further be appreciated that these spray dryers, and specifically their atomizers, may be modified or customized for specialized applications, such as the simultaneous spraying of two solutions using a double nozzle technique. More specifically, a water-in-oil emulsion can be atomized from one nozzle and a solution containing an anti- adherent such as mannito! can be co-atomized from a second nozzle. In other cases it may be desirable to push the feed solution though a custom designed nozzle using a high pressure liquid chromatography (HPLC) pump. Provided that microstructures comprising the correct morphology and/or composition are produced the choice of apparatus is not critical and would be apparent to the skilled artisan in view of the teachings herein.
The temperature of both the inlet and outlet of the gas used to dry the sprayed material is such that it does not cause degradation of the enzyme in the sprayed material. Such temperatures are typically determined experimentally, although generally, the inlet temperature will range from about 50 0C to about 225 0C1 while the outlet temperature will range from about 30 0C to about 150 0C. Preferred parameters include atomization pressures ranging from about 20-150 psi (0.14 MPa - 1.03 MPa), and preferably from about 30- 40 to 100 psi (0.21-0.28 MPa to 0.69 MPa). Typically the atomization pressure employed will be one of the following (MPa) 0.14, 0.21, 0.28, 0.34, 0.41 , 0.48, 0.55, 0.62, 0.69, 0.76, 0.83 or above.
The enzyme powder or a formulation of the enzyme powder in carboxylic acid ester substantially retains its enzymatic activity for an extended period of time when stored at ambient temperature. The enzyme powder or a formulation of the spray-dried enzyme powder in carboxylic acid ester substantially retains its enzymatic activity at elevated temperatures for short periods of time. In one embodiment, "substantially retains its enzymatic activity" is meant that the spray-dried enzyme powder or a formulation of the spray-dried enzyme powder in carboxylic acid ester retains at least about 75 percent of the enzyme activity of the enzyme in the spray-dried enzyme powder or a formulation of the spray-dried enzyme powder after an extended storage period at ambient temperature and/or after a short storage period at an elevated temperature (above ambient temperature) in a formulation comprised of a carboxylic acid ester and the enzyme powder as compared to the initial enzyme activity of the enzyme powder prior to the preparation of a formulation comprised of the carboxyϋc acid ester and the enzyme powder. The extended storage period is a period of time of from about one year to about two years at ambient temperature, In one embodiment, the short storage period is at an elevated temperature for a period of time of from when the formulation comprised of a carboxylic acid ester and the enzyme powder is produced at 40 0C to about eight weeks at 40 0C. In another embodiment, the elevated temperature is in a range of from about 30 °C to about 52 0C. In a preferred embodiment, the elevated temperature is in a range of from about 30 0C to about 40 0C.
In some embodiments, the spray-dried enzyme powder has at least 75 percent of the enzyme activity of the at least one enzyme after eight weeks storage at 40 °C in a formulation comprised of a carboxylic acid ester and the enzyme powder as compared to the initial enzyme activity of the enzyme powder prior to the preparation of a formulation comprised of the carboxyiic acid ester and the enzyme powder at 40 0C. In other embodiments, the enzyme powder has at least 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99, or 100 percent of the enzyme activity of the at least one enzyme after eight weeks storage at 40 0C in a formulation comprised of a carboxylic acid ester and the enzyme powder as compared to the initial enzyme activity of the enzyme powder prior to the preparation of a formulation comprised of the carboxylic acid ester and the enzyme powder at 40 0C. Preferably, perhydrolysis activity is measured as described in Example 8-13, infra, but any method of measuring perhydrolysis activity can be used in the practice of the present invention.
In some embodiments, further improvement in enzyme activity over the stated periods of time can be achieved by adding a buffer having a buffering capacity in a pH range of from about 5.5 to about 9.5 to the formulation comprised of the carboxylic acid ester and the spray-dried enzyme powder. Suitable buffer for use in the formuiation may include, but is not iimited to, sodium sa!t, potassium salt, or mixtures of sodium or potassium salts of bicarbonate, pyrophosphate, phosphate, methyiphosphonate, citrate, acetate, malate, fumarate, tartrate maleate or succinate. Preferred buffers for use in the formulation comprised of the carboxylic acid ester and the spray-dried enzyme powder include the sodium salt, potassium salt, or mixtures of sodium or potassium salts of bicarbonate, phosphate, methyiphosphonate, or citrate. In embodiments where a buffer is present in the carboxylic acid ester and enzyme powder formulation, the buffer may be present in an amount in a range of from about 0.01 wt% to about 50 wt% based on the weight of carboxylic acid ester in the formulation comprised of carboxylic acid ester and enzyme powder. The buffer may be present in a more preferred range of from about 0.10 % to about 10 % based on the weight of carboxylic acid ester in the formulation comprised of carboxylic acid ester and enzyme powder. Further, in these embodiments, the comparison between perhydrolysis activities of the enzyme is determined as between (a) an enzyme powder which retains at least 75 percent of the perhydrolysis activity of the at least one enzyme after eight weeks storage at 40 0C in a formulation comprised of a carboxylic acid ester, a buffer having a buffering capacity in a pH range of from about 5.5 to about 9.5, and the enzyme powder and (b) the initial perhydrolysis activity of the enzyme powder prior to the preparation of a formuiation comprised of the carboxyiic acid ester, the buffer having a buffering capacity in a pH range of from about 5.5 to about 9.5, and the enzyme powder. it is intended that the enzyme powder be stored as a formulation in the organic compound that is a substrate for the at least one enzyme, such as triacetin. In the absence of added hydrogen peroxide, triacetin is normally hydroiyzed in aqueous solution by a CE-7 carbohydrate esterase to produce diacetin and acetic acid, and the production of acetic acid results in a decrease in the pH of the reaction mixture. One requirement for long term storage stability of the enzyme in triacetin is that there not be significant reaction of the triacetin with any water that might be present in the triacetin; the specification for water content in one commercial triacetin (supplied by Tessenderlo Group, Brussels, Belgium) is 0.03 wt% water (300 ppm). Any hydrolysis of triacetin that occurs during storage of the enzyme in triacetin would produce acetic acid, which could result in a decrease in activity or inactivation of the perhydrolysis activity of the CE-7 carbohydrate esterases; the perhydrolase activity of the CE-7 carbohydrate esterases is typically inactivated at or below a pH of 5.0 (see U.S. Patent Application No. 12/539,025 to DiCosimo, R., et a/.). The oligosaccharide excipient selected for use in the present application must provide stability of the enzyme in the organic substrate for the enzyme under conditions where acetic acid might be generated due to the presence of low concentrations of water in the formuiation.
Suitable Reaction Conditions for the Enzyme-catalyzed Preparation of Peracids from Carboxylic Acid Esters and Hydrogen Peroxide In one aspect of the invention, a process is provided to produce an aqueous formulation comprising a peracid by reacting one or more carboxylic acid esters with source of peroxygen (hydrogen peroxide, sodium perborate or sodium percarbonate) in the presence of an enzyme catalyst having perhydrolysis activity. In one embodiment, the enzyme catalyst comprises at ϊeast one enzyme having perhydrolysis activity, wherein said enzyme is structurally classified as a member of the CE-7 carbohydrate esterase family (CE-7; see Coutinho, P.M., Henrissat, B., supra). In another embodiment, the perhydrolase catalyst is structurally classified as a cephalosporin C deacetylase. In another embodiment, the perhydrolase catalyst is structurally classified as an acetyl xylan esterase.
In one embodiment, the perhydrolase catalyst comprises an enzyme having perhydrolysis activity and a signature motif comprising: a) an RGQ motif as amino acid residues 1 18-120; b) a GXSQG motif at amino acid residues 179-183; and c) an HE motif as amino acid residues 298-299 when aligned to reference sequence SEQ ID NO:1 using CLUSTALW.
In a further embodiment, the signature motif additional comprises a fourth conserved motif defined as an LXD motif at amino acid residues 267- 269 when aligned to reference sequence SEQ ID NO:1 using CLUSTALW,
In another embodiment, the perhydroiase catalyst comprises an enzyme having the present signature motif and at least 30% amino acid to SEQ ID NO:1. In another embodiment, the perhydroiase catalyst comprises an enzyme having perhydroiase activity selected from the group consisting of SEQ ID NOs: 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 19, 20, 21 , 22, 23, 24, and 25.
In another embodiment, the perhydroiase catalyst comprises an enzyme having at least 40% amino acid identity to a contiguous signature motif defined as SEQ ID NO: 18 wherein the conserved motifs described above (i.e., RGQ, GXSQG, and HE, and optionally, LXD) are conserved.
In another embodiment, the perhydroiase catalyst comprises an enzyme having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19, 20, 21 , 22, 23, 24, and 25, wherein said enzyme may have one or more additions, deletions, or substitutions so long as the signature motif is conserved and perhydroiase activity is retained.
Suitable carboxylic acid ester substrates may include esters provided by the following formula:
Figure imgf000043_0001
wherein X = an ester group of the formula R6C(O)O R6 = C1 to C7 linear, branched or cyclic hydrocarbyl moiety, optionally substituted with hydroxy! groups or C1 to C4 alkoxy groups, wherein R6 optionally comprises one or more ether linkages for R6 = C2 to C7; R5 = a C1 to C6 linear, branched or cyclic hydrocarbyl moiety optionally substituted with hydroxy! groups; wherein each carbon atom in R5 individually comprises no more than one hydroxyl group or no more than one ester group; wherein R5 optionally comprises one or more ether linkages; m=1 to the number of carbon atoms in R5; and wherein said esters have solubility in water of at least 5 ppm at 25 °C.
In other embodiments, suitable substrates may also include esters of the formula:
Figure imgf000044_0001
wherein Ri= C1 to C7 straight chain or branched chain alkyl optionally substituted with a hydroxyl or a C1 to C4 alkoxy group and R2= C1 to C10 straight chain or branched chain alkyl, alkenyl, alkynyl, aryl, alkylaryl, alkylheteroaryl, heteroaryl, (CH2CH2-O)nH or (CH2CH(CH3)-O)nH and n=1 to
10.
In other embodiments, suitable carboxylic acid ester substrates may include glycerides of the formula:
Ri -o- -CH, -CH- -CH9- -OR,
ORa wherein R1= C1 to C7 straight chain or branched chain alkyl optionaily substituted with a hydroxy! or a C1 to C4 alkoxy group and R3 and R4 are individually H or R1C(O).
In other embodiments, Rg is C1 to C7 linear hydrocarbyl moiety, optionally substituted with hydroxy! groups or C1 to C4 alkoxy groups, optionally comprising one or more ether linkages. In further preferred embodiments, R6 is C2 to C7 linear hydrocarbyl moiety, optionally substituted with hydroxy! groups, and/or optionally comprising one or more ether linkages. In other embodiments, suitable carboxyiic acid ester substrates may also include acetylated saccharides selected from the group consisting of acetylated mono-, di-, and polysaccharides. In preferred embodiments, the acetylated saccharides include acetylated mono- , di-, and polysaccharides. In other embodiments, the acetylated saccharides are selected from the group consisting of acetylated xylan, fragments of acetyiated xylan, acetylated xylose(such as xylose tetraacetate), acetylated glucose (such as glucose pentaacetate), β-D-ribofuranose-1 ,2,3,5-tetraacetate, tri-O-acetyl-D-galactal, tri-O-acetyl-D-glucal, and acetylated cellulose. In preferred embodiments, the acetylated saccharide is selected from the group consisting of β-D- ribofuranose-1 ,2,3,5-tetraacetate, tri-O-acetyl-D-gaiactal, tri-O-acetyl-D-glucai, and acetylated cellulose. As such, acetylated carbohydrates may be suitable substrates for generating percarboxylic acids using the present methods and systems (Ae., in the presence of a peroxygen source).
In additional embodiments, the carboxyiic acid ester substrate may be monoacetin; triacetin; monopropionin; dipropionin; tripropionin; monobutyrin; dibutyrin; tributyrin; glucose pentaacetate; xylose tetraacetate; acetylated xyian; acetylated xylan fragments; β-D-ribofuranose-1 ,2,3,5-tetraacetate; tri-O- acetyl-D-galactal; tri-O-acetyl-glucal; propylene glycol diacetate; ethylene glycol diacetate; monoesters or diesters of 1 ,2-ethanediol; 1 ,2-propanediol; 1 ,3-propanediol; 1 ,2-butanediol; 1 ,3-butanediol; 2,3-butanediol; 1 ,4-butanediol; 1 ,2-pentanediol; 2,5-pentanediol; 1 ,6-pentanediol; 1 ,2-hexanediol; 2,5- hexanediol; 1 ,6-hexanediol; and mixtures thereof. In preferred embodiments of the present methods and systems, the substrate comprises triacetin. The carboxyiic acid ester is present in the reaction formulation at a concentration sufficient to produce the desired concentration of peracid upon enzyme-catalyzed perhydrolysis. The carboxyiic acid ester need not be completely soluble in the reaction formulation, but has sufficient solubility to permit conversion of the ester by the perhydrolase catalyst to the corresponding peracid. The carboxyiic acid ester is present in the reaction formulation at a concentration of 0.05 wt % to 40 wt % of the reaction formulation, preferably at a concentration of 0.1 wt % to 20 wt % of the reaction formulation, and more preferably at a concentration of 0.5 wt % to 10 wt % of the reaction formulation.
The peroxygen source may include, but is not limited to, hydrogen peroxide, hydrogen peroxide adducts (e.g., urea-hydrogen peroxide adduct (carbamide peroxide)} perborate salts and percarbonate salts. The concentration of peroxygen compound in the reaction formulation may range from 0.0033 wt % to about 50 wt %, preferably from 0,033 wt % to about 40 wt %, more preferably from 0.33 wt % to about 30 wt %,
Many perhydrolase catalysts (whole cells, permeabilized whole cells, and partially purified whole cell extracts) have been reported to have catalase activity (EC 1.1 1.1.6). Catalases catalyze the conversion of hydrogen peroxide into oxygen and water. In one aspect, the perhydrolysis catalyst lacks catalase activity. In another aspect, a catalase inhibitor is added to the reaction formulation. Examples of catalase inhibitors include, but are not limited to, sodium azide and hydroxylamine sulfate. One of skill in the art can adjust the concentration of catalase inhibitor as needed. The concentration of the catalase inhibitor typically ranges from 0.1 mM to about 1 M; preferably about 1 mM to about 50 mM; more preferably from about 1 mM to about 20 mM. In one aspect, sodium azide concentration typically ranges from about 20 m M to about 60 mM whife hydroxylamine sulfate is concentration is typically about 0.5 mM to about 30 mM, preferably about 10 mM. In another embodiment, the enzyme catalyst lacks significant catalase activity or is engineered to decrease or eliminate catalase activity. The catalase activity in a host cell can be down-regulated or eliminated by disrupting expression of the gene(s) responsible for the catalase activity using well known techniques including, but not limited to, transposon mutagenesis, RNA antisense expression, targeted mutagenesis, and random mutagenesis. In a preferred embodiment, the gene(s) encoding the endogenous catalase activity are down-reguiated or disrupted (i.e. knocked-out). As used herein, a "disrupted" gene is one where the activity and/or function of the protein encoded by the modified gene is no longer present. Means to disrupt a gene are weli-known in the art and may include, but are not limited to, insertions, deletions, or mutations to the gene so long as the activity and/or function of the corresponding protein is no longer present. In a further preferred embodiment, the production host is an E. coli production host comprising a disrupted catalase gene selected from the group consisting of katG and katE (see Published U.S. Patent Application No. 20080176299). In another embodiment, the production host is an E. coli strain comprising a down-regulation and/or disruption in both /cafcji and a katE catalase genes. The concentration of the catalyst in the aqueous reaction formulation depends on the specific catalytic activity of the catalyst, and is chosen to obtain the desired rate of reaction. The weight of catalyst in perhydrolysis reactions typically ranges from 0.0001 mg to 10 mg per mL of total reaction volume, preferably from 0.001 mg to 2.0 mg per mL. The catalyst may also be immobilized on a soluble or insoluble support using methods well-known to those skilled in the art; see for example, Immobijization.pf Enzymes and Cells; Gordon F. Bickerstaff, Editor; Humana Press, Totowa, NJ, USA; 1997. The use of immobilized catalysts permits the recovery and reuse of the catalyst in subsequent reactions. The enzyme catalyst may be in the form of whole microbial cells, permeabilized microbial cells, microbial cell extracts, partially- purified or purified enzymes, and mixtures thereof.
In one aspect, the concentration of peracid generated by the combination of chemical perhydrolysis and enzymatic perhydrolysis of the carboxylic acid ester is sufficient to provide an effective concentration of peracid for bleaching or disinfection at a desired pH. In another aspect, the present methods provide combinations of enzymes and enzyme substrates to produce the desired effective concentration of peracid, where, in the absence of added enzyme, there is a significantly lower concentration of peracid produced. Although there may in some cases be substantia! chemical perhydrolysis of the enzyme substrate by direct chemical reaction of inorganic peroxide with the enzyme substrate, there may not be a sufficient concentration of peracid generated to provide an effective concentration of peracid in the desired applications, and a significant increase in total peracid concentration is achieved by the addition of an appropriate perhydrolase catalyst to the reaction formulation.
The concentration of peracid generated (such as peracetic acid) by the perhydrolysis of at least one carboxylic acid ester is at least about 20 ppm, preferably at least 100 ppm, more preferably at least about 200 ppm peracid, more preferably at least 300 ppm, more preferably at feast 500 ppm, more preferably at least 700 ppm, more preferably at least about 1000 ppm peracid, most preferably at least 2000 ppm peracid within 10 minutes, preferably within 5 minutes, more preferably within 1 minute of initiating the perhydrolysis reaction. The product formulation comprising the peracid may be optionally diluted with water, or a solution predominantly comprised of water, to produce a formulation with the desired lower concentration of peracid. In one aspect, the reaction time required to produce the desired concentration of peracid is not greater than about two hours, preferably not greater than about 30 minutes, more preferably not greater than about 10 minutes, and most preferably in about 5 minutes or less. In other aspects, a hard surface or inanimate object contaminated with a biological contaminant(s) is contacted with the peracid formed in accordance with the processes described herein within about 5 minutes to about 168 hours of combining said reaction components, or within about 5 minutes to about 48 hours, or within about 5 minutes to 2 hours of combining said reaction components, or any such time interval therein.
In another aspect, the peroxycarboxylic acid formed in accordance with the processes describe herein is used in a laundry care application wherein the peroxycarboxylic acid is contacted with at least one article of clothing or textile to provide a benefit, such as disinfecting, bleaching, destaining, sanitizing, deodorizing or a combination thereof. The peroxycarboxylic acid may be used in a variety of laundry care products including, but not limited to, textile pre- wash treatments, laundry detergents, stain removers, bleaching compositions, deodorizing compositions, and rinsing agents. In one embodiment, the present process to produce a peroxycarboxyiic acid for a target surface is conducted in situ.
In the context of laundry care applications, the term "contacting an article of clothing or textile" means that the article of clothing or textile is exposed to a formulation disclosed herein. To this end, there are a number of formats the formulation may be used to treat fabric including, but not limited to, liquid, solids, gel, paste, bars, tablets, spray, foam, powder, or granules and can be delivered via hand dosing, unit dosing, dosing from a substrate, spraying and automatic dosing from a laundry washing or drying machine. Granular compositions can also be in compact form; liquid compositions can also be in a concentrated form.
When the formulations disclosed herein are used in a laundry machine, the formulation can further contain components typical to laundry detergents. For example, typical components included, but are not limited to, surfactants, bleaching agents, bleach activators, additional enzymes, suds suppressors, dtspersants, lime-soap dispersants, soil suspension and anti-redeposition agents, softening agents, corrosion inhibitors, tarnish inhibitors, germicides, pH adjusting agents, non-builder alkalinity sources, chelating agents, organic and/or inorganic fillers, solvents, hydrotropes, optical brighteners, dyes, and perfumes.
The formulations disclosed herein can also be used as detergent additive products in solid or liquid form. Such additive products are intended to supplement or boost the performance of conventional detergent compositions and can be added at any stage of the cleaning process.
In connection with the present systems and methods for laundry care where the peracid is generated for one or more of bleaching, stain removal, and odor reduction, the concentration of peracid generated (e.g., peracetic acid) by the perhydrolysis of at least one carboxylic acid ester may be at least about 2 ppm, preferably at least 20 ppm, preferably at least 100 ppm, and more preferably at least about 200 ppm peracid. In connection with the present systems and methods for laundry care where the peracid is generated for disinfection or sanitization, the concentration of peracid generated (e.g., peracetic acid) by the perhydrolysis of at least one carboxyiic acid ester may be at ieast about 2 ppm, more preferably at ieast 20 ppm, more preferably at least 200 ppm, more preferably at least 500 ppm, more preferably at least 700 ppm, more preferably at least about 1000 ppm peracid, most preferably at least 2000 ppm peracid within 10 minutes, preferably within 5 minutes, and most preferably within 1 minute of initiating the perhydrolysis reaction. The product mixture comprising the peracid may be optionally diluted with water, or a solution predominantly comprised of water, to produce a mixture with the desired lower concentration of peracid. In one aspect of the present methods and systems, the reaction time required to produce the desired concentration of peracid is not greater than about two hours, preferably not greater than about 30 minutes, more preferably not greater than about 10 minutes, even more preferably not greater than about 5 minutes, and most preferably in about
1 minute or less. The temperature of the reaction is chosen to control both the reaction rate and the stability of the enzyme catalyst activity. The temperature of the reaction may range from just above the freezing point of the reaction formulation (approximately 0 0C) to about 95 0C, with a preferred range of reaction temperature of from about 5 0C to about 55 0C. The pH of the final reaction formulation containing peracid is from about
2 to about 9, preferably from about 3 to about 8, more preferably from about 5 to about 8, even more preferably about 5.5 to about 8, and yet even more preferably about 6.0 to about 7.5. In another embodiment, the pH of the reaction formulation is acidic (pH <7). The pH of the reaction, and of the final reaction formulation, may optionally be controlled by the addition of a suitable buffer, including, but not limited to, bicarbonate, pyrophosphate, phosphate, methylphosphonate, citrate, acetate, malate, fumarate, tartrate maleate or succinate. The concentration of buffer, when employed, is typically from 0.1 mM to 1.0 M, preferably from 1 mM to 300 mM, most preferably from 10 mM to 10O mM.
In another aspect, the enzymatic perhydrolysis reaction formulation may contain an organic solvent that acts as a dispersant to enhance the rate of dissolution of the carboxyiic acid ester in the reaction formulation. Such solvents include, but are not limited to, propylene glycol methy! ether, acetone, cyclohexanone, diethylene glycol butyl ether, tripropylene glycol methy! ether, diethylene glycol methyl ether, propylene glycol butyl ether, di propylene glycol methyl ether, cyclohexanol, benzyl alcohol, isopropanol, ethanol, propylene glycol, and mixtures thereof.
In another aspect, the enzymatic perhydrolysis product may contain additional components that provide desirable functionality. These additional components include, but are not limited to, buffers, detergent builders, thickening agents, emulsifiers, surfactants, wetting agents, corrosion inhibitors (such as benzotriazoie), enzyme stabilizers, and peroxide stabilizers (e.g., metal ion chelating agents). Many of the additional components are well known in the detergent industry (see, for example, U.S. Patent 5,932,532; hereby incorporated by reference). Examples of emulsifiers include, but are not limited to polyvinyl alcohol or polyvinylpyrrolidone. Examples of thickening agents include, but are not limited to, LAPONITE® RD, corn starch, PVP,
CARBOWAX®, CARBOPOL®, CABOSI L®, polysorbate 20, PVA, and lecithin. Examples of buffering systems include, but are not limited to, sodium phosphate monobasic/sodium phosphate dibasic; sulfamic acid/triethanolamine; citric acid/triethanolamine; tartaric actd/triethanolamine; succinic acid/triethanolamine; and acetic acid/triethanolamine. Examples of surfactants include, but are not limited to, a) non-ionic surfactants such as block copolymers of ethylene oxide or propylene oxide, ethoxylated or propoxylated linear and branched primary and secondary alcohols, and aliphatic phosphine oxides; b) cationic surfactants such as quaternary ammonium compounds, particularly quaternary ammonium compounds having a C8-C20 alkyl group bound to a nitrogen atom additionally bound to three C1- C2 alky! groups; c) anionic surfactants such as alkane carboxylic acids (e.g., C8-C20 fatty acids), alkyl phosphonates, alkane sulfonates (e.g., sodium dodecylsulphate "SDS") or linear or branched alkyl benzene sulfonates, aikene sulfonates; and d) amphoteric and zwttterionic surfactants, such as aminocarboxylic acids, aminodicarboxylic acids, alkybetaines, and mixtures thereof. Additional components may include fragrances, dyes, stabilizers of hydrogen peroxide (e.g., metal chelators such as 1-hydroxyethylidene -1 ,1- diphosphonic acid (DEQUEST® 201 O1 Soiutia Inc., St. Louis, MO and ethyienediaminetetraacetic acid (EDTA)), TURPINAL® SL (CAS# 2809-21-4), DEQUEST® 0520, DEQUEST® 0531 , stabilizers of enzyme activity (e.g., polyethylene glycol (PEG)), and detergent builders.
In Situ Production of Peracids using a Perhydrolase Catalyst
Cephalosporin C deacetylases (E. C. 3.1.1.41 ; systematic name cephalosporin C acetylhjdrolases; CAHs) are enzymes having the ability to hydrolyze the acetyl ester bond on cephalosporins such as cephalosporin C, 7- aminocephalosporanic acid, and 7-(thiophene~2-acetamido)cepha!osporanic acid (Abbott, B. and Fukuda, D., Appl. Microbiol. 30(3):413-419 (1975)). CAHs belong to a larger family of structurally related enzymes referred to as the carbohydrate esterase family seven ("CE-7n; Coutinho, P.M., Henrissat, B., supra). The CE-7 carbohydrate esterase family includes both CAHs and acetyl xylan esterases (AXEs; E. C. 3.1.1.72). CE-7 family members share a common structural motif and are quite unusual in that they typically exhibit ester hydrolysis activity for both acetyiated xylooligosaccharides and acetySated cephalosporin C, suggesting that the CE-7 family represents a single class of proteins with a multifunctional deacetyiase activity against a range of small substrates (Vincent et a/., supra). Vincent et a/, describes the structural similarity among the members of this family and defines a signature sequence motif characteristic of the CE-7 family.
Members of the CE-7 family are found in plants, fungi (e.g., Cephalosporidium acremonium), yeasts (e.g., Rhodosporidium toruloides, Rhodotorula glutinis), and bacteria such as Thermoanaerobacterium sp.; Norcardia lactamdurans, and various members of the genus Bacillus (Politino et at., Appl, Environ. Microbiol., 63(12):4807-4811 (1997); Sakai et al., J. Ferment. Bioeng. 85:53-57 (1998); Lorenz, W. and Wiegel, J., J. Bacteήol 179:5436-5441 (1997); Cardoza et a/., Appl. Microbiol. BiotechnoL, 54(3):406- 412 (2000); Mitsushima et a/., supra; Abbott, B. and Fukuda, D., Appl. Microbiol. 30(3):413-419 (1975); Vincent et al., supra, Takami et al., NAR1 28(21 ):4317-4331 (2000); Rey et al., Genome BbL1 5(10): article 77 (2004); Degrassi et al., Microbiology,, 146:1585-1591 (2000); U.S. Patent 6,645,233; U.S. Patent 5,281 ,525; U.S. Patent 5,338,676; and WO 99/03984.
WO2007/070609 and U.S. Patent Application Publication Nos. 2008/0176299 and 2008/176783 to DiCosimo et a/, disclose various enzymes structurally classified as CE-7 enzymes that have perhydrolysis activity suitable for producing efficacious concentrations of peracids from a variety of carboxylic acid ester substrates when combined with a source of peroxygen. Variant CE- 7 enzymes having improved perhydrolysis activity are also described in a co- fiied, co-owned, and copending U.S. Patent Application (Attorney Docket No, CL4392 US NA, incorporated herein by reference in its entirety).
The present method produces industrially-useful, efficacious concentrations of peracids in situ under aqueous reaction conditions using the perhydroiase activity of an enzyme belonging to the CE-7 family of carbohydrate esterases.
HPLC Assay Method for Determining the Concentration of Peracid and Hydrogen Peroxide.
A variety of analytical methods can be used in the present methods to analyze the reactants and products including, but not limited to, titration, high performance liquid chromatography (HPLC), gas chromatography (GC), mass spectroscopy (MS), capillary electrophoresis (CE), the analytical procedure described by U. Karst et a/., (Anal. Chem., 69(17):3623-3627 (1997)), and the 2,2'-azino-bis (3-ethy!benzothazoline)-6-sulfonate (ABTS) assay (S. Minning, et al., Analytica Chimica Acta 378:293-298 (1999) and WO 2004/058961 A1) as described in the present examples.
Determination of Minimum Biocidai Concentration of Peracids
The method described by J. Gabrielson, et al, (J. Microbiol. Methods 50: 63-73 (2002)) can be employed for determination of the Minimum Biocidai Concentration (MBC) of peracids, or of hydrogen peroxide and enzyme substrates. The assay method is based on XTT reduction inhibition, where XTT ^^-bisp-methoxy^-nitro-δ-sulfophenyiJ-S-IfpheπyiamiπoJcarboπylj^H- tetrazolium, inner salt, monosodium salt) is a redox dye that indicates microbial respiratory activity by a change in optical density (OD) measured at 490 nm or 450 nm. However, there are a variety of other methods available for testing the activity of disinfectants and antiseptics including, but not limited to, viable piate counts, direct microscopic counts, dry weight, turbidity measurements, absorbance, and biojumiπesceπce (see, for example Brock, Semour S.,
Disinfection, Sterilization, and Preservation, 5th edition, Lippincott Williams & Wiikins, Philadelphia, PA, USA; 2001).
Uses of Enzvmaticailv Prepared Peroxycarboxyiic acid Compositions The enzyme catalyst-generated peroxycarboxyiic acid produced according to the present method can be used in a variety of hard surface/inanimate object applications for reduction of concentrations of biological contaminants, such as decontamination of medical instruments (e.g., endoscopes), textiles (e.g., garments, carpets), food preparation surfaces, food storage and food-packaging equipment, materials used for the packaging of food products, chicken hatcheries and grow-out facilities, animal enclosures, and spent process waters that have microbial and/or virucidal activity. The enzyme-generated peroxycarboxyfic acids may be used in formulations designed to inactivate prions (e.g., certain proteases) to additionally provide biocida! activity. In a preferred aspect, the present peroxycarboxyiic acid compositions are particularly useful as a disinfecting agent for non- autoclavable medical instruments and food packaging equipment. As the peroxycarboxyiic acid-containing formulation may be prepared using GRAS or food-grade components (enzyme, enzyme substrate, hydrogen peroxide, and buffer), the enzyme-generated peroxycarboxyiic acid may also be used for decontamination of animal carcasses, meat, fruits and vegetables, or for decontamination of prepared foods. The enzyme-generated peroxycarboxyiic acid may be incorporated into a product whose final form is a powder, liquid, gel, film, solid or aerosol. The enzyme-generated peroxycarboxyiic acid may be diluted to a concentration that still provides an efficacious decontamination.
The compositions comprising an efficacious concentration of peroxycarboxyiic acid can be used to disinfect surfaces and/or objects contaminated (or suspected of being contaminated) with biological contaminants by contacting the surface or object with the products produced by the present processes. As used herein, "contacting" refers to placing a disinfecting composition comprising an effective concentration of peroxycarboxyiic acid in contact with the surface or inanimate object suspected of contamination with a biological contaminant for a period of time sufficient to clean and disinfect. Contacting includes spraying, treating, immersing, flushing, pouring on or in, mixing, combining, painting, coating, applying, affixing to and otherwise communicating a peroxycarboxyiic acid solution or composition comprising an efficacious concentration of peroxycarboxyiic acid, or a solution or composition that forms an efficacious concentration of peroxycarboxyiic acid, with the surface or inanimate object suspected of being contaminated with a concentration of a biological contaminant The disinfectant compositions may be combined with a cleaning composition to provide both cleaning and disinfection. Alternatively, a cleaning agent (e.g., a surfactant or detergent) may be incorporated into the formulation to provide both cleaning and disinfection in a single composition.
The compositions comprising an efficacious concentration of peroxycarboxyiic acid can also contain at least one additional antimicrobial agent, combinations of prion-degradiπg proteases, a virucide, a sporicide, or a biocide. Combinations of these agents with the peroxycarboxyiic acid produced by the claimed processes can provide for increased and/or synergistic effects when used to clean and disinfect surfaces and/or objects contaminated (or suspected of being contaminated) with biological contaminants. Suitable antimicrobial agents include carboxylic esters (e.g., p~ hydroxy alkyi beπzoates and alky! ciπnamates); sulfonic acids (e.g., dodecylbenzene sulfonic acid); iodo-compounds or active halogen compounds (e.g., elemental halogens, halogen oxides (e.g., NaOCi, HOCI, HOBr, CIO2), iodine, interhalides (e.g., iodine monochloride, iodine dichloride, iodine trichloride, iodine tetrachloride, bromine chloride, iodine monobromide, or iodine dibromide), polyhalides, hypochlorite salts, hypochlorous acid, hypobromite salts, hypobromous acid, chloro- and bromo-hydantoins, chlorine dioxide, and sodium chlorite); organic peroxides including benzoyl peroxide, alkyi benzoyl peroxides, ozone, singlet oxygen generators, and mixtures thereof; phenolic derivatives (such as o-phenyl phenol, o-benzyl-p- chlorophenol, terf-amyl phenol and Ci-Ce aikyl hydroxy benzoates); quaternary ammonium compounds (such as alkyidimethylbenzyl ammonium chloride, diaikyldimethyl ammonium chloride and mixtures thereof); and mixtures of such antimicrobial agents, in an amount sufficient to provide the desired degree of microbial protection. Effective amounts of antimicrobial agents include about 0.001 wt% to about 60 wt% antimicrobial agent, about 0.01 wt% to about 15 wt% antimicrobial agent, or about 0.08 wt% to about 2,5 wt% antimicrobial agent. in one aspect, the peroxycarboxylic acids formed by the present process can be used to reduce the concentration of viable biological contaminants (such as a viable microbial population) when applied on and/or at a locus. As used herein, a "locus" comprises part or all of a target surface suitable for disinfecting or bleaching. Target surfaces include all surfaces that can potentially be contaminated with biological contaminants. Non-limiting examples include equipment surfaces found in the food or beverage industry (such as tanks, conveyors, floors, drains, coolers, freezers, equipment surfaces, walls, valves, belts, pipes, drains, joints, crevasses, combinations thereof, and the like); building surfaces (such as walls, floors and windows); non-food-industry related pipes and drains, including water treatment facilities, pools and spas, and fermentation tanks; hospital or veterinary surfaces (such as wails, floors, beds, equipment (such as endoscopes), clothing worn in hospital/veterinary or other healthcare settings, including clothing, scrubs, shoes, and other hospital or veterinary surfaces); restaurant surfaces; bathroom surfaces; toilets; clothes and shoes; surfaces of barns or stables for livestock, such as poultry, cattle, dairy cows, goats, horses and pigs; hatcheries for poultry or for shrimp; and pharmaceutical or biopharmaceutical surfaces (e.g., pharmaceutical or biopharmaceutical manufacturing equipment, pharmaceutical or biopharmaceutical ingredients, pharmaceutical or biopharmaceutical excipients). Additional hard surfaces also include food products, such as beef, poultry, pork, vegetables, fruits, seafood, combinations thereof, and the like. The locus can also include water absorbent materials such as infected linens or other textiles. The locus also includes harvested plants or plant products including seeds, corms, tubers, fruit, and vegetables, growing plants, and especially crop growing plants, including cereals, leaf vegetables and salad crops, root vegetables, legumes, berried fruits, citrus fruits and hard fruits. Non-limiting examples of hard surface materials are metals (e.g., steel, stainless steel, chrome, titanium, iron, copper, brass, aluminum, and alloys thereof), minerals (e.g., concrete), polymers and plastics (e.g., polyolefins, such as polyethylene, polypropylene, polystyrene, poly(meth)acrylate, polyacrylonitrile, polybutadiene, poly(acrylonitrile, butadiene, styrene), poly(acrylonitrile, butadiene), acrylonitrile butadiene; polyesters such as polyethylene terephthalate; and polyamides such as nylon). Additional surfaces include brick, tile, ceramic, porcelain, wood, vinyl, linoleum, and carpet.
The peroxycarboxylic acids formed by the present process may be used to provide a benefit to an article of clothing or textile including, but not limited to, bleaching, destaining, sanitizing, disinfecting, and deodorizing. The peroxycarboxylic acids formed by the present process may be used in any number of laundry care products including, but not limited to, textile pre-wash treatments, laundry detergents, stain removers, bleaching compositions, deodorizing compositions, and rinsing agents.
Recombinant Microbial Expression
The genes and gene products of the instant sequences may be produced in heterologous host cells, particularly in the cells of microbial hosts. Preferred heterologous host cells for expression of the instant genes and nucleic acid molecules are microbial hosts that can be found within the fungal or bacterial families and which grow over a wide range of temperature, pH values, and solvent tolerances. For example, it is contemplated that any of bacteria, yeast, and filamentous fungi may suitably host the expression of the present nucleic acid molecules. The perhydrolase may be expressed intracellular^, extracellulariy, or a combination of both intracellularly and extracellularly, where extracellular expression renders recovery of the desired protein from a fermentation product more facile than methods for recovery of protein produced by intracellular expression. Transcription, translation and the protein biosynthetic apparatus remain invariant relative to the cellular feedstock used to generate cellular biomass; functional genes will be expressed regardless. Examples of host strains include, but are not limited to, bacterial, fungal or yeast species such as Aspergillus, Trichoderma, Saccharomyces, Pichia, Phaffia, Kluyveromyces, Candida, Hansenula, Yarrowia, Salmonella, Bacillus, Acinetobacter, Zymomonas, Agrobacterium, Erythrobacter, Chlorobium, Chromatium, Flavobacterium, Cytophaga, Rhodobacter, Rhodococcus, Streptomyces, Brevibacterium, Corynebacteria, Mycobacterium, Deinococcus, Escherichia, Erwinia, Pantoea, Pseudomonas, Sphingomonas, Methylomonas, Methylobacter, Methylococcus, Methylosinus, Methylomicrobium, Methylocystis, Alcaligenes, Synechocystis, Synechococcus, Anabaena, Thiobacillus, Methanobacterium, Klebsiella, and Myxococcus, In one embodiment, bacterial host strains include Escherichia, Bacillus, Kluyveromyces, and Pseudomonas. In a preferred embodiment, the bacteria! host cell is Escherichia coli.
Large-scale microbial growth and functional gene expression may use a wide range of simple or complex carbohydrates, organic acids and alcohols or saturated hydrocarbons, such as methane or carbon dioxide in the case of photosynthetic or chemoautotrophic hosts, the form and amount of nitrogen, phosphorous, sulfur, oxygen, carbon or any trace micronutrient including small inorganic ions. The regulation of growth rate may be affected by the addition, or not, of specific regulatory molecules to the culture and which are not typically considered nutrient or energy sources. Vectors or cassettes useful for the transformation of suitable host cells are well known in the art. Typically the vector or cassette contains sequences directing transcription and translation of the relevant gene, a selectable marker, and sequences allowing autonomous replication or chromosomal integration. Suitable vectors comprise a region 5' of the gene which harbors transcriptional initiation controls and a region 3' of the DNA fragment which controls transcriptional termination. It is most preferred when both control regions are derived from genes homologous to the transformed host cell and/or native to the production host, although such control regions need not be so derived. Initiation control regions or promoters, which are useful to drive expression of the present cephalosporin C deacetyiase coding region in the desired host celi are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving these genes is suitable for the present invention including, but not limited to, CYC1, HIS3, GAL1, GAL10, ADH1, PGK1 PH05, GAPDH, ADC1, TRP1, URA3, LEU2, ENO, TPI (useful for expression in Saccharomyces); A0X1 (useful for expression in Pichia); and lac, araB, tet, trp, Pj_, IPR, Tl, tac, and trc (useful for expression in Escherichia coli) as well as the amy, apr, npr promoters and various phage promoters useful for expression in Bacillus.
Termination control regions may also be derived from various genes native to the preferred host cell. In one embodiment, the inclusion of a termination control region is optional. In another embodiment, the chimeric gene includes a termination control region derived from the preferred host cell.
Industrial Production
A variety of culture methodologies may be applied to produce the perhydrolase catalyst. For example, large-scale production of a specific gene product overexpressed from a recombinant microbial host may be produced by batch, fed-batch, and continuous culture methodologies. Batch and fed-batch cuituring methods are common and well known in the art and examples may be found in Thomas D. Brock in Biotechnology: A Textbook of Industrial Microbiology, Second Edition, Sinauer Associates, Inc., Sunderland, MA (1989) and Deshpande, Mukund V., Appl. Biochem. Biotechnol., 36:227 (1992).
Commercial production of the desired perhydrolase catalyst may also be accomplished with a continuous culture. Continuous cultures are an open system where a defined culture media is added continuously to a btoreactor and an equal amount of conditioned media is removed simultaneously for processing. Continuous cultures generally maintain the cells at a constant high liquid phase density where cells are primarily in iog phase growth. Alternatively, continuous culture may be practiced with immobilized ceils where carbon and nutrients are continuously added and valuable products, by- products or waste products are continuously removed from the ceil mass. Cell immobilization may be performed using a wide range of solid supports composed of natural and/or synthetic materials.
Recovery of the desired perhydrolase catalysts from a batch fermentation, fed-batch fermentation, or continuous culture, may be accomplished by any of the methods that are known to those skilled in the art. For example, when the enzyme catalyst is produced intracellularly, the cell paste is separated from the culture medium by centrifugatioπ or membrane filtration, optionally washed with water or an aqueous buffer at a desired pH, then a suspension of the cell paste in an aqueous buffer at a desired pH is homogenized to produce a cell extract containing the desired enzyme catalyst. The cell extract may optionally be filtered through an appropriate filter aid such as celite or silica to remove eel! debris prior to a heat-treatment step to precipitate undesired protein from the enzyme catalyst solution. The solution containing the desired enzyme catalyst may then be separated from the precipitated cell debris and protein by membrane filtration or centrifugation, and the resulting partially-purified enzyme catalyst solution concentrated by additional membrane filtration, then optionally mixed with an appropriate carrier (for example, maltodextrin, phosphate buffer, citrate buffer, or mixtures thereof) and spray-dried to produce a solid powder comprising the desired enzyme catalyst.
When an amount, concentration, or other value or parameter is given either as a range, preferred range, or a list of upper preferable values and lower preferable values, this is to be understood as specifically disclosing all ranges formed from any pair of any upper range limit or preferred value and any lower range limit or preferred value, regardless of whether ranges are separately disclosed. Where a range of numerical values is recited herein, unless otherwise stated, the range is intended to include the endpoiπts thereof, and all integers and fractions within the range. It is not intended that the scope be limited to the specific values recited when defining a range. GENERAL METHODS
The following examples are provided to demonstrate preferred embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the methods disclosed herein, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the presently disclosed methods.
All reagents and materiais were obtained from DIFCO Laboratories (Detroit, Ml), GIBCO/BRL (Gaithersburg, MD), TCI America (Portland, OR), Roche Diagnostics Corporation (Indianapolis, IN) or Sigma-Aldrich Chemical Company (St. Louis, MO), unless otherwise specified. The following abbreviations in the specification correspond to units of measure, techniques, properties, or compounds as follows: "sec" or "s" means second(s), "min" means minute(s), "h" or "hr" means hour(s), "μL" means microliter(s), "mL" means milliliters), "L" means iiter(s), "mM" means miilimolar, "M" means molar, "mmol" means miliimole(s), "ppm" means part(s) per million, "wf means weight, "wt%" means weight percent, "g" means gram(s), "mg" means miliigram(s), "μg" means microgram(s), "ng!1 means nanogram(s), "g" means gravity, "HPLC" means high performance liquid chromatography, "dd H2O" means distilled and deionized water, "dew" means dry cell weight, "ATCC" or 'ΑTCC®" means the American Type Culture Collection (Manassas, VA), "U" means unit(s) of perhydrolase activity, "rpm" means revolution(s) per minute, "Tg" means glass transition temperature, and ΕDTA" means ethylenediaminetetraacetic acid.
EXAMPLE 1 Construction of a katG Catalase Disrupted E, coli Strain
The coding region of the kanamycin resistance gene (/can; SEQ ID NO:26) was amplified from the plasmid pKD13 (SEQ ID NO: 27) by PCR (0.5 min at 94 0C, 0.5 min at 55 0C, 1 min at 70 0C, 30 cycles) using primers identified as SEQ ID NO: 28 and SEQ ID NO: 29 to generate the PCR product identified as SEQ ID NO: 30. The katG nucleic acid sequence is provided as SEQ ID NO: 31 and the corresponding amino acid sequence is SEQ ID NO: 32. E. colt MG1655 (ATCC® 47076™) was transformed with the temperature- sensitive plasmid pKD46 (SEQ ID NO: 33), which contains the λ~Red recombiπase genes (Datsenko and Wanner, (2000), PNAS USA 97:6640» 6645), and selected on LB-amp plates for 24 h at 30 0C. MG1655/pKD46 was transformed with 50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0.2 cm cuvette, 2.5 kV, 200 W, 25 μF), and selected on LB-kan plates for 24 h at 37 0C. Several colonies were streaked onto LB-kan plates and incubated overnight at 42 0C to cure the pKD46 plasmid. Colonies were checked to confirm a phenotype of kanR/ampS. Genomic DNA was isolated from several colonies using the PUREGENE® DNA purification system (Geπtra Systems, Minneapolis, MN), and checked by PCR to confirm disruption of the katG gene using primers identified as SEQ ID NO:34 and SEQ ID NO:35. Several /fafG-disrupted strains were transformed with the temperature- sensitive plasmid pCP20 (SEQ ID NO:36), which contains the FLP recombinase, used to excise the kan gene, and selected on LB-amp plates for 24 h at 37 0C. Several colonies were streaked onto LB plates and incubated overnight at 42 0C to cure the pCP20 plasmid. Two colonies were checked to confirm a phenotype of kanS/ampS, and called MG1655 KatG1 and MG1655 KatG2.
EXAMPLE 2 Construction of a katE ^ Catalase Disrypted E. coll Strain
The kanamycjπ resistance gene (SEQ ID NO:26) was amplified from the plasmid pKD13 (SEQ ID NO:27) by PCR (0.5 min at 94 0C, 0.5 miπ at 55 0C, 1 miπ at 70 0C, 30 cycles) using primers identified as SEQ ID NO:37 and SEQ ID NO:38 to generate the PCR product identified as SEQ ID NO:39. The katE nucleic acid sequence is provided as SEQ ID NO:40 and the corresponding amino acid sequence is SEQ ID NO:41. E coli MG 1655 (ATCC® 47076™) was transformed with the temperature-sensitive plasmid pKD46 (SEQ ID NO:33), which contains the λ-Red recombinase genes, and selected on LB- amp plates for 24 h at 30 0C. MG1655/pKD46 was transformed with 50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0,2 cm cuvette, 2.5 kV, 200 W, 25 μF), and selected on LB-kan plates for 24 h at 37 0C. Several colonies were streaked onto LB-kan plates and incubated overnight at 42 0C to cure the pKD46 plasmid. Colonies were checked to confirm a phenotype of kanR/ampS. Genomic DNA was isolated from several colonies using the PUREGENE® DNA purification system, and checked by PCR to confirm disruption of the katE gene using primers identified as SEQ ID NO:42 and SEQ ID NO:43. Several /cafE-disrupted strains were transformed with the temperature-sensitive plasmid pCP20 (SEQ ID NO:36), which contains the FLP recombinase, used to excise the kan gene, and selected on LB-amp plates for 24 h at 37 0C. Several colonies were streaked onto LB plates and incubated overnight at 42 0C to cure the pCP20 plasmid. Two colonies were checked to confirm a phenotype of kanS/ampS, and called MG 1655 KatE1 and MG 1655 KatE2.
EXAMPLE 3
Construction of a katG catalase and katE Catalase Disrupted E, coli Strain
(KLP18) The kanamycin resistance gene (SEQ ID NO:26) was amplified from the piasmid pKD13 (SEQ ID NO:27) by PCR (0.5 miπ at 94 0C1 0.5 min at 55 0C1 1 min at 70 0C, 30 cycles) using primers identified as SEQ ID NO:37 and SEQ ID NO:38 to generate the PCR product identified as SEQ ID NO:39. E. coll MG 1655 KatG1 (EXAMPLE 1) was transformed with the temperature-sensitive pfasmid pKD46 (SEQ ID NO:33), which contains the λ-Red recombinase genes, and selected on LB-amp plates for 24 h at 30 0C. MG1655 KatG1/pKD46 was transformed with 50-500 ng of the PCR product by electroporation (BioRad Gene Pulser, 0.2 cm cuvette, 2.5 kV, 200 W, 25 μF), and selected on LB-kan plates for 24 h at 37 0C. Several colonies were streaked onto LB-kan plates and incubated overnight at 42 0C to cure the pKD46 plasmid. Colonies were checked to confirm a phenotype of kanR/ampS. Genomic DNA was isolated from several colonies using the PUREGENE® DNA purification system, and checked by PCR to confirm disruption of the katE. gene using primers identified as SEQ ID NO:42 and SEQ ID NO:43. Several /ca^E-disrupted strains (Δ katE) were transformed with the temperature-sensitive plasmid pCP20 (SEQ ID NO:36), which contains the FLP recombtnase, used to excise the kan gene, and selected on LB-amp plates for 24 h at 37 0C. Several colonies were streaked onto LB plates and incubated overnight at 42 0C to cure the pCP20 plasmid. Two colonies were checked to confirm a phenotype of kanS/ampS, and called MG1655 KatG1 KatE18.1 and MG1655 KatG1 KatE23. MG1655 KatG1 KatE18.1 is designated E. coli KLP18.
EXAMPLE 4 Cloning and Expression of Perhvdrolase from Thermotoga neapolitana
The coding region of the gene encoding acetyl xylan esterase from Thermotoga neapolitana as reported in GENBANK® (accession number AE000512; region 80481-81458; SEQ ID NO:44) was synthesized using codons optimized for expression in E. coli (DNA 2.0, Menlo Park, CA). The coding region of the gene was subsequently amplified by PCR (0.5 min at 94 0C, 0.5 mtn at 55 0C, 1 min at 70 DC, 30 cycles) using primers identified as SEQ ID NO:45 and SEQ ID NO:46. The resulting nucleic acid product (SEQ ID NO:47) was subcloned into pTrcHis2-TOPO® to generate the plasmid identified as pSW196. The plasmid pSW196 was used to transform E. coli KLP 18 (EXAMPLE 3) to generate the strain KLP18/pSW196. KLP18/pSW196 was grown in LB media at 37 DC with shaking up to OD60onm = 0.4-0.5, at which time IPTG was added to a final concentration of 1 mM, and incubation continued for 2-3 h. Cells were harvested by centrifugation and SDS-PAGE was performed to confirm expression of the perhydroiase at 20-40% of total soluble protein.
EXAMPLE 5 Cloning and Expression of Perhvdrolase from Thermotoga maritjma MSB8
The coding region of the gene encoding acety! xylan esterase from Thermotoga maritima MSB8 as reported in GENBANK® (accession # NP_227893.1 ; SEQ ID NO: 48) was synthesized (DNA 2.0, Menlo Park, CA). The coding region of the gene was subsequently amplified by PCR (0.5 min @ 94 0C, 0.5 min @ 55 0C, 1 min @ 70 0C, 30 cycles) using primers identified as SEQ ID NO:49 and SEQ ID NO:50. The resulting nucleic acid product (SEQ ID NO:51) was cut with restriction enzymes Pstl and Xbal and subcloned between the Pst\ and Xba\ sites in pUC19 to generate the plasmid identified as pSW207. The plasmid pSW207 was used to transform E. coli KLP18 (EXAMPLE 3) to generate the strain identified as KLP18/pSW207. KLP18/pSW207 was grown in LB media at 37 0C with shaking up to OD60onm = 0.4-0.5, at which time IPTG was added to a final concentration of 1 mM, and incubation continued for 2-3 h. Cells were harvested by centrifugation and
SDS-PAGE was performed to confirm expression of the perhydrolase enzyme at 20-40% of total soluble protein.
EXAMPLE 6 Fermentation of E. co// KLP18 Traηsforrnants Expressing Perhydrolase
A fermentor seed culture was prepared by charging a 2-L shake flask with 0.5 L seed medium containing yeast extract (Amberex 695, 5.0 g/L), K2HPO4 (10.0 g/L), KH2PO4 (7.0 g/L), sodium citrate dihydrate (1.0 g/L), (NH4J2SO4 (4.0 g/L), MgSO4 heptahydrate (1.0 g/L) and ferric ammonium citrate (0.10 g/L). The pH of the medium was adjusted to 6.8 and the medium was sterilized in the fiask. Post sterilization additions included glucose (50 wt %, 10.0 mL) and 1 mL ampiciiliπ (25 mg/mL) stock solution. The seed medium was inoculated with a 1-mL culture of E. coli KLP18/pSW196 or E. coli KLP18/pSW207 in 20% glycerol, and cultivated at 35 0C and 300 rpm. The seed culture was transferred at ca. 1-2 OD55onm to a 14-L fermentor (Braun Biotech, ASientown, PA) with 8 L of medium at 35 0C containing KH2PO4 (3,50 g/L), FeSO4 heptahydrate (0.05 g/L), MgSO4 heptahydrate (2.0 g/L), sodium citrate dihydrate (1.90 g/L), yeast extract (Amberex 695, 5.0 g/L), Biospumex153K aπtifoam (0.25 ml_/L, Cognis Corporation, Monheim, Germany), NaCI (1.0 g/L), CaCI2 dihydrate (10 g/L), and NIT trace elements solution (10 mL/L). The trace elements solution contained citric acid monohydrate (10 g/L), MnSO4 hydrate (2 g/L), NaCi (2 g/L), FeSO4 heptahydrate (0.5 g/L), ZnSO4 heptahydrate (0.2 g/L), CuSO4 pentahydrate (0.02 g/L) and NaMoO4 dihydrate (0.02 g/L). Post sterilization additions included glucose solution (50% w/w, 80.0 g) and ampicillin (25 mg/mL) stock solution (16.00 mL). Glucose solution (50% w/w) was used for fed batch. Glucose feed was initiated when glucose concentration decreased to 0.5 g/L, starting at 0.31 g feed/miπ and increasing progressively each hour to 0.36, 0.42, 0.49, 0.57, 0.66, 0.77, 0.90, 1.04, 1.21, 1.41 , and 1.63 g/min respectively; the rate remained constant afterwards. Glucose concentration in the medium was monitored and if the concentration exceeded 0.1 g/L the feed rate was decreased or stopped temporarily. Induction was initiated between ODssoπm = 56 and ODssoπm = 80 with addition of 16 mL IPTG (0.5 M) for the various strains. The dissolved oxygen (DO) concentration was controlled at 25% of air saturation. The DO was controlled first by impeller agitation rate (400 to 1400 rpm) and later by aeration rate (2 to 10 slpm). The pH was controlled at 6.8. NH4OH (29% w/w) and H2SO4 (20% w/v) were used for pH control. The head pressure was 0.5 bars. The cells were harvested by ceπtrifugation 16 h post IPTG addition.
EXAMPLE 7 Preparation of Heat-Treated Cell Extracts of CE-7 Esterases/Perhydrolases A cell extract of an E. coli transformaπt expressing perhydrolase from
Thermotoga neapolitana (KLP18/pSW196) or Thermotoga maritima MSB8 (KLP18/pSW207) was prepared by passing a suspension of cell paste (20 wt % wet cell weight) in 0.05 M potassium phosphate buffer (pH 7.0) containing dithiothreitol (1 mM) twice through a French press having a working pressure of 16,000 psi (-110 MPa). The crude extract was then centrifuged at 20,000 x g to remove cellular debris, producing a clarified cell extract that was assayed for total soluble protein (Bicinchoninic Acid Kit for Protein Determination, Sigma Aidrich catalog # BCA1-KT). The clarified Thermotoga maritima MSB8 or Thermotoga neapolitana perhydrolase-containing extract was heated for 20 min at 75 0C, followed immediately by cooling in an ice/water bath to 5 0C. The resulting mixture was centrifuged to remove precipitated protein, and the supernatant collected and assayed for total soluble protein as before. SDS- PAGE of the heat-treated supernatant indicated that the perhydrolase constituted at least ca. 90 % of the total soluble protein present in the supernatant.
EXAMPLE 8 Temperature Stability of J,, neaffoZtfaga PprhydrolaseZTrehaiose Spray-Dried
Enzyme Powders
A set of ten aqueous mixtures were prepared that contained varying concentrations of the heat-treated cell extract protein of E. coli KL P 18/pSW 196 (> 90 % T. neapolitana perhydroiase by PAGE), trehalose (Cargill), and, optionally, polysorbate 80 (p80) as surfactant in sodium bicarbonate buffer (50 mM, pH = 8.1) (Table 1). These solutions were spray-dried using a Buchi B- 290 glass-chamber spray dryer (inlet temperature = 170 0C, exit temperature = 90 0C1 feed rate = 3 mL/min to 10 mL/min) to produce ten spray-dried enzyme powders; the weight percent protein in the powders was determined using the BCA (Bicinchoninic acid) protein assay, and the glass transition temperatures (Tg) of these powders were measured using modulated differential scanning caiorimetry (Table 1 ).
Table 1. Composition of protein/excipient solutions used to produce T. neapolitana perhydrolase/trehaiose spray-dried enzyme powders, and Tg of corresponding powders.
Figure imgf000067_0001
S6-1 40 20 S7-1 40 20 S8-1 20 20 S9-1 20 20 S 10-1 52.5 35
Figure imgf000068_0001
The spray-dried enzyme powders were stored in sealed vials at 40 0C and sampled at one-week intervals, and the samples assayed for the concentration of peracetic acid produced in 5 minutes in reactions containing T. neapolitana perhydrolase (50 μg protein/ml_), H2O2 (100 imM), triacetin (100 mM) and TURPINAL® SL (500 ppm) in sodium bicarbonate buffer (50 mM, pH 7.2) at 25 0C, and analyzed for production of peracetic acid using a modification of the analytical method reported by Karst et a!, (beiow). A sample (0.040 ml_) of the reaction mixture was removed at a predetermined time (5 min) and immediately mixed with 0.960 ml_ of 5 mM phosphoric acid in water to terminate the reaction by adjusting the pH of the diluted sample to less than pH 4. The resulting solution was filtered using an ULTRAFREE® MC-filter unit (30,000 Normal Molecular Weight Limit (NMWL), MiHi pore Corp., Billerica, MA, cat # UFC3LKT 00) by centrifugation for 2 min at 12,000 rpm. An aliquot (0.100 mL) of the resulting filtrate was transferred to a 1.5-mL screw cap HPLC vial (Agilent Technologies, Palo Alto, CA; #5182- 0715) containing 0.300 mL of deionized water, then 0.100 mL of 20 mM MTS (methyl-p-tolyl sulfide) in acetonitrile was added, the vial capped, and the contents briefly mixed prior to a 10 mih incubation at ca. 25 0C in the absence of light. To the vial was then added 0.400 mL of acetonitriie and 0.100 mL of a solution of triphenylphosphine (TPP, 40 mM) in acetonitriie, the vial re-capped, and the resulting solution mixed and incubated at ca. 25 0C for 30 min in the absence of light. To the vial was then added 0.100 mL of 10 mM N,N-diethyl- m-toluamide (DEET; HPLC external standard) and the resulting solution analyzed by HPLC for MTSO (methyl-p-tolyi sulfoxide), the stoichiometric oxidation product produced by reaction of MTS with peracetic acid. A control reaction was run in the absence of added extract protein or triacetin to determine the rate of oxidation of MTS in the assay mixture by hydrogen peroxide, for correction of the rate of peracetic acid production for background MTS oxidation. HPLC method; Supeico Discovery C8 column (10-cm X 4.0- mm, 5 μm) (cat. #569422-U) with Supeico Supelguard Discovery C8 precolumn (Sigma-Aldrich; cat # 59590-U); 10 microliter injection volume; gradient method with CH3CN (Sigma-Aldrich; catalog #270717) and deionized water at 1.0 mL/min and ambient temperature.
Table 2. HPLC Gradient for analysis of peracetic acid.
Figure imgf000069_0001
The perhydrolytic activity of the T, neapolitana perhydrolase/trehalose spray-dried powder was stable over eight weeks of storage at 40 0C (Table 3).
Table 3. Temperature stability of T. neapolitana perhydrolase/trehaiose spray- dried enzyme powders during storage at 40 0C. PAA (ppm) produced in 5 min at 25 0C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitana perhydrolase/ trehalose spray-dried powder (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000069_0002
Figure imgf000070_0001
EXAMPLE 9 Temperature Stability of T. neapolitana Perhydrolase/Trehalose Spray-Dried
Enzyme Powders in a Mixture of Enzyme Powder and Triacetin The spray-dried enzyme powders prepared as described in Example 8 were evaluated for stability when stored for eight weeks at 40 0C as a mixture of the spray-dried powder in triacetin. Spray-dried enzyme powders were added to triacetin to produce a mixture containing 0.200 g of protein in 87.2 g of triacetin. The resulting mixtures were stored at 40 0C, and a 2.19 g sample of the well-stirred mixture was assayed weekly at 25 0C in a 100-mL reaction containing 100 mM hydrogen peroxide and TURPINAL® SL (500 ppm) in 50 mM sodium bicarbonate buffer at pH 7.2, where the resulting concentration of triacetin and protein was 100 mM and 50 μg/mL, respectively. Comparison of the data in Table 4 with the data in Example 8, Table 3, demonstrates the instability of T. neapolitana perhydrolase/trehalose spray-dried enzyme powders when stored as a mixture with triacetin.
Table 4. Temperature stability of T. neapolitana perhydrolase/trehalose spray- dried enzyme powders during storage in a mixture of enzyme powder and triacetin at 40 0C. PAA (ppm) produced in 5 min at 25 0C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitana perhydroiase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
time PAA (ppm) in 5 minutes at 40 P1-2 P2-2 P3-2 P4-2 P5-2 P6-2 P7-2 P8-2 P9-2 P10-
Figure imgf000071_0001
EXAMPLE 10
Temperature Stability of T. neapolitana Perhydroiase/Maltodextrin Spray-Dried Enzyme Powder
An aqueous mixture was prepared containing heat-treated cell extract protein of E. coll KLP18/pSW196 (34 g protein/L, > 90 % T. neapolitana perhydrolase by PAGE) and maltodextrin (66.7 g/L MALTRIN® M100 maltodextrin, 14.7 g/L MALTRIN® M250, 14.7 g/L MALTRIN® M040, Grain Processing Corporation, Muscatine, IA) as excipient in 50 mM sodium bicarbonate (pH 8.1). This solution was spray-dried using a spray dryer (GEA Niro, 3-ft diameter, inlet temperature = 226 0C1 exit temperature = 76 0C, feed rate = 60 g/min) to produce a spray-dried enzyme powder; the weight percent protein in the powder (20.3 wt%) was determined using the BCA (Biciπchoninic acid) protein assay, and the glass transition temperature of this powder (Tg = 54 0C) was measured using modulated differential scanning calorimetry. This solution was spray-dried to produce a powder that was then tested for stability during storage at 40 0C for 9 weeks. The spray-dried enzyme powder (stored at 40 °C) was sampled at one-week intervals and assayed for activity using 50 μg protein/mL of T. neapolitana perhydrolase, H2O2 (100 mM), triacetin (100 mM) and TURPINAL® SL (500 ppm) in 50 mM bicarbonate buffer (pH 7.2) at 25°C, and analyzed for production of peracetic acid using a modification of the analytical method reported by Karst et a/., supra. The perhydroiytic activity of the T. neapolitana perhydroiase/maltodextrin spray-dried powder was stable over eight weeks of storage at 40 0C (Table 5).
Table 5. Temperature stability of T. neapolitana perhydroiase/maitodextrin spray-dried enzyme powder during storage at 40 °C. PAA (ppm) produced in 5 min at 25 °C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitana perhydrolase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000072_0001
EXAMPLE 1 1
Temperature Stability of T. neapolitana perhydrolase/Maitodextrin Spray-Dried Enzyme Powder Stored in a Mixture of Enzyme Powder and Triacetin
The spray-dried enzyme powder prepared as described in Example 10 was evaluated for stability when stored for twenty-one weeks at 40 °C as a mixture of the spray-dried powder in triacetin. The spray-dried enzyme powder (1.235 g, 20.3 wt % protein) was added to 109 g of triacetin. The resulting mixture was stored at 40 0C, and a 2.19 g sample of the weli-stirred mixture assayed in duplicate at 25 0C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPINAL® SL (500 ppm) in 50 mM sodium bicarbonate buffer at pH 7.2, where the resulting concentration of triacetin and protein was 100 mM and 50 μg/mL, respectively. Comparison of the data in Table 6 with the data in Example 10, Table 5, demonstrates the stability of T. neapolitana perhydrolase/maltodextrin spray-dried enzyme powders when stored as a mixture with triacetin.
Table 6. Temperature stability of T. neapolitana perhydrolase/maltodextrin spray-dried enzyme powder during storage in a mixture of enzyme powder and triacetin at 40 0C. PAA (ppm) produced in 5 min at 25 °C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitana perhydrolase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000073_0001
ND = a duplicate assay was not done
EXAMPLE 12 Temperature Stability of T, neapolitana Perhydrolase/Maltodextrin Spray-Dried Enzyme Powder Stored in a Mixture of Enzyme Powder, Sodium Bicarbonate and Triacetin
The spray-dried enzyme powder prepared as described in Example 10 was evaluated for stability when stored for 21 weeks at 40 0C as a mixture of the spray-dried powder in a mixture of triacetin and sodium bicarbonate. The spray-dried enzyme powder (0.988 g, 20.3 wt % protein) was added to a mixture of 87.2 g of triacetin and 16.8 g of sodium bicarbonate (Grade 3DF (powder), Church & Dwight). The resulting mixture was stored at 40 °C, and a 2.62 g sample of the well-stirred mixture was assayed in duplicate at 25 0C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPINAL® SL (500 ppm), where the resulting concentrations of triacetin, sodium bicarbonate and protein were 100 mM, 50 mM (pH 7,2) and 50 μg/mL, respectively. Comparison of the data in Table 7 with the data in Example 11 , Table 6, demonstrates the stability of T. neapolitana perhydrolase/maϊtodextrin spray- dried enzyme powders when stored for twenty-one weeks at 40 0C as a mixture with triacetin and solid sodium bicarbonate is improved when compared to the stability of T. neapolitana perhydrolase/maltodextrtn spray- dried enzyme powders when stored for twenty-one weeks at 40 0C as a mixture with triacetin alone. At the longer storage times, e.g. 21 weeks, the perhydrolase still retains ca. 100 % of initial activity in a mixture of triacetin and sodium bicarbonate.
Table 7. Temperature stability of T. neapolitana perhydrolase/maltodextrin spray-dried enzyme powder during storage in a mixture of enzyme powder, sodium bicarbonate and triacetin at 40 0C. PAA (ppm) produced in 5 min at 25 0C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. neapolitana perhydrolase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000074_0001
Figure imgf000075_0001
ND = a duplicate assay was not done
EXAMPLE 13
Temperature Stability of T. maritima Perhydrolase/Maitodextrin Spray-Dried Enzyme Powder
An aqueous mixture was prepared containing heat-treated cell extract protein of E. coli KLP 18/pSW207 (21 g protein/L, > 90% T. maritima perhydrolase by PAGE) and maitodextrin (31 g/L maltodextrin DE 13-17 and 31 g/L maltodextrin DE 4-7, Aldrich) as excipient in 50 mM sodium bicarbonate (pH 8.1). This solution was spray-dried using a Buchi B-290 glass-chamber spray dryer (inlet temperature = 170 0C, exit temperature - 90 0C, feed rate = 4.5 mL/min) to produce a spray-dried enzyme powder; the weight percent protein in the powder (18.0 wt %) was determined using the BCA (Bicinchoninic acid) protein assay, and the glass transition temperature of this powder (Tg = 90 0C) was measured using modulated differential scanning calorimetry. This solution was spray-dried to produce a powder that was then tested for stability during storage at 40 °C for 7 weeks. The spray-dried enzyme powder (stored at 40 0C) was sampled at one-week intervals and assayed for activity using 50 μg protein/mL of T. maritima perhydrolase, H≥O≥ (H2O2 (100 mM)), triacetin (100 mM) and TURPINAL® SL (500 ppm) in 50 mM bicarbonate buffer (pH 7.2) at 25 0C, and analyzed for production of peracetic acid using a modification of the analytical method reported by Karst et at,, supra. The perhydrolytic activity of the T. maritima perhydroiase/maltodextrin spray-dried powder was stable over seven weeks of storage at 40 0C (Table 8).
Table 8. Temperature stability of T. maritima perhydroiase/maltodextrin spray- dried enzyme powder during storage at 40 0C. PAA (ppm) produced in 5 min at 25 0C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. maritima perhydrolase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000076_0001
EXAMPLE 14
Temperature Stability of T. maritima Perhydroiase/Maltodextrin Spray-Dried Enzyme Powder Stored in a Mixture of Enzyme Powder and Triacetin
The spray-dried enzyme powder prepared as described in Example 13 was evaluated for stability when stored for seven weeks at 40 DC as a mixture of the spray-dried powder in triacetin. The spray-dried enzyme powder (0.556 g, 18.0 wt % protein) was added to 43.6 g of triacetin. The resulting mixture was stored at 40 0C1 and a 2.21 g sample of the well-stirred mixture assayed in duplicate at 25 °C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPINAL® SL (500 ppm) in 50 mM sodium bicarbonate buffer at pH 7.2, where the resulting concentration of triacetin and protein was 100 mM and 50 μg/mL, respectively. Comparison of the data in Table 9 with the data in Example 13, Table 8, demonstrates the stability of T. maritima perhydroiase/maltodextrin spray-dried enzyme powders when stored as a mixture with triacetin.
Table 9. Temperature stability of T. maritima perhydroiase/maltodextrin spray- dried enzyme powder during storage in a mixture of enzyme powder and triacetin at 40 0C. PAA (ppm) produced in 5 min at 25 DC by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T. maritima perhydrolase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000077_0001
EXAMPLE 15
Temperature Stability of T. maritima Perhydrolase/Maitodextrin Spray-Dried Enzyme Powder Stored in a Mixture of Enzyme Powder, Sodium Bicarbonate and Triacetin
The spray-dried enzyme powder prepared as described in Example 13 was evaluated for stability when stored for seven weeks at 40 0C as a mixture of the spray-dried powder in a mixture of triacetin and sodium bicarbonate. The spray-dried enzyme powder (0.556 g, 18.0 wt % protein) was added to 43.6 g of triacetin and 8.4 g of sodium bicarbonate (Grade 3DF (powder), Church & Dwight). The resulting mixture was stored at 40 °C; and a 2.63 g sample of the weli-stirred mixture assayed in duplicate at 25 0C in a 100-mL reaction containing hydrogen peroxide (100 mM) and TURPI NAL® SL (500 ppm), where the resulting concentrations of triacetin, sodium bicarbonate buffer (pH 7.2) and protein were 100 mM, 50 mM and 50 μg/mL, respectively. Comparison of the data in Table 10 with the data in Example 14, Table 9, demonstrates the improved stability of T, maritima perhydrolase/maltodextrin spray-dried enzyme powders when stored for five, six and seven weeks at 40 0C as a mixture with triacetin and solid sodium bicarbonate when compared to the stability of T. neapoiitana perhydrolase/maltodextrin spray-dried enzyme powders when stored for five, six and seven weeks at 40 0C as a mixture with triacetin alone. Table 10. Temperature stability of T. maritima perhydrolase/maltodextrin spray- dried enzyme powder during storage in a mixture of enzyme powder, sodium bicarbonate and triacetin at 40 0C. PAA (ppm) produced in 5 min at 25 0C by reaction of triacetin (100 mM) and H2O2 (100 mM) in sodium bicarbonate buffer (50 mM, pH 7.2) containing T, maritima perhydrolase (50 μg protein/mL) and TURPINAL® SL (500 ppm).
Figure imgf000078_0001
EXAMPLE 16 Perhydroiysis of Propylene Giycoi Diacetate or Ethylene Glycol Diacetate
Using Bacillus subtilis ATCC® 31954™ Perhvdrolase A homogenate of a transformant expressing wild-type perhydrolase from
Bacillus subtilis ATCC® 31954™ (KLP18/pSW194) was prepared from a suspension of cell paste (20 wt % wet cell weight) in 0.05 M potassium phosphate buffer (pH 7.0) containing dithiothreitol (1 mM). The crude homogenate was centrifuged to remove cellular debris, producing a clarified cell extract that was heat-treated at 65 0C for 30 min. The resulting mixture was centrifuged, and the heat-treated supernatant concentrated on a 3OK MWCO (molecular weight cutoff) membrane to a concentration of 32 mg/mL total dissolved solids; a SDS-PAGE of the clarified, heat-treated cell extract indicated that the perhydroiase was at least 85-90 % pure. To this concentrate was then added 2.06 grams of NaH2PO4 and 1.17 grams Na2HPO4 per gram of soiids was added to this concentrate to produce an approximate 3:1 ratio (wt/wt) of phosphate buffer to heat-treated cell extract protein. This solution was diluted by 30 wt% with deionized water, then spray-dried (180 °C iniet temperature, 70 0C exit temperature) using a Buchi B-290 laboratory spray dryer); the resulting spray-dried powder contained 25.5 wt % protein (Bradford protein assay) and was 94.3 wt % dry soiids.
Reactions (10 ml_ total volume) were run at 23 0C in 50 mM sodium bicarbonate buffer (initial pH 7.2) containing propylene glycol diacetate (PGDA) or ethylene glycol diacetate (EGDA)1 hydrogen peroxide (100 mM) and 123 μg/mL of a heat-treated extract protein from the spray-dried E coli KLP18/pSW194 (expressing Bacillus subtilis ATCC® 31954™ wild-type perhydroiase) (prepared as described above). A control reaction for each reaction condition was run to determine the concentration of peracetic acid produced by chemical perhydrolysis of triacetin by hydrogen peroxide in the absence of added heat-treated extract protein. The reactions were sampled at 1 , 5, and 30 minutes and the samples analyzed for peracetic acid using the Karst derivatization protocol (Karst et al., supra); aiiquots (0.040 ml_) of the reaction mixture were removed and mixed with 0.960 ml_ of 5 mM phosphoric acid in water; adjustment of the pH of the diluted sample to less than pH 4 immediately terminated the reaction. The resulting solution was filtered using an ULTRAFREE® MC-fϊlter unit (30,000 Normal Molecular Weight Limit (NMWL), Mϋlipore cat # UFC3LKT 00) by centrifugation for 2 min at 12,000 rpm. An aliquot (0.100 mL) of the resulting filtrate was transferred to 1.5-mL screw cap HPLC vial (Agilent Technologies, Palo Alto, CA; #5182-0715) containing 0.300 mL of deionized water, then 0.100 mL of 20 mM MTS (methy!-p-to!yl-sulfide) in acetonitrile was added, the vials capped, and the contents briefly mixed prior to a 10 min incubation at ca. 25 0C in the absence of fight. To each vial was then added 0.400 mL of acetonitrile and 0.100 m L of a solution of triphenylphosphine (TPP, 40 mM) in acetonitrile, the vials recapped, and the resulting solution mixed and incubated at ca. 25 0C for 30 min in the absence of ϋght. To each vial was then added 0.100 mL of 10 mM N, N- diethyl-m-toluamide (DEET; HPLC external standard) and the resulting solution analyzed by HPLC. The peracetic acid concentrations produced in 1 min, 5 min and 30 min are listed in Table 11.
Table 11 : Peracetic acid (PAA) concentration produced in reactions utilizing propylene glycol diacetate (PGDA) or ethylene glycol diacetate (EGDA) and hydrogen peroxide (100 mM) in sodium bicarbonate buffer (50 mM, initial pH 7.2) at 23 0C using 123 μg/mL of heat-treated extract protein from E. coli KLP18/pSW194 {Bacillus subtilis ATCC® 31954™ perhydrolase).
PAA1 PAA, PAA, perhydrolase substrate 1 min 5 min 30 mtn
(50 μg/mL) (10O mM) (ppm) (ppm) (ppm) no enzyme (control) PGDA 0 64 241 β. subtilis ATCC® 31954 PGDA 666 781 815
no enzyme (control) EGDA 0 18 141
B. subtilis ATCC® 31954 EGDA 747 931 963
EXAMPLE 17
Perhydrolysis of Propylene Glycol Diacetate or Ethylene Glycol Diacetate Using T. maritime and T. neapolitana Wild-type and Variant Perhydrolases
Cell extracts of transformaπts expressing Thermotoga neapolitana wild- type perhydrolase (KLP18/pSW196), Thermotoga neapolitana C277S variant perhydroiase (KLP18/pSW196/C277S), Thermotoga neapolitana C277T variant perhydrolase (KLP18/pSW196/C277T), Thermotoga maritima wild-type perhydrolase (KLP18/pSW228), Thermotoga maritima C277S variant perhydrolase (KLP18/pSW228/C277S), and Thermotoga maritima C277T variant perhydrolase (KLP18/pSW228/C277T) were each prepared by passing a suspension of cell paste (20 wt % wet cell weight) in 0.05 M potassium phosphate buffer (pH 7.0) containing dithiothreitol (1 mM) twice through a French press having a working pressure of 16,000 psi (~110 MPa). The lysed cells were centrifuged for 30 minutes at 12,000 x g, producing a clarified cell extract that was assayed for total soluble protein (Bradford assay). The supernatant was heated at 75 DC for 20 minutes, followed by quenching in an ice bath for 2 minutes. Precipitated protein was removed by centrifugation for 10 minutes at 1 1 ,000 x g. SDS-PAGE of the resulting heat-treated extract protein supernatant indicated that the CE-7 enzyme comprised approximately 85-90% of the total protein in the preparation. The heat-treated extract protein supernatant was frozen in dry ice and stored at -80 °C until use.
A first set of reactions (10 ml_ total volume) were run at 20 0C in 10 mM sodium bicarbonate buffer (initial pH 8.1) containing propylene glycol diacetate (PGDA) or ethylene glycol diacetate (EGDA) (100 mM), hydrogen peroxide (100 mM) and 25 μg/mL of heat-treated extract protein from one of E coli KLP18/pSW196 (Thermotoga neapolitana wild-type perhydroiase), E coli KLP18/pSW196/C277S {Thermotoga neapolitana C277S variant perhydroiase), E. coli KLP18/pSW196/C277T ( Thermotoga neapolitana C277T variant perhydroiase), E. coli KLP18/pSW228 (Thermotoga maritime wild-type perhydroiase), E coli KLP18/pSW228/C277S (Thermotoga maritime C277S variant perhydroiase), and E. coli KLP18/pSW228/C277T (Thermotoga maritime C277T variant perhydroiase) (prepared as described above). A control reaction for each reaction condition was run to determine the concentration of peracetic acid produced by chemical perhydroiysis of triacetin by hydrogen peroxide in the absence of added extract protein. The reactions were sampled at 1 , 5, and 30 minutes and the samples analyzed for peracetic acid using the Karst derivatization protocol (Karst et al., supra) and HPLC analytical method (supra). The peracetic acid concentrations produced in 1 min, 5 min and 30 min are listed in Table 12.
Table 12: Peracetic acid (PAA) concentration produced utilizing T. maritima and T neapolitana wild-type and variant perhydroiases in reactions at 20 0C in sodium bicarbonate buffer (10 mM, initial pH 8.1 ) containing propylene glycol diacetate (PGDA) (100 mM) or ethylene glycol diacetate (EGDA) (100 mM), hydrogen peroxide (100 mM) and 25 μg/mL of heat-treated extract protein. substrate PAA, PAA1 PAA, cone. H2O2 1 min 5 min 30 min perhydrolase substrate (mM) (mM) (ppm) (ppm) (ppm) no enzyme (contro!) PGDA 100 100 0 15 165
T maritima WT PGDA 100 100 534 1104 1695
T. maritima C277S PGDA 100 100 647 1320 1864
T. maritima C277T PGDA 100 100 656 1174 1418
T. neapolitana WT PGDA 100 100 513 1052 1946
T. neapolitana C277S PGDA 100 100 875 1327 1707
T neapolitana C277T PGDA 100 100 724 1325 1864
no enzyme (control) EGDA 100 100 0 70 229
T maritima WT EGDA 100 100 765 1 182 1595
T maritima C277S EGDA 100 100 725 1240 1724
T, maritima C277T EGDA 100 100 802 1218 1734
T neapolitana WT EGDA 100 100 603 1 132 1643
T, neapolitana C277S EGDA 100 100 680 1305 1698
T. neapolitana C277T EGDA 100 100 688 1 164 1261
A second set of reactions (10 ml. total volume) were run at 20 0C in 10 mM sodium bicarbonate buffer (initial pH 8.1) containing propylene glycol diacetate (PGDA) or ethylene glycol diacetate (EGDA) (2 mM), hydrogen peroxide (10 mM) and 10 μg/mL of heat-treated extract protein from one of E. coli KLP18/pSW196 (Thermotoga neapolitana wild-type perhydrolase), E. coli KLP18/pSW196/C277S (Thermotoga neapolitana C277S variant perhydrolase), E coli KLP18/pSW196/C277T (Thermotoga neapolitana C277T variant perhydroiase), E. coli KLP18/pSW228 (Thermotoga maritima wild-type perhydrolase), E colt KLP18/pSW228/C277S (Thermotoga maritima C277S variant perhydrolase), and E. coli KLP18/pSW228/C277T (Thermotoga maritima C277T variant perhydroiase) (prepared as described above). A control reaction for each reaction condition was run to determine the concentration of peracetic acid produced by chemical perhydrolysis of triacetin by hydrogen peroxide in the absence of added extract protein. The reactions were sampled at 5 minutes and the samples analyzed for peracetic acid using the Karst derivatization protocol (Karst et al., supra) and HPLC analytical method {supra). The peracetic acid concentrations produced in 5 min are listed in Table 13.
Table 13: Peracetic acid (PAA) concentration produced utilizing T, maritima and T. neapolitana wild-type and variant perhydrolases in reactions at 20 0C in sodium bicarbonate buffer (10 mM, initial pH 8.1) containing propylene glycol diacetate (PGDA) (2 mM) or ethylene glycol diacetate (EGDA) (2 mM), hydrogen peroxide (10 mM) and 10 μg/mL of heat-treated extract protein.
substrate PAA, cone. H2O2 5 min perhydroiase substrate (mM) (mM) (ppm) no enzyme (control) PGDA 2 10 3.6
T. maritima WT PGDA 2 10 5.0
T. maritima C277S PGDA 2 10 7.2
T, maritima C277T PGDA 2 10 7.9
T. neapolitana WT PGDA 2 10 5.7
T. neapolitana C277S PGDA 2 10 7.9
T. neapolitana C277T PGDA 2 10 3.9
no enzyme (control) EGDA 2 10 3.3
T. maritima WT EGDA 2 10 9.9
T. maritima C277S EGDA 2 10 13.6
T. maritima C277T EGDA 2 10 22.9
T, neapolitana WT EGDA 2 10 6.6
T. neapolitana C277S EGDA 2 10 18.4
T. neapoiitana C277T EGDA 2 10 20.2

Claims

CLAIMS What is claimed is;
1. A process to stabilize the perhydrolysϊs activity of an enzyme when present in a formulation comprised of said enzyme and a carboxylic acid ester, the process comprising:
(a) providing an aqueous formulation comprising at least one enzyme structurally classified as a CE-7 enzyme having perhydrolysis activity, at least one excipient, and optionally at least one surfactant;
(b) spray-drying the aqueous formulation of (a) to produce an enzyme powder comprising said at ieast one enzyme, said at least one excipient, and optionally said at least one surfactant; and
(c) combining the enzyme powder of (b) with at least one buffer and a carboxylic acid ester to form a formulation, wherein the addition of the at least one buffer to the formulation enhances the stability of the perhydrolysis activity of said at least one enzyme when present in said formuiation.
2. The process of claim 1 , wherein the at least one excipient ranges from about 95 wt% to about 25 wt% of the enzyme powder.
3. The process of claim 2, wherein the at least one excipient is selected from the group consisting of maltodextrin, trehalose, xylan, mannaπ, fucoidan, galactomannaπ, chitosan, raffinose, stachyose, pectin, inulin, ievan, graminan, amyiopectin, and mixtures thereof.
4. The process of claim 3, wherein the at least one excipient is maltodextrin.
5. The process of claim 3, wherein the at ieast one excipient is trehalose.
6. The process of claim 1, wherein the carboxylic acid ester is selected from the group consisting of monoacetin, diacetin, triacetin, monopropionin, dipropionin, tripropionin, monobutyrin, dibutyrin, tributyrin, and mixtures thereof.
7. The process of claim 6, wherein the carboxyiic acid ester is triacetin.
8. The process of claim 1 , wherein the at least one surfactant is present and is polysorbate 80.
9. The process of claim 2, wherein the at least one excipient is an oligosaccharide excipient having a number average molecular weight of at least about 1250 and a weight average molecular weight of at least about 9000.
10. The process of claim 9, wherein the oligosaccharide excipient has a number average molecular weight of at least about 1700 and a weight average molecular weight of at least about 15000.
11. The process of claim 1 , wherein the formulation of step (c) is substantially free of water.
12. The process of any of claims 1-11, wherein the at least one buffer is sodium bicarbonate, potassium bicarbonate, a mixture of sodium bicarbonate and potassium bicarbonate, sodium phosphate, potassium phosphate, or a mixture of sodium phosphate and potassium phosphate.
13. The process of claim 12, wherein the at least one buffer has a buffering capacity in a pH range of from about 5.5 to about 9.5.
14. The process of claim 12, wherein:
(a) the at least one enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:19, and SEQ ID NO:20, wherein amino acid residue 277 of SEQ ID NO: 19 or SEQ ID NO: 20 is selected from the group consisting of alanine, valine, serine, and threonine, and (b) the carboxylic acid ester is selected from the group consisting of diacetin, triacetin, and mixtures thereof.
15. The process of claim 14, wherein said at least one excipient is maltodextrin.
16. The process of claim 12, wherein:
(a) the at least one enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6 and SEQ ID NO:7;
(b) the at least one excipient is maltodextrin;
(c) the at least one buffer is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, and mixtures thereof; and
(d) said carboxylic acid ester is triacetin.
17. The process of claim 16, wherein the at least one buffer is sodium bicarbonate.
18. A formulation used as a first component in a multi-component peracid generation system, said formulation comprising a mixture of:
(a) at ieast one carboxylic acid ester selected from the group consisting of monoacetin, diacetin, triacetin, monopropionin, dipropionin, tripropionin, monobutyrin, dibutyrin, tributyrin, and mixtures thereof;
(b) an enzyme powder comprising at least one enzyme structurally classified as a CE-7 enzyme and having perhydrolysis activity, at least one excipient, and optionally at least one surfactant; and (c) at least one buffer; wherein said at least one buffer enhances the stability of said at least one enzyme when present in said formulation.
19. The formulation of claim 18, wherein the at least one excipient is an oligosaccharide excipient having a number average molecular weight of at ieast about 1250 and a weight average molecular weight of at least about 9000.
20. A disinfectant system comprising a first component and a second component, said first component comprising the formulation of claims 18 or 19 and said second component comprising a source of peroxygen in water, and optionally a hydrogen peroxide stabilizer.
21. A laundry care formulation comprising a first component and a second component, said first component comprising the formulation of claims 18 or 19 and said second component comprising an aqueous solution of hydrogen peroxide and optionally a hydrogen peroxide stabilizer.
22. A process for enzymatically producing a peroxycarboxylic acid comprising:
(a) providing a set of reaction components, said components comprising:
(1) the formulation of claims 18 or 19; and
(2) a source of peroxygen in water; and
(b) combining said reaction components whereby a peroxycarboxylic acid is produced.
23. The process of claim 22, wherein:
(a) the at least one enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:19 and SEQ ID NO:20, wherein amino acid residue 277 of SEQ ID NO: 19 or SEQ ID NO: 20 is selected from the group consisting of alanine, valine, serine, and threonine.; (b) the at least one excipieπt is maltodextrin;
(c) the at least one buffer is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, a mixture of sodium bicarbonate and potassium bicarbonate, sodium phosphate, potassium phosphate, and a mixture of sodium phosphate and potassium phosphate;
(d) the at least one carboxyiic acid ester is triacetin; and
(e) the peroxycarboxyiic acid produced is peracetic acid.
24. A process to disinfect a hard surface or inanimate object using an eπzymatically-produced peroxycarboxyiic acid composition, said process comprising:
(a) providing a set of reaction components, said components comprising:
(1 ) the formulation of claim 18; and
(2) a source of peroxygen in water;
(b) combining said reaction components whereby a peroxycarboxyiic acid product is produced;
(c) optionally diluting said peroxycarboxyiic acid product; and
(d) contacting said hard surface or inanimate object with the peroxycarboxyiic acid produced in step (b) or step (c) whereby said surface or said inanimate object is disinfected.
25. A process for treating an article of clothing or a textile for bleaching, stain removal, odor reduction, saπitizatioπ or disinfection using an eπzymaticaily- produced peroxycarboxyiic acid composition, said process comprising:
(a) providing a set of reaction components, said components comprising:
(1) a mixture comprising
(i) the formulation of claim 18; and (ii) a carboxyiic acid ester; and
(2) a source of peroxygen; (b) combining said reaction components under suitable aqueous reaction conditions whereby a peroxycarboxylic acid product is formed;
(c) optionaily diluting said peroxycarboxylic acid product; and
(d) contacting said article of clothing or textile with the peroxycarboxylic acid produced in step (b) or step (c); wherein said article of clothing or textile is cleaned, destained, deodorized, sanitized, disinfected, or a combination thereof.
26. The process of claim 24 or 25, wherein:
(a) the at least one enzyme comprises an amino acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:19 and SEQ ID NO:20S wherein amino acid residue 277 of SEQ ID NO: 19 or SEQ ID NO: 20 is selected from the group consisting of alanine, valine, serine, and threonine.
(b) the at least one excipient is maltodextrin;
(c) the at least one buffer is selected from the group consisting of sodium bicarbonate, potassium bicarbonate, a mixture of sodium bicarbonate and potassium bicarbonate, sodium phosphate, potassium phosphate, and a mixture of sodium phosphate and potassium phosphate;
(d) the at least one carboxylic acid ester is triacetin; and
(e) the peroxycarboxylic acid produced is peracetic acid.
PCT/US2009/059232 2008-10-03 2009-10-01 Stabilization of perhydrolases in a formulation with a carboxylic acid ester WO2010039960A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2011530232A JP5777517B2 (en) 2008-10-03 2009-10-01 Perhydrolase stabilization
BRPI0913702A BRPI0913702B8 (en) 2008-10-03 2009-10-01 process for stabilizing the activity of perhydrolysis of an enzyme
CN2009801485098A CN102239264B (en) 2008-10-03 2009-10-01 Stabilization of perhydrolases in a formulation with a carboxylic acid ester
EP09793245.3A EP2342349B1 (en) 2008-10-03 2009-10-01 Stabilization of perhydrolases in a formulation with a carboxylic acid ester
BR122018012459A BR122018012459B1 (en) 2008-10-03 2009-10-01 formulation, disinfectant system and formulation for clothing care
ZA2011/01650A ZA201101650B (en) 2008-10-03 2011-03-03 Stabilization of perhydrolases in a formulation with a carboxylic acid ester

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US10251408P 2008-10-03 2008-10-03
US10253108P 2008-10-03 2008-10-03
US10253908P 2008-10-03 2008-10-03
US10250508P 2008-10-03 2008-10-03
US10251208P 2008-10-03 2008-10-03
US10252008P 2008-10-03 2008-10-03
US61/102,514 2008-10-03
US61/102,520 2008-10-03
US61/102,531 2008-10-03
US61/102,505 2008-10-03
US61/102,539 2008-10-03
US61/102,512 2008-10-03

Publications (1)

Publication Number Publication Date
WO2010039960A1 true WO2010039960A1 (en) 2010-04-08

Family

ID=41338635

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2009/059232 WO2010039960A1 (en) 2008-10-03 2009-10-01 Stabilization of perhydrolases in a formulation with a carboxylic acid ester
PCT/US2009/059230 WO2010039958A1 (en) 2008-10-03 2009-10-01 Improved perhydrolases for enzymatic peracid generation
PCT/US2009/059223 WO2010039953A1 (en) 2008-10-03 2009-10-01 Multi-component peracid generation system
PCT/US2009/059231 WO2010039959A1 (en) 2008-10-03 2009-10-01 Stabilization of perhydrolases with excipients
PCT/US2009/059227 WO2010039956A1 (en) 2008-10-03 2009-10-01 Enzymatic peracid generation formulation
PCT/US2009/059233 WO2010039961A1 (en) 2008-10-03 2009-10-01 Enzymatic peracid production using a cosolvent

Family Applications After (5)

Application Number Title Priority Date Filing Date
PCT/US2009/059230 WO2010039958A1 (en) 2008-10-03 2009-10-01 Improved perhydrolases for enzymatic peracid generation
PCT/US2009/059223 WO2010039953A1 (en) 2008-10-03 2009-10-01 Multi-component peracid generation system
PCT/US2009/059231 WO2010039959A1 (en) 2008-10-03 2009-10-01 Stabilization of perhydrolases with excipients
PCT/US2009/059227 WO2010039956A1 (en) 2008-10-03 2009-10-01 Enzymatic peracid generation formulation
PCT/US2009/059233 WO2010039961A1 (en) 2008-10-03 2009-10-01 Enzymatic peracid production using a cosolvent

Country Status (12)

Country Link
US (14) US8337905B2 (en)
EP (6) EP2342327B1 (en)
JP (6) JP5701762B2 (en)
CN (6) CN102264893B (en)
AU (1) AU2009298420B2 (en)
BR (3) BRPI0913701B1 (en)
CA (1) CA2736907C (en)
DK (1) DK2342324T3 (en)
ES (1) ES2735230T3 (en)
MX (1) MX2011003528A (en)
WO (6) WO2010039960A1 (en)
ZA (2) ZA201101650B (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011119706A1 (en) * 2010-03-26 2011-09-29 E.I. Dupont De Nemours And Company Perhydrolase providing improved specific activity
WO2011119712A1 (en) * 2010-03-26 2011-09-29 E.I. Dupont De Nemours And Company Perhydrolase providing improved specific activity
WO2011119714A1 (en) * 2010-03-26 2011-09-29 E.I. Dupont De Nemours And Company Perhydrolase providing improved specific activity
WO2012087785A1 (en) * 2010-12-21 2012-06-28 E.I. Dupont De Nemours And Company Perhydrolase variant providing improved specific activity
US8389255B2 (en) 2010-03-26 2013-03-05 E.I. De Pont De Nemours And Company Perhydrolase providing improved specific activity
US8445242B2 (en) 2010-03-26 2013-05-21 E. I. Du Pont De Nemours And Company Perhydrolase providing improved specific activity
US8586339B2 (en) 2010-03-26 2013-11-19 E. I. Du Pont De Nemours And Company Facilitated process for purification of proteins
US9783766B2 (en) 2015-04-03 2017-10-10 Ecolab Usa Inc. Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid
US10280386B2 (en) 2015-04-03 2019-05-07 Ecolab Usa Inc. Enhanced peroxygen stability in multi-dispense TAED-containing peroxygen solid
US10870818B2 (en) 2018-06-15 2020-12-22 Ecolab Usa Inc. Enhanced peroxygen stability using fatty acid in bleach activating agent containing peroxygen solid

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337905B2 (en) * 2008-10-03 2012-12-25 E. I. Du Pont De Nemours And Company Multi-component peracid generation system
US20110177148A1 (en) * 2009-07-27 2011-07-21 E. I. Du Pont De Nemours And Company Enzymatic in situ preparation of peracid-based removable antimicrobial coating compositions and methods of use
JP5730306B2 (en) * 2009-07-27 2015-06-10 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーE.I.Du Pont De Nemours And Company Enzymatic in situ preparation and use of peracid-based removable antimicrobial coating compositions
US8222012B2 (en) * 2009-10-01 2012-07-17 E. I. Du Pont De Nemours And Company Perhydrolase for enzymatic peracid production
US7927854B1 (en) 2009-12-07 2011-04-19 E. I. Du Pont De Nemours And Company Perhydrolase providing improved peracid stability
US7960528B1 (en) 2009-12-07 2011-06-14 E. I. Du Pont De Nemours And Company Perhydrolase providing improved peracid stability
US7910347B1 (en) 2009-12-07 2011-03-22 E. I. Du Pont De Nemours And Company Perhydrolase providing improved peracid stability
US7923233B1 (en) 2009-12-07 2011-04-12 E. I. Du Pont De Nemours And Company Perhydrolase providing improved peracid stability
US7932072B1 (en) 2009-12-07 2011-04-26 E. I. Du Pont De Nemours And Company Perhydrolase providing improved peracid stability
EP2377914B1 (en) 2010-04-19 2016-11-09 The Procter & Gamble Company Mildly alkaline, low-built, solid fabric treatment detergent composition comprising perhydrolase
EP2380957A1 (en) 2010-04-19 2011-10-26 The Procter & Gamble Company Solid laundry detergent composition having a dynamic in-wash ph profile
CN103282016A (en) * 2010-12-20 2013-09-04 纳幕尔杜邦公司 An aqueous stable composition for delivering substrates for a depilatory product using peracetic acid
US8663616B2 (en) * 2010-12-20 2014-03-04 E I Du Pont De Nemours And Company Enzymatic peracid generation for use in oral care products
KR20140114269A (en) 2010-12-20 2014-09-26 이 아이 듀폰 디 네모아 앤드 캄파니 Targeted perhydrolases
US8389256B2 (en) 2010-12-21 2013-03-05 E.I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
WO2012087788A1 (en) * 2010-12-21 2012-06-28 E.I. Dupont De Nemours And Company Perhydrolase variant providing improved specific activity
WO2012087792A1 (en) * 2010-12-21 2012-06-28 E.I. Dupont De Nemours And Company Perhydrolase variant providing improved specific activity
US8389258B2 (en) 2010-12-21 2013-03-05 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8394617B2 (en) 2010-12-21 2013-03-12 E.I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8394616B2 (en) 2010-12-21 2013-03-12 E.I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8389259B2 (en) 2010-12-21 2013-03-05 E.I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
WO2012084426A1 (en) * 2010-12-22 2012-06-28 Unilever Nv Enzymatic laundry detergent composition for the promotion of hygiene and the prevention of malodour
JP6312973B2 (en) * 2011-06-30 2018-04-18 アークロマ・インテレクチュアル・プロパティ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Washing method
US8883848B2 (en) 2011-07-14 2014-11-11 Ecolab Usa Inc. Enhanced microbial peracid compositions and methods of use at reduced temperatures in aseptic cleaning
US8906963B2 (en) * 2011-07-14 2014-12-09 Ecolab Usa Inc Deodorization of peracids
EP2755626B1 (en) 2011-09-14 2017-08-16 Colgate-Palmolive Company Tooth whitening strip
WO2013062885A1 (en) 2011-10-25 2013-05-02 E.I. Dupont De Nemours And Company Perhydrolase variant providing improved specific activity
US8501447B2 (en) 2011-10-25 2013-08-06 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8546120B2 (en) 2011-10-25 2013-10-01 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8956843B2 (en) 2011-10-25 2015-02-17 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8486679B2 (en) 2011-10-25 2013-07-16 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8962294B2 (en) 2011-10-25 2015-02-24 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8735125B2 (en) 2011-10-25 2014-05-27 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8557556B2 (en) 2011-10-25 2013-10-15 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
US8809030B2 (en) 2011-10-25 2014-08-19 E. I. Du Pont De Nemours And Company Perhydrolase variant providing improved specific activity
KR101311007B1 (en) * 2011-11-15 2013-09-24 (주)엔비엠 Peracetic acid production method and acetyl xylan esterase for peracetic acid production
US20130158115A1 (en) * 2011-12-19 2013-06-20 E. I. Du Pont De Nemours And Company Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant
WO2013096045A1 (en) 2011-12-19 2013-06-27 E. I. Du Pont De Nemours And Company Perhydrolase variants providing improved specific activity in the presence of surfactant
US20130158118A1 (en) * 2011-12-19 2013-06-20 E. I. Du Pont De Nemours And Company Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant
US20130158117A1 (en) * 2011-12-19 2013-06-20 E. I. Du Pont De Nemours And Company Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant
AU2012355355B2 (en) 2011-12-19 2015-04-16 Colgate-Palmolive Company Peracid-generating compositions
EP2793824B1 (en) * 2011-12-19 2016-07-13 Colgate-Palmolive Company System providing perhydrolase-catalyzed reaction
JP6141316B2 (en) * 2011-12-19 2017-06-07 コルゲート・パーモリブ・カンパニーColgate−Palmolive Company Systems that provide enzyme-catalyzed reactions
US20130158116A1 (en) * 2011-12-19 2013-06-20 E. I. Du Pont De Nemours And Company Perhydrolase Variant Providing Improved Specific Activity In the Presence of Surfactant
US20140342431A1 (en) 2011-12-22 2014-11-20 Danisco Us Inc. Variant Alpha-Amylases and Methods of Use, Thereof
US9133417B2 (en) * 2012-03-23 2015-09-15 The Procter & Gamble Company Liquid cleaning and disinfecting compositions comprising an assymetrically branched amine oxide
CN104350154B (en) * 2012-03-30 2020-12-29 纳幕尔杜邦公司 Enzymes useful for peracid production
WO2013148184A1 (en) 2012-03-30 2013-10-03 E. I. Du Pont De Nemours And Company Enzymes useful for peracid production
US8865436B2 (en) 2012-03-30 2014-10-21 E. I. Du Pont De Nemours And Company Enzymes useful for peracid production
WO2013148188A1 (en) 2012-03-30 2013-10-03 E. I. Du Pont De Nemours And Company Enzymes useful for peracid production
EP2831253B1 (en) 2012-03-30 2021-11-24 DuPont US Holding, LLC Enzymes useful for peracid production
US20130284637A1 (en) * 2012-04-30 2013-10-31 Danisco Us Inc. Unit-dose format perhydrolase systems
US8835140B2 (en) 2012-06-21 2014-09-16 Ecolab Usa Inc. Methods using peracids for controlling corn ethanol fermentation process infection and yield loss
US9481879B2 (en) * 2012-06-26 2016-11-01 Avent, Inc. Preparation of stabilized catalase enzymes with a surfactant
CN103566850B (en) * 2012-07-20 2019-09-20 黄太清 Biomass and the decomposition product original position controlled syntheses of other more structural body lightings and regeneration and the system recycled
US9487759B2 (en) * 2013-02-26 2016-11-08 Avent, Inc. Preparation of stabilized catalase enzymes using polyvinyl alcohol
WO2014200658A1 (en) 2013-06-13 2014-12-18 Danisco Us Inc. Alpha-amylase from promicromonospora vindobonensis
WO2014200657A1 (en) 2013-06-13 2014-12-18 Danisco Us Inc. Alpha-amylase from streptomyces xiamenensis
WO2014200656A1 (en) 2013-06-13 2014-12-18 Danisco Us Inc. Alpha-amylase from streptomyces umbrinus
WO2014204596A1 (en) 2013-06-17 2014-12-24 Danisco Us Inc. Alpha-amylase from bacillaceae family member
WO2015050723A1 (en) 2013-10-03 2015-04-09 Danisco Us Inc. Alpha-amylases from exiguobacterium, and methods of use, thereof
US20160186102A1 (en) 2013-10-03 2016-06-30 Danisco Us Inc. Alpha-amylases from exiguobacterium, and methods of use, thereof
WO2015077126A1 (en) 2013-11-20 2015-05-28 Danisco Us Inc. Variant alpha-amylases having reduced susceptibility to protease cleavage, and methods of use, thereof
CN104611319B (en) * 2015-01-26 2016-09-07 温州医科大学 A kind of method improving liquid fructose amino-acid oxidase enzyme heat stability
MX2018007051A (en) * 2015-12-17 2018-08-15 Colgate Palmolive Co Multicomponent bleaching system.
WO2017173324A2 (en) 2016-04-01 2017-10-05 Danisco Us Inc. Alpha-amylases, compositions & methods
WO2017173190A2 (en) 2016-04-01 2017-10-05 Danisco Us Inc. Alpha-amylases, compositions & methods
EA037209B1 (en) * 2016-07-22 2021-02-19 Джапан Тобакко Инк. Tobacco filler for non-combustion type heat smoking article
RU2728608C1 (en) 2016-12-20 2020-07-30 Колгейт-Палмолив Компани Two-phase bleaching compositions for oral cavity care
EP3541354B1 (en) 2016-12-20 2021-04-28 Colgate-Palmolive Company Oral care compositions and methods for whitening teeth
CN110087626B (en) 2016-12-20 2022-11-22 高露洁-棕榄公司 Oral care compositions and methods for whitening teeth
EP3668960B1 (en) 2017-08-18 2021-08-11 The Procter & Gamble Company Method of treating fabrics
DE102018113300A1 (en) * 2018-06-05 2019-12-05 Krones Ag Method and measuring device for determining a peracetic acid concentration in a peracetic acid and hydrogen peroxide-containing sterilizing medium
CN108731120A (en) * 2018-06-20 2018-11-02 南京海洛阿姆生物科技有限公司 A kind of air pollution treatment purifier
US10973885B2 (en) 2018-12-27 2021-04-13 Colgate-Palmolive Company Oral care compositions
WO2020154340A1 (en) 2019-01-22 2020-07-30 Colgate-Palmolive Company Whitening system
US20220112445A1 (en) * 2019-01-29 2022-04-14 Manna Pro Products, Llc Composition, system and method for treating stains and odors
EP3924004A4 (en) * 2019-02-11 2023-11-22 HAI Solutions, Inc. Fiber optic sterilization device
CA3129914A1 (en) 2019-02-11 2020-08-20 Hai Solutions, Inc. Instrument sterilization device
CN113490735A (en) 2019-02-28 2021-10-08 埃科莱布美国股份有限公司 Hardness additive and detergent bar containing same for improving edge hardening
US11312922B2 (en) 2019-04-12 2022-04-26 Ecolab Usa Inc. Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same
JP2020193157A (en) * 2019-05-27 2020-12-03 株式会社バイオシールドサイエンス Aqueous solution of composite metal ion
JP7397465B2 (en) 2019-08-27 2023-12-13 株式会社ジョイン How to keep cows calm
CN111676254B (en) * 2020-06-23 2021-11-16 江南大学 Application of acetyl xylan esterase in degradation of polyethylene glycol terephthalate
CN111778229B (en) * 2020-07-23 2022-02-22 江南大学 Cyclohexene carboxylate hydrolase, mutant thereof, encoding gene, expression vector, recombinant bacterium and application
CN115058405B (en) * 2021-04-28 2023-08-29 中国农业科学院生物技术研究所 Method for improving activity of esterase DcaE4 based on Tyr285 transformation and application
CN117019155B (en) * 2023-10-10 2023-12-29 江苏省农业科学院 Monoatomic defect carbon quantum dot nano-enzyme with multienzyme catalytic activity and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080176299A1 (en) * 2005-12-13 2008-07-24 Dicosimo Robert Production of peracids using an enzyme having perhydrolysis activity

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017A (en) * 1851-04-01 Splint-machine
US528525A (en) * 1894-11-06 Combined mop and wringer
US3974082A (en) 1972-08-21 1976-08-10 Colgate-Palmolive Company Bleaching compositions
US4444886A (en) 1982-08-11 1984-04-24 Eastman Kodak Company Diacetinase from Bacillus subtilis
US4585150A (en) 1983-09-07 1986-04-29 The Clorox Company Multiple liquid proportional dispensing device
US5116575A (en) 1986-02-06 1992-05-26 Steris Corporation Powdered anti-microbial composition
US4678103A (en) * 1986-03-27 1987-07-07 The Procter & Gamble Company Plural-chambered dispensing device exhibiting constant proportional co-dispensing and method for making same
US5364554A (en) 1986-06-09 1994-11-15 The Clorox Company Proteolytic perhydrolysis system and method of use for bleaching
US5296161A (en) * 1986-06-09 1994-03-22 The Clorox Company Enzymatic perhydrolysis system and method of use for bleaching
US5030240A (en) * 1986-06-09 1991-07-09 The Clorox Company Enzymatic peracid bleaching system
US5108457A (en) 1986-11-19 1992-04-28 The Clorox Company Enzymatic peracid bleaching system with modified enzyme
US5338678A (en) * 1989-06-09 1994-08-16 Oncogen, A Limited Partnership Expression of DNA sequences encoding a thermally stable cytosine deaminase from saccharomyces
CA2040707C (en) * 1990-04-27 2002-07-09 Kenji Mitsushima Cephalosporin acetylhydrolase gene and protein encoded by said gene
US5152461A (en) * 1990-10-01 1992-10-06 Proctor Rudy R Hand operated sprayer with multiple fluid containers
JPH04271785A (en) * 1991-02-28 1992-09-28 Kao Corp Enzymic solid pharmaceutical and its production
EP0668930B1 (en) 1991-10-01 2002-12-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES A method of identifying ligands and antagonists of ligands
GB9122048D0 (en) * 1991-10-17 1991-11-27 Interox Chemicals Ltd Compositions and uses thereof
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5683724A (en) 1993-03-17 1997-11-04 Ecolab Inc. Automated process for inhibition of microbial growth in aqueous food transport or process streams
US5398846A (en) 1993-08-20 1995-03-21 S. C. Johnson & Son, Inc. Assembly for simultaneous dispensing of multiple fluids
US5932532A (en) 1993-10-14 1999-08-03 Procter & Gamble Company Bleach compositions comprising protease enzyme
ATE245185T1 (en) * 1993-10-14 2003-08-15 Procter & Gamble BLEACHING AGENT COMPOSITIONS CONTAINING PROTEASES
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
JP2861808B2 (en) 1994-04-20 1999-02-24 日立電線株式会社 High-frequency transmission parameter measurement method for balanced pair stranded wire
GB2297976A (en) 1995-02-01 1996-08-21 Reckitt & Colmann Prod Ltd Improvements in or relating to a bleaching process
US5534179A (en) * 1995-02-03 1996-07-09 Procter & Gamble Detergent compositions comprising multiperacid-forming bleach activators
US5862949A (en) 1996-09-27 1999-01-26 Lever Brothers Company, Division Of Conopco, Inc. Dual container and individual chamber therefor
US5954213A (en) * 1996-12-27 1999-09-21 Lever Brothers Company Dual container and individual chamber therefor
EP0991754A2 (en) 1997-07-15 2000-04-12 Genencor International, Inc. Proteases from gram-positive organisms
GB9718518D0 (en) * 1997-09-01 1997-11-05 Dalgety Plc Fractionation of Hemicellulosic Materials
DE19757215A1 (en) * 1997-12-22 1999-06-24 Henkel Kgaa Enzyme granules for use in detergents
AT408660B (en) * 1998-01-28 2002-02-25 Biochemie Gmbh NUCLEIC ACID MOLECULE CODING FOR CEPHALOSPORINE ACETYLESTERASE
US6223942B1 (en) 1998-07-28 2001-05-01 Lever Brothers Company, Division Of Conopco, Inc. Container and closure
AU758625B2 (en) 1998-08-20 2003-03-27 Ecolab Inc. The treatment of meat products
US6010729A (en) * 1998-08-20 2000-01-04 Ecolab Inc. Treatment of animal carcasses
US6210639B1 (en) * 1998-10-26 2001-04-03 Novartis Ag Apparatus, method and composition for cleaning and disinfecting
DE60016727T2 (en) 1999-04-12 2005-05-19 Unilever N.V. MORE COMPONENTS BLEACH COMPOSITIONS
US20040147423A1 (en) * 1999-06-28 2004-07-29 The Procter & Gamble Company Dual-compartment laundry composition containing peroxyacids
US6245729B1 (en) * 1999-07-27 2001-06-12 Ecolab, Inc. Peracid forming system, peracid forming composition, and methods for making and using
US6342528B1 (en) * 2000-01-18 2002-01-29 Lynntech, Inc. Control of microbial populations in the gastrointestinal tract of animals
US6995125B2 (en) 2000-02-17 2006-02-07 The Procter & Gamble Company Detergent product
DE60043693D1 (en) * 2000-05-05 2010-03-04 Procter & Gamble Multi-compartment container with tap
WO2002022467A1 (en) 2000-09-15 2002-03-21 The Procter & Gamble Company Multi-compartment container and dispensing device
US6635286B2 (en) 2001-06-29 2003-10-21 Ecolab Inc. Peroxy acid treatment to control pathogenic organisms on growing plants
US6513807B1 (en) * 2001-09-06 2003-02-04 James P. Lynch Gaming apparatus and method for playing a game therewith
US6645233B1 (en) * 2001-09-27 2003-11-11 Gregory M. Ayers Drainage tube with heat transfer function and methods of use
US20040127381A1 (en) 2001-11-30 2004-07-01 The Procter & Gamble Company Dual-compartment laundry composition containing equilbrium peracid solution
US7172886B2 (en) * 2001-12-06 2007-02-06 The Regents Of The University Of California Biosynthesis of isopentenyl pyrophosphate
TW200302056A (en) * 2002-01-18 2003-08-01 Kaneka Corp Method for stabilizing reduced coenzyme Q10 and composition therefor
US6758411B2 (en) * 2002-08-09 2004-07-06 S. C. Johnson & Son, Inc. Dual bottle for even dispensing of two flowable compositions
US7448556B2 (en) * 2002-08-16 2008-11-11 Henkel Kgaa Dispenser bottle for at least two active fluids
DE10260903A1 (en) 2002-12-20 2004-07-08 Henkel Kgaa New perhydrolases
DE60320778D1 (en) 2003-07-08 2008-06-19 Procter & Gamble Liquid bleach activator composition
CN1321180C (en) * 2004-04-09 2007-06-13 江南大学 Method for raising stability for preserving catalase prepared by microbiological method
US7550420B2 (en) 2005-04-29 2009-06-23 E. I. Dupont De Nemours And Company Enzymatic production of peracids using perhydrolytic enzymes
EP1877566B1 (en) 2005-04-29 2009-02-18 E.I. Du Pont De Nemours And Company Enzymatic production of peracids using perhydrolytic enzymes
US7384787B2 (en) 2005-06-06 2008-06-10 Regents Of The University Of Minnesota Increasing perhydrolase activity in esterases and/or lipases
JP2007302760A (en) * 2006-05-10 2007-11-22 Kao Corp Composite particle
US7723083B2 (en) 2005-12-13 2010-05-25 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
EP1960529B1 (en) 2005-12-13 2010-02-24 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
US7951566B2 (en) * 2005-12-13 2011-05-31 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
US7964378B2 (en) * 2005-12-13 2011-06-21 E.I. Du Pont De Nemours And Company Production of peracids using an enzyme having perhydrolysis activity
JP2007228840A (en) * 2006-02-28 2007-09-13 Toyobo Co Ltd Method for stabilizing enzyme
WO2007106293A1 (en) 2006-03-02 2007-09-20 Genencor International, Inc. Surface active bleach and dynamic ph
DE502007006185D1 (en) * 2006-03-10 2011-02-17 Basf Se SOLID ENYMFORMULATIONS AND PROCESS FOR THEIR PREPARATION
US8399230B2 (en) * 2006-10-12 2013-03-19 Kemin Industries, Inc. Heat-stable enzyme compositions
JP5504268B2 (en) 2008-08-13 2014-05-28 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー Control of enzymatic peracid production
US8337905B2 (en) 2008-10-03 2012-12-25 E. I. Du Pont De Nemours And Company Multi-component peracid generation system
US8222012B2 (en) 2009-10-01 2012-07-17 E. I. Du Pont De Nemours And Company Perhydrolase for enzymatic peracid production

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080176299A1 (en) * 2005-12-13 2008-07-24 Dicosimo Robert Production of peracids using an enzyme having perhydrolysis activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASTILLO ET AL: "On the activity loss of hydrolases in organic solvents", JOURNAL OF MOLECULAR CATALYSIS. B, ENZYMATIC, ELSEVIER, AMSTERDAM, NL, vol. 35, no. 4-6, 1 September 2005 (2005-09-01), pages 147 - 153, XP005027022, ISSN: 1381-1177 *
MICHAEL T. RU ET AL.: "On the Salt-Induced Activation of Lyophilized Enzymes in Organic Solvents: Effect of Salt Kosmotropicity on Enzyme Activity", J. AM. CHEM. SOC.,, vol. 122, no. 8, 9 February 2000 (2000-02-09), pages 1565 - 1571, XP002559192 *
SERDAKOWSKI ET AL: "Enzyme activation for organic solvents made easy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 26, no. 1, 26 November 2007 (2007-11-26), pages 48 - 54, XP022400617, ISSN: 0167-7799 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8586339B2 (en) 2010-03-26 2013-11-19 E. I. Du Pont De Nemours And Company Facilitated process for purification of proteins
WO2011119712A1 (en) * 2010-03-26 2011-09-29 E.I. Dupont De Nemours And Company Perhydrolase providing improved specific activity
WO2011119714A1 (en) * 2010-03-26 2011-09-29 E.I. Dupont De Nemours And Company Perhydrolase providing improved specific activity
US8206964B2 (en) 2010-03-26 2012-06-26 E. I. Du Pont De Nemours And Company Perhydrolase providing improved specific activity
WO2011119706A1 (en) * 2010-03-26 2011-09-29 E.I. Dupont De Nemours And Company Perhydrolase providing improved specific activity
US8389255B2 (en) 2010-03-26 2013-03-05 E.I. De Pont De Nemours And Company Perhydrolase providing improved specific activity
US8389254B2 (en) 2010-03-26 2013-03-05 E.I. Du Pont De Nemours And Company Perhydrolase providing improved specific activity
US8445242B2 (en) 2010-03-26 2013-05-21 E. I. Du Pont De Nemours And Company Perhydrolase providing improved specific activity
US8450091B2 (en) 2010-03-26 2013-05-28 E. I. Du Pont De Nemours And Company Perhydrolase providing improved specific activity
WO2012087785A1 (en) * 2010-12-21 2012-06-28 E.I. Dupont De Nemours And Company Perhydrolase variant providing improved specific activity
US9783766B2 (en) 2015-04-03 2017-10-10 Ecolab Usa Inc. Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid
US10280386B2 (en) 2015-04-03 2019-05-07 Ecolab Usa Inc. Enhanced peroxygen stability in multi-dispense TAED-containing peroxygen solid
US10557106B2 (en) 2015-04-03 2020-02-11 Ecolab Usa Inc. Enhanced peroxygen stability using anionic surfactant in TAED-containing peroxygen solid
US11053459B2 (en) 2015-04-03 2021-07-06 Ecolab Usa Inc. Enhanced peroxygen stability in multi-dispense TAED-containing peroxygen solid
US11731889B2 (en) 2015-04-03 2023-08-22 Ecolab Usa Inc. Enhanced peroxygen stability in multi-dispense TAED-containing peroxygen solid
US10870818B2 (en) 2018-06-15 2020-12-22 Ecolab Usa Inc. Enhanced peroxygen stability using fatty acid in bleach activating agent containing peroxygen solid
US11193093B2 (en) 2018-06-15 2021-12-07 Ecolab Usa Inc. Enhanced peroxygen stability using fatty acid in bleach activating agent containing peroxygen solid

Also Published As

Publication number Publication date
US8148314B2 (en) 2012-04-03
JP5665747B2 (en) 2015-02-04
US20100087529A1 (en) 2010-04-08
US20120276609A1 (en) 2012-11-01
CN102264893A (en) 2011-11-30
CN102239256A (en) 2011-11-09
CN102264894A (en) 2011-11-30
DK2342324T3 (en) 2015-06-08
CN102239255B (en) 2015-11-25
ES2735230T3 (en) 2019-12-17
US20100086510A1 (en) 2010-04-08
US20130004479A1 (en) 2013-01-03
AU2009298420B2 (en) 2016-05-05
EP2342328A1 (en) 2011-07-13
EP2342324B1 (en) 2015-03-04
CN102239264A (en) 2011-11-09
US8367597B2 (en) 2013-02-05
AU2009298420A1 (en) 2010-04-08
US8148316B2 (en) 2012-04-03
US20120094342A1 (en) 2012-04-19
JP5701762B2 (en) 2015-04-15
US20110306667A1 (en) 2011-12-15
US8334120B2 (en) 2012-12-18
US20110305683A1 (en) 2011-12-15
JP5656845B2 (en) 2015-01-21
JP2012504692A (en) 2012-02-23
BRPI0913701A2 (en) 2015-08-04
JP5694938B2 (en) 2015-04-01
EP2342349B1 (en) 2017-04-05
US20110300121A1 (en) 2011-12-08
EP2342327A1 (en) 2011-07-13
CN102264894B (en) 2014-08-27
EP2342325B1 (en) 2016-12-14
US20100086535A1 (en) 2010-04-08
US8486380B2 (en) 2013-07-16
CA2736907A1 (en) 2010-04-08
WO2010039953A1 (en) 2010-04-08
WO2010039956A1 (en) 2010-04-08
BRPI0913702B8 (en) 2019-03-19
US20100087528A1 (en) 2010-04-08
US20120016025A1 (en) 2012-01-19
CA2736907C (en) 2018-06-05
JP2012504418A (en) 2012-02-23
CN102239255A (en) 2011-11-09
US8030038B2 (en) 2011-10-04
JP2012504419A (en) 2012-02-23
MX2011003528A (en) 2011-04-21
US8252562B2 (en) 2012-08-28
US8283142B2 (en) 2012-10-09
WO2010039959A1 (en) 2010-04-08
US20110306103A1 (en) 2011-12-15
JP5777516B2 (en) 2015-09-09
EP2342324A1 (en) 2011-07-13
EP2342326B1 (en) 2019-05-01
US8337905B2 (en) 2012-12-25
JP2012504421A (en) 2012-02-23
BR122018012459B1 (en) 2020-02-04
US8293221B2 (en) 2012-10-23
ZA201101649B (en) 2012-05-30
BRPI0913701B1 (en) 2018-06-05
US8062875B2 (en) 2011-11-22
CN102239264B (en) 2013-11-20
CN102239257A (en) 2011-11-09
ZA201101650B (en) 2012-07-25
BRPI0913702B1 (en) 2018-10-09
EP2342326A1 (en) 2011-07-13
US8445247B2 (en) 2013-05-21
EP2342325A1 (en) 2011-07-13
US20100086621A1 (en) 2010-04-08
BRPI0913702A2 (en) 2015-08-18
CN102264893B (en) 2014-08-27
EP2342327B1 (en) 2016-02-24
WO2010039958A1 (en) 2010-04-08
EP2342349A1 (en) 2011-07-13
JP2012504422A (en) 2012-02-23
JP2012504420A (en) 2012-02-23
JP5777517B2 (en) 2015-09-09
US8105810B2 (en) 2012-01-31
US8304218B2 (en) 2012-11-06
US20100086534A1 (en) 2010-04-08
WO2010039961A1 (en) 2010-04-08
EP2342328B1 (en) 2016-04-20

Similar Documents

Publication Publication Date Title
US8283142B2 (en) Stabilization of perhydrolases
US8222012B2 (en) Perhydrolase for enzymatic peracid production

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980148509.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09793245

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1847/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 12011500663

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2011530232

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2009793245

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009793245

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0913702

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110330